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A balanced regulation of bone formation and resorption in the healthy individual is 
required for a healthy bone. On the other side, there are many factors which can lead to 
alterations in bone density and microarchitecture. Menopause is a condition which can 
increase the remodeling process in favor of resorption. Moreover, there are also some 
diseases, i.e. chronic kidney bone disease, that increase the possibility of fractures 
and the subsequent disability leading to increased mortality. However, it is clear that 
drugs are an essential element of the therapy and this issue is analyzed extensively 
in this book. Some novel pathophysiological mechanisms are also presented, offering 
advanced knowledge to the reader. The book includes chapters from scientific 
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A balanced regulation of bone formation and resorption in the healthy individual is re‐
quired for a healthy bone. On the other side, there are many factors which can lead to altera‐
tions in bone density and microarchitecture. Menopause is a condition which can increase
the remodeling process in favor of resorption. Moreover, there are also some diseases, i.e.
chronic kidney bone disease, that increase the possibility of fractures and the subsequent
disability leading to increased mortality. However, it is clear that drugs are an essential ele‐
ment of the therapy and this issue is analyzed extensively in this book. Some novel patho‐
physiological mechanisms are also presented, offering advanced knowledge to the reader.
The book includes chapters from scientific departments and researchers from all over the
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1. Introduction
Previously, osteoporosis was diagnosed as an absolute decrease in the amount of bone and
fracture after minimal trauma[1]. The disadvantage with this definition is patients already
have fractures and osteoporosis is sufficiently advanced for it to be visualized on the plain X-
ray. The National Institute of Health (NIH) has redefined osteoporosis as a skeletal disorder
characterized by compromised bone strength that increases the risk of fracture2. Bone strength
primarily reflects the integration of bone density and bone quality. Bone quality refers to
architecture, turnover, damage accumulation and mineralization. Currently there is no
accurate measure of the overall bone quality. The ability to precisely measure bone mineral
density (BMD) has only become available in the past few decades and accounts for approxi‐
mately 70% of bone strength [3,4].
2. Bone densitometry
Traditional X-rays cannot measure bone density, however, they may provide suggestive
evidence of osteoporosis. However, this is not accurate and BMD must be decreased by
approximately 50% to be appreciated on a plain X-ray. Moreover, radiologist subjective
assessments are not always correct. Therefore, routine X-rays are not intended to assess BMD
and an apparently normal appearance cannot exclude osteoporosis.[5] Dual-energy X-ray
absorptiometry (DXA, previously DEXA[6, 7]), designed to determine bone minerals in central
sites such as lumbar spine and the hip, is of greater relevance to clinical osteoporosis. Some‐
times forearm measurements can also be made, but they are not routine. Central DXA
examinations have three major roles, namely the diagnosis of osteoporosis, the assessment of
patients' risk of fracture, and monitoring the response to treatment. Different centres use
different machines with different software that make it imperative to perform the follow up
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
on the same machine. Usually, DXA gives a precise and accurate measurement of BMD, but
under certain conditions this may lead to an over or under estimation[8] (Table1).











Table 1. Pitfalls in Measurements of Bone Mineral Density.
3. Diagnosis of osteoporosis
The DXA report provides the bone mineral content in a given area of bone. This gives a BMD
in grams per square centimetre (g/cm2). However, The BMD values in (g/cm2) are not used for
diagnosing osteoporosis. Instead, a working group of the World Health Organization (WHO)
proposed defining osteoporosis on the basis of the T-score measured by the central DXA at the
lumbar spine, total hip or femoral neck (or 1/3 radius if the lumber spine or hip cannot be
measured) in a postmenopausal woman and men 50 years and older. A BMD T-score that is
2.5 standard deviation or more below the young-adult mean BMD is defined as osteoporosis,
provided that the other causes of low BMD have been excluded (such as osteomalacia). (Table2)
Category Bone mass
Normal




A value for BMD of more than 1 but less than 2.5 SD below the young adult female
reference mean (T-score between -1.0 and -2.5)
Osteoporosis
A value for BMD of 2.5 or more SD below the young adult female reference mean (T-
score at or below -2.5)
Severe (established)
osteoporosis
A value for BMD of 2.5 or more SD below the young adult female reference mean in
the presence of one or more fragility fractures
Table 2. Diagnostic categories for osteoporosis and low bone mass based upon bone mineral density measurements by
DXA.
The WHO group also described a second diagnostic category, which was termed “osteopenia”
defined as a T-score between-1.0 and-2.5 standard deviation. Experts are moving away from
the term osteopenia and instead simply labelling it as low bone density. However, there are
more fractures in this range because there are so many more patients in this category.
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A T-score calculated using the formula: (patient's BMD − young normal mean)/SD of young
normal (same gender and ethnicity). For example, if a patient has a BMD of 0.700 (g/cm2), the
young normal mean is 1.000(g/cm2), and the young normal SD is 0.100 (g/cm2), then this
patient's T-score would be (0.700−1.000)/0.100, or −0.300/0.100, or −3.0. A T-score of 0 is equal
to the young normal mean value, −1.0 is 1 SD low, and −3.0 is 3 SD low[8]. Usually, 1 SD is
equal to 10 to 15 percent of the BMD value in (g/cm2). In addition to the T-scores, DXA reports
also provide Z-scores, which are calculated similarly to the T-score, except that the patient's
BMD is compared with an age-matched (race and gender-matched) mean, and the result is
expressed as an SD score. Since bone density declines with age, using the Z score for a diagnosis
would suggest that the prevalence of osteoporosis does not increase with age.
The WHO classification should not applied to healthy premenopausal women, men less than
50 years of age and children. In these groups, Osteoporosis cannot be diagnosed on the basis
of densitometric criteria alone. The international society for clinical densitometry (ISCD)
recommends using the Z-scores rather than T-scores. A Z-score of-2.0 or lower is defined as
“below the expected range for age” and a Z-score above-2.0 is “within the expected range for
age” [9].
Although not part of the WHO classification, a clinical osteoporosis, regardless of T-score,
should be considered in the presence of a fragility fracture (that occurs as a result of a minimal
trauma, such as a fall from a standing height or less, or no identifiable trauma) particularly at
the spine, proximal femur (hip), distal forearm (wrist) and proximal hummers. Provided other
causes for fractures have been excluded, such as a motor vehicle accident, pathological
fractures and stress fractures. Certain skeletal locations, including the skull, cervical spine, feet
and hands are not associated with fragility fractures [7,10].
4. Site of measurement of BMD
The international society for clinical densitometry (ISCD) recommends obtaining BMD
measurements of the posteroanterior spine and hip (right or left) in very obese patients, those
with primary hyperparathyroidism, or those in whom the hip or the spine, or both, cannot be
measured or interpreted such as with degenerative arthritis, prior vertebral fractures, verte‐
broplasty and total hip arthroplasty, BMD may be measured in the forearm, using a 33% radius
on the nondominant forearm by DXA or peripheral DXA[9], otherwise non-central DXA bone
mass measurement devices cannot be used for the diagnosis using the WHO classification.
However, it may be used to assess fracture risk.
5. Conclusion
Osteoporosis can be diagnosed clinically or radiographically by DXA. BMD assessment by a
central DXA scan of the total hip, femoral neck, or lumbar spine is the standard test to diagnose
osteoporosis in a postmenopausal woman or men over age 50, based on the WHO classifica‐
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tion. A BMD T-score of 2.5 or more below the young-adult mean BMD is defined as osteopo‐
rosis. It is appropriate to consider a clinical diagnosis of osteoporosis in individuals who have
sustained fragility fracture(s) even if BMD is not in the osteoporotic range, as the majority of
fractures occur in those who have a T-score above-2.5. The WHO classification should not be
applied to premenopausal women and men less than 50 years of age and children. Z–scores,
not T-scores are preferred. A Z-score of-2.0 or lower is defined as “below the expected range
for age”. However, in these groups osteoporosis cannot be diagnosed on densitometric criteria
alone[9].
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1. Introduction
Estrogen plays a principal role in skeletal growth and bone homeostasis. In women, estrogen
deficiency after menopause accelerates frequently osteoclastic bone resorption. It was believed
that the accelerated phase in women is most apparent during the first 3 to 5 years after
menopause, involved unproportional loss of trabecular bone [1].
We know that the mechanisms of how estrogen deficiency causes bone losses are complex.
Researches during the last decade have demonstrated that estrogen regulates bone homeo‐
stasis through unexpected regulatory effects on the immune system and on oxidative stres and
direct effects on bone cells [2].
We review how the differential effects of estrogen on cortical and trabecular bone might occur
and how estrogen might interact with other age-related processes. Estrogen has three funda‐
mental effects on bone metabolism:
1. It inhibits the activation of bone remodeling and the initiation of new basic multicellular
units (BMUs);
2. It inhibits differentiation and promotes apoptosis of osteoclasts, therefore bone resorption
reduces and
3. While estrogen suppresses self-regeneration of early mesenchymal progenitors, it
organizes the commitment and differentiation and prevents apoptosis of osteoblastic cells,
therefore bone formation is maintaining at the cellular level [1].
In this review, we summarized each of these actions of estrogen Figure 1,2.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
2. The effects of estrogen on the bone cells
At the tissue level, estrogen reduces bone turnover [4]. It would appear that osteocytes may
regulate the activation of bone remodeling via connections with bone lining cells [5]. It is
likely that  the antiremodeling effects  of  estrogen are mediated via  the osteocyte.  Osteo‐
cytes are cells embedded within the bone matrix, derived from the osteoblast that helps to
bone remodeling. The bone lining cells comprise a subpopulation of the osteoblast family.
These cells  are related with the bone surface at sites where a thin no mineralized colla‐
gen layer is present. The bone lining cells migrate to form a canopy over the remodeling
area,  especially  at  sites  adjacent  to  osteoclasts  [6,7].  Indeed,  withdrawal  of  estrogen  is
associated  with  increased  apoptosis  of  osteocytes  in  humans  [8].  Recent  studies  have
reported that serum estradiol levels are inversely associated with serum levels of the key
inhibitor of  Wnt signaling produced by osteocytes,  sclerostin,  and estrogen treatment of
postmenopausal women reduces circulating sclerostin levels [9,10]. Moreover, it has been
suggested that Wnt/β-catenin signaling is important to respond to mechanical strain of the
osteocyte, and this response also depends on estrogen receptor α (ERα). Wnt signaling is
interrupted  in  the  mesenchyme,  osteoblast  differantiation  is  reduced  and  the  skeletal
development is affected [11]. Thus there is a likely important argument between estrogen
and Wnt signaling pathways mediated by the osteocyte [1] Figure 1.
Figure 1. Schematic of the bone remodeling compartment [3] The bone remodeling compartment (BRC) consists of the
cells comprising the basic multicellular unit (BMU)-osteoclasts (OCs), osteoblasts (OBs), and osteocytes-as well as the
cover bone-lining cells and capillary. These cells are connected with gap junctions. Note also the potential direct physi‐
cal contact between OCs and OBs, which would allow for signaling between these cells [3].
Estrogen suppresses both directly and indirectly bone resorption [1]. The dominant acute effect
of estrogen is blocking the new osteoclast formation. In addition, estrogen also modulates
RANK (Receptor activator of nuclear factor κB) signaling in osteoclastic cells [12,13] and
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induces apoptosis of osteoclasts [14,15]. Osteoclasts are cells of hematopoietic origin respon‐
sible for resorbing bone. These are originated from proliferation that occurs by cytokines and
differantiation of the monocyte precursors. They are located on endosteal surfaces within the
Haversian system and on the periosteal surface [7].
Osteoclast differantiation is supported by cells of the osteoblast lineage. Osteoblast lineage
cells consist of osteoblasts, osteocytes and bone lining cells [7]. Osteoclast differantiation
process is facilitated by stromal cells of bone marrow that provides physical support to
immature OCs. The basic cytokines, need to OC formation under basal conditions are RANKL
(Receptor activator of nuclear factor kappa-B ligand) and M-CSF (Macrophage colony-
stimulating factor). These factors are produced by major stromal cells of bone marrow, OBs
and active T cells. RANKL is a TNF superfamily member. RANKL links transmembrane
receptor RANK expressed from OC surface and OC precursors. RANKL also links OPG
(Osteoprotegerin), a soluble fake receptor produced by several hemapoietic cells. Therefore
OPG functions as an power antiosteoclastogenic cytokine, secreting RANKL and blocking its
binding to RANK. RANKL promotes differantiation of OC precursors from early stage of
maturation to full maturation (multinucleated OCs) [16] Figure 2.
Figure 2. Working model for estrogen regulation of bone turnover via effects on osteocytes, osteoblasts, osteoclasts,
and T-cells [3] The main effect of estrogen is inhibition of bone remodeling, likely via the osteocyte. Estrogen also in‐
hibits bone resorption, by direct effects on osteoclasts, although effects of estrogen on osteoblast/osteocyte and T cell
regulation of osteoclasts likely also play a role. Estrogen deficiency associated with a gap between bone resorption and
formation, likely due to the loss of the effects of estrogen on decreasing osteoblast apoptosis, oxidative stres, osteoblas‐
tic NF-κB activity, and perhaps other, as yet undefined mechanisms [3].
Estrogen Deficiency and Osteoporosis
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Detection of molecular mekanisms that are regulate the osteoclast formation and activation
won a big acceleration by survey of RANK/RANKL signal system. M-CSF expression that is
secreted by osteoblastic stromal cells need to differentiation to osteoclasts of progenitor cells
but, M-CSF expression is not itself sufficient to differentiation of osteoclast. RANKL ekspres‐
sion by osteoblastic stromal cells and RANK expression by osteoclast precursors need to be
completed osteoclast differentiation [17] Figure 3.
Osteoblasts are cell of mesenchymal origin responsible for forming bone. These cells are found
along the bone surface at sites of active bone formation. The principal function of the osteo‐
blasts is bone formation [17].
Finally, estrogen is important for the maintenance of bone formation. Human studies show that
acute (3 weeks) estrogen deficiency [18] is associated with a fall in bone-formation markers.
Chronically estrogen deficient increased both bone-resorption and bone-formation markers
[19]. It also appears that the effects of estrogen on progenitor and osteoblastic cells may be stage-
specific. Thus, estrogen reduces the self-innovation of early mesenchymal progenitors [20].
Figure 3. Cells and cytokines responsible for physiological OC renewal. OC precursors may differentiate from the pop‐
ulation of monocytes/macrophages. When RANKL binds to receptor RANK in the presence of the trophic factor M-
CSF, which in turn binds to its receptor, colony-stimulating factor receptor 1 (c-Fms), OC precursors differentiate and
fuse together to multinucleated bone-resorbing OCs. Under physiological conditions the dominant source of RANKL
and M-CSF in the bone marrow microenvironment is from the bone-forming cells, the OBs, and their stromal cell (SC)
precursors.
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and M-CSF in the bone marrow microenvironment is from the bone-forming cells, the OBs, and their stromal cell (SC)
precursors.
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It  was  reported  that  osteoblasts,  osteocytes  and  osteoclasts  express  functional  estrogen
receptors (ERs). These receptors are also expressed in bone marrow stromal cells (SCs), the
precursors of osteoblasts [21-24]. Estrogen signals through two receptors, ERalpha and beta
[21]. Bone cells contain both receptors, but their distributions within bone are not homoge‐
neous. In hümans, ER alpha is the predominant in cortical bone, but ER beta is predomi‐
nant in trabecular bone. Although many estrogenic effects are mediated by nuclear ERs,
some effects originate in the plazma membrane. Estrogen produces rapid effects in various
cell  types such as bone cells.  These nongenomic effects are due to signaling by a mem‐
brane receptor. The induce OC apoptosis and inhibit OB apoptosis of estrogen is linked to
its  ability  to  increase  ERK1 and ERK2 phosphorylation and repression c-jun N-terminal
kinase (JNK) activity [25,26].
It is well recognized that c-jun N-terminal kinases (JNKs) play important roles in cellular
functions such as proliferation, differentiation, and cell death in a variety of cell types [24].
JNK activity is essential for the late-stage differentiation of osteoblasts [22].
Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in the lineage
specification of mesenchymal cells. Inactivation of ERK1 and ERK2 significantly reduced
RANKL expression, accounting for a delay in osteoclast formation. ERK1 and ERK2 not only
play essential roles in the lineage specification of osteo-chondroprogenitor cells but also
support osteoclast formation in vivo [27]. The phosphorylation of these cytoplasmic kinases
and their transport to the nucleus modulates the activity transcription factors required for
antiapoptotic actions of estrogen [16,26].
3. Estrogen loss and immune system
The immune system plays an important role in the pathophysiology of postmenopausal
osteoporosis Figure 4. Estrogen deficiency induces bone loss and increases in production of
cytokines, such as IL-1, IL-6, and TNFα. These cytokines are well known regulators of the
immune system and T cell function [1,6]. The most important cytokine in the context of
estrogen deficiency-induced bone loss has been shown to be TNFα produced by bone marrow
T lymphocytes. T lymphocytes are stimulated by a complex mechanism involving several
cytokines, such as IL-7, IFN-gamma, and TGF-beta [28].
Estrogen deficiency up-regulates TNF-alpha production by T cells through a complex pathway
relative to the thymus and bone marrow. TNF-alpha increases OC formation by up-regulating
stromal cell production of RANKL and M-CSF [28,29].
Another cytokine involving OC formation is interleukin-7 (IL-7). It has been reported that IL-7
promotes osteoclastogenesis by up-regulating T cell-derived osteoclastogenic cytokines
including RANKL [28,30,31].
INFgamma influences OC formation both via direct and indirect effects [32]. It directly blocks
OC formation and provides T cell activation inducing antigen presentation [28,33].
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Estrogen deficiency induces the imbalance between RANKL and OPG. This situation is
important in the occurance of postmenopausal bone loss [34,35].
Recent  studies  show that  postmenopausal  wonen have a  significantly  higher  concentra‐
tion of circulating sclerostin than premenopausal women [28,36]. In vivo and in vitro studies
report that TNF-alpha may stimulate the expression of sclerostin. Therefore, the increase
of sclerostin mediated by TNF-alpha may contribute to the pathogenesis of postmenopaus‐
al women [28,37].
Sclerostin is a protein encoded by the SOST gene in osteocytes. It is a modulator of osteoblast
function. Sclerostin antagonizes Wnt signaling and inhibits osteoblastic bone formation [38,
39].
Tyagi et al suggest that Th17 cells may be refer to the pathogenesis of bone loss. Th17 cells
produce IL-17. Therefore, IL-17 plays a critical role in Ovx-induced bone loss and may be
considered as a potential therapeutic target in pathogenesis of postmenopausal osteoporo‐
sis [40].
The thymus undergoes progressive structural and functional decline with age [41]. By middle
age most parenchymal tissue is replaced by fat, and fewer T cells are produced, but the thymus
progresses to generate new T cells even into old age [16,42,43]. The mechanism of thymic
Figure 4. Estrogen suppresses T cell TNF production by regulating T cell differentiation and activity in the bone mar‐
row, thymus, and peripheral lymphoid organs. In the bone marrow, estrogen downregulates the proliferation of hema‐
topoietic stem cells through an IL-7 dependent mechanism. Estrogen prevents T cell activation both directly blunting
antigen presentation and via repression of IL-7 and IFN-γ production. This effect is extended by the upregulation of
the IL-7 suppressor TGF-β. The net result of them is a decrease in the number of TNF producing T cells. The blunted
levels of TNF diminish RANKL-induced OC formation.
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rebound is not completely understood, but may be involving IL-7 [44]. IL-7 alone is not
sufficient to enhance thymopoiesis in young mice [45].
Estrogen have suppressive effect on thymic function. Estrogen deficiency induces a rebound
in thymic function. Stimulated thymic T cell output accounts for approximately 50% of the
increase in the number of T cells in the periphery. Thymectomy also reduces by approximately
50% the bone loss induced by ovariectomy (ovx). This finding shows that estrogen deficiency
induced thymic rebound may be responsible for exaggerated bone loss after surgical meno‐
pause or in the first 5-7 years after natural menopause [16].
4. Estrogen loss and oxidative stress
In fact, estrogen deficiency accelerates the effects of aging on bone by decreasing defense
against oxidative stres (OS). Estrogen protects the adult skeleton against bone loss by slowing
the rate of bone remodeling and by maintaining a focal balance between bone formation and
resorption. The acut loss of sex steroids shows an increase in the rate of bone remodeling,
resulting from an increase in both osteoclastogenesis and osteoblastogenesis [16].
Recent studies report that Reactive oxygen species (ROS) may play a role in postmenopausal
bone loss by creating a more oxidized bone microenvironment [46,47] and increase the
intracellular concentration of the antioxidant glutathione in bone prevents bone loss during
estrogen deficiency in mice [48]. Glutathione peroxidase is responsible for intracellular
degradation of hydrogen peroxide. It is the predominant antioxidant enzyme expressed by
OCs. Its overexpression abolishes OC formation [49].
Though the mechanisms of ROS action on bone during estrogen deficiency are not well-known,
it is reported that immune cells are biological targets of ROS. ROS are important stimulators
of antigen presentation by dendritic cell (DC) as well as DC-induced T cell activation [50,51].
ROS are also raised upon dendritic cell interaction with T cells [52]. ROS can decrease T cell
lifespan by stimulating T cell apoptosis [53].
It has been shown that NO donor nitroglycerin significantly prevents osteoporotic fractures
in postmenopausal women [54] and N-acetyl-cysteine (NAC) treatment prevents against ovx-
induced bone loss [48]. NAC treatment blunts ovx-induced dendritic cell activation in the bone
marrow, and prevents T cell activation and TNF-alpha production [16].
5. Conclusion
Bone tissue is continually being renewed by osteoclast and osteoblast cells during normal
physiology, but excessive resorption occurs without adequate new bone formation during
postmenopausal osteoporosis. It has been suggested that such cellular changes are a result of
postmenopausal estrogen deficiency. Recent studies report that estrogen deficiency exacer‐
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bates bone loss due to aging by diminishing the cells resistance to oxidative stres (OS).
Moreover, a relationship between the immune system and bone has been speculated.
Remarkable progression has been registered for our understanding to the mechanisms of bone
destruction during estrogen deficiency in the last 2 decades, but additional animal models and
long-term human studies are needed.
Future studies will be guide to a new therapeutic advance in the treatment of osteoporosis
with a novel mechanism of action that leads to the decrease of bone resorption and fractur risk.
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1. Introduction
Osteoporosis (OP) is a common skeletal disease and a global problem. The prevalence of OP
is approximately 10.3% in the general population and affects over 200 million women world‐
wide [1]. Approximately 30% of postmenopausal women suffer from OP in Western nations.
About 50% of affected women and at least 15% of affected men will undergo fragility fractures
in their lifetime. OP is chronic and does not present with apparent symptoms before osteo‐
porostic fractures occur. This can cause disability, a decreased quality of life, and even death.
As a result, OP imposes a heavy financial burden on society that includes not only the direct
cost of osteoporostic fractures but also the indirect costs of disablement. In the United States,
the direct cost of OP was over USD 13.7 billion in 2005 and may reach USD 25.3 billion by 2025.
Therefore, OP is a pressing public health concern and greater understanding of its mechanisms
is imperative.
Population ageing is accelerating worldwide, and OP is becoming increasingly prevalent.
However, the risk factors that contribute to OP are not clear. Many factors have been suggested
to affect the likelihood of OP, including genetics, gender, age, poor diet, smoking and medi‐
cations (Figure 1). It has been reported that the genetic heritability of bone loss in humans is
up to 56% [2,3]. This has been found through comparisons of bone mineral density (BMD), the
hallmark trait of OP, in monozygotic (MZ) and dizygotic (DZ) twins after menopause.
Additionally, a genome-wide association study (GWAS) of 37,534 individuals in Europe and
North America has confirmed that LRP5 (lipoprotein-receptor-related protein) significantly
increases the risk of OP and osteoporotic fractures [4]. Therefore, genetic factors play a
significant role in the aetiology of OP and its complications.
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Figure 1. Bone mass is affected by genetic (60%~80% contribution) and other factors (20%~40% contribution) including
exercise, sunlight, nutrition, smoking, alcohol, medication and ageing. Factors along the upline potentially contribute
to higher bone mass and along the downline cause lower bone mass.
OP is characterized by reduced BMD, impaired microarchitecture of bone tissue and increased
risk of fractures. OP has a wide range of phenotypes including abnormal BMD, bone turnover,
osteoporotic fracture, skeletal growth, and fracture risk. Although OP genetics aims to identify
pathological genes that increase the chance of bone fragility, osteoporotic fractures are not
appropriate candidate phenotypes for heritability studies. As fractures occur due to a wide
variety of reasons, not necessarily as a result of bone fragility, fractures alone are insufficient
qualifiers for studies. In contrast, previous studies have reported a strong genetic correlation
between BMD and bone mass/fracture phenotypes [5]. To this date, most OP studies have
focused on BMD because of the high heritability and relative ease of measurement. This chapter
will discuss the hereditary factors in pursuit of a new understanding of pathological genes in
OP, including an overview of current technology at the cutting-edge of OP testing.
2. Non-genetic factors in the risk of osteoporosis
OP may be caused by primary and secondary factors (Table 1). Mostly, OP results from primary
factors; in approximately 20%~40% of patients the condition has secondary causes [5,6].
Primary OP has two categories: type I (postmenopausal) and type II (senile) OP. Type I OP is
believed to be associated with oestrogen deficiency and usually occurs in women between the
ages of 51 and 75. It results in excessive bone resorption and fractures, including in the
Advances in Osteoporosis20
Figure 1. Bone mass is affected by genetic (60%~80% contribution) and other factors (20%~40% contribution) including
exercise, sunlight, nutrition, smoking, alcohol, medication and ageing. Factors along the upline potentially contribute
to higher bone mass and along the downline cause lower bone mass.
OP is characterized by reduced BMD, impaired microarchitecture of bone tissue and increased
risk of fractures. OP has a wide range of phenotypes including abnormal BMD, bone turnover,
osteoporotic fracture, skeletal growth, and fracture risk. Although OP genetics aims to identify
pathological genes that increase the chance of bone fragility, osteoporotic fractures are not
appropriate candidate phenotypes for heritability studies. As fractures occur due to a wide
variety of reasons, not necessarily as a result of bone fragility, fractures alone are insufficient
qualifiers for studies. In contrast, previous studies have reported a strong genetic correlation
between BMD and bone mass/fracture phenotypes [5]. To this date, most OP studies have
focused on BMD because of the high heritability and relative ease of measurement. This chapter
will discuss the hereditary factors in pursuit of a new understanding of pathological genes in
OP, including an overview of current technology at the cutting-edge of OP testing.
2. Non-genetic factors in the risk of osteoporosis
OP may be caused by primary and secondary factors (Table 1). Mostly, OP results from primary
factors; in approximately 20%~40% of patients the condition has secondary causes [5,6].
Primary OP has two categories: type I (postmenopausal) and type II (senile) OP. Type I OP is
believed to be associated with oestrogen deficiency and usually occurs in women between the
ages of 51 and 75. It results in excessive bone resorption and fractures, including in the
Advances in Osteoporosis20
trabecular bone in the vertebrae and distal radius. Type II OP usually results from age-related
vitamin D deficiency and affects women and men over the age of 70. It mainly causes hypo‐
calcaemia, increased parathyroid hormone (PTH) release, bone resorption and fractures,
including in both the trabecular and cortical bone on the long bones, causing fractures of the
femoral neck, proximal, humerus and tibia, and pelvis.
Identifiable Causes
Primary cause Secondary cause
Personal condition Chronic glucocorticoid therapy
Oestrogen deficiency Thyrotoxicosis
Low weight and body mass index Vitamin D deficiency
Increased age Alcoholism and smoking
Gender Hypogonadism (men)
Family history Malnutrition
Table 1. Identifiable causes of osteoporosis
As discussed in detail in other chapters of this book, OP is a chronic and complex disease that
is influenced by both non-genetic and genetic factors. Non-genetic factors are common and
worthy of consideration (Table 2). One of the most important is oestrogen, which changes with
age [6, 7]. Oestrogen acts directly on oestrogen receptors in osteoblasts and its deficiency affects
BMD, which leads to the risk of OP in postmenopausal women and contributes to the devel‐
opment of OP in elderly men. The chemical element lead is another potential risk factor for
OP. Lead impairs cell proliferation and viability by affecting the response of cells to hormonal
stimuli, which interferes with hormone and cytokine signal-transduction processes. This
causes a toxic effect in skeleton systems and influences bone mineral homeostasis and growth.
Calcium is one of our most common body minerals and is required for normal skeletal growth
and maintenance [8]. A low-calcium diet causes loss of trabecular bone by affecting the function
and phenotype of bone-marrow cells [8-10]. This has been shown to further accelerate bone
loss in ovariectomized (OVX) rats, though BMD levels were partially rescued by calcium
supplements [8-10]. Cadmium is toxic and causes bone loss after the start of dietary cadmium
exposure [11-12]. It has been demonstrated that cadmium exposure leads to an increase in
serum calcium, phosphorous and PTH levels in concomitant with significant reduction in
serum vitamin D (3), osteocalcin (OC) levels and bone-specific alkaline phosphatase (BALP)
activity [11-12]. Reduced BMD is usually associated with kidney impairment in response to
cadmium exposure [12]. Although the toxic effects of aluminium overload on bone metabolism
were first reported with a severe form of osteomalacic osteodystrophy [13], recently it has been
reported that accumulated aluminium content in bone during life does not substantially
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influence the level of BMD [14-15]. Additionally, no clinical symptoms of bone disease were
found in individuals with aluminium contamination, but its accumulation in tissue was
significant [14-15]. Interestingly, dual X-ray absorptiometry (DXA) was found to induce BMD
recovery in osteopenic rats affected by aluminium [16]. Alcohol slows cell proliferation and
viability to arrest longitudinal bone growth, and affects dry weight, mineral content and
mechanical integrity [17-18]. This may increase the risk of developing OP – further confirma‐
tion is given by epidemiological findings. Additionally, studies on animals have reported that
alcohol suppresses young bone growth and inhibits adult bone formation – alcohol has greater
deleterious effects on bone formation than on bone resorption [18]. Smoking, particularly
heavy smoking, may affect nutritional absorption, decrease absorption of calcium, and
interfere with oestrogen. This eventually results in lower oestrogen levels, lower bone density,
a dramatic decrease in the bone mass/mineralization, and a higher incidence of bone fractures
[19-21]. Notably, smoking duration was not associated with BMD in 1,054 subjects, including
26.2% of current smokers (n=276), 17.7% of former smokers (n=187), and 56.1% of never
smokers (n=591) [21].
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Figure 2. Strategies in the identification of genetic variants of osteoporosis and other complex diseases. Linkage studies
in families and sibling pairs refer to phenotyping members of extended families for the feature of interest (e.g., BMD).
The control study looks for the association of a marker allele with disease by comparison among unrelated subjects.
Experimental crosses in animals are performed to prove the findings from linkage and candidate gene studies.
3. Genes associated with BMD in monogenic skeletal diseases
Ever since Mendel first elucidated the concept of inheritance in the pea plant, genetic analyses
have used families, which often share similar genes, to study gene characteristics. With the
development of genomic technology, the discovery of genetic markers spanning the entire
human genome for Mendelian diseases and traits has been achieved after widespread mapping
efforts. Major monogenic skeletal disorders with OP that have been identified to date include
osteogenesis imperfecta, Bruck syndrome, osteopetrosis, high-bone-mass syndrome, osteopo‐
rosis-pseudoglioma syndrome, von Buchem disease, sclerosteosteosis, familial expansile
osteolysis, juvenile Paget’s disease, hypophosphatasia, neonatal hyperparathyroidism and
pyknodysostosis. These diseases affect BMD and can cause either high- or low-mass syndrome.
Although many pathogenic genes have been identified (Table 3), many do not qualify as
osteoporosis genes due to a lack of robustness. Low-density lipoprotein receptor-related 5
(LRP5) protein is a transmembrane low-density lipoprotein receptor which functions in
receptor-mediated endocytosis [22-24]. The LRP5 gene was identified as the cause of the
monogenic disease osteoporosis-pseudoglioma by mapping and candidate gene screening
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[22-24]. Inactivation of LRP5 leads to the suppression of mechano-responsiveness and reduces
bone mass and Young’s modulus in osteoporosis-pseudoglioma [25, 26]. Activation of LRP5
increases bone mass in osteosarcoma. Furthermore, population-based and cohort studies have
confirmed the significant association of LRP5 with BMD in Asian and European populations
[27-29]. Bone fragility and risk of fracture have been reported with the mutation of LRP5 in
families of affected patients. Patients with multiple thoracic vertebral fractures were confirmed
to have about two compound heterozygous missense mutations in LRP5 [30, 31]. Meta-
analyses and genome-wide studies carried out for separate large populations have revealed
consistency between LRP5 variants in BMD and fracture risk – this will be further addressed
in the next part. In addition to LRP5, low-density lipoprotein-related 4 (LRP4) protein was
identified as a candidate sclerostin interaction partner by an unbiased proteomics approach
[32]. The mutation of LRP4 has been reported to be associated with bone overgrowth by
impairing the sclerostin facilitator function.
AR AHSG ApoE BMP2 BGP CASR
CLCN7 COL1A1 COL1A2 CT CYR1B1 COMT
CYP1A1 CYP17 CTR CYP19 CCR2 DBP
DRD4 ERbeta ERalpha FRA-1 GH1 GnRH
HLA-A IL-6 LRP5 LRP4 LCT IL-1RA
LEPR IL-10 I-TRAF IRAK1 IGF-1 IGF-II
Klotho MMP-1 MGP MTHFR MMP-9 NPY
NCOA3 OSCAR OPG P57(KIP2) PON1 PDE4
PPARG PLDO1 PTHR1 PTH PDE4D QPCT
RIL RUNX2 Sox4 SERT SOST TNFalpha
TNFR2 TCIRG1 TGFbeta WRN
Table 3. Genes associated with BMD/osteoporosis. These genes are identified through association studies and correlate
with BMD and osteoporosis-related phenotype.
Vitamin D receptor (VDR) is one of the trans-acting transcriptional regulatory factors that
regulate proteins involved in bone mineral homeostasis. It has been reported that the poly‐
morphism of the third region of VDR is significantly associated with BMD, and the allelic
variation of this gene may contribute 75% of the genetic effect on BMD change [33]. Addition‐
ally, the polymorphism of the VDR gene, including Bsml, Apal, Fokl and Taq genotypes,
regulates BMD and is associated with OP [34-37]. VDR polymorphisms emerge in the rheu‐
matoid-related OP and the ApaI, BsmI and TaqI polymorphisms may be susceptible risk
factors for rheumatoid arthritis (RA). Interestingly, the Ff genotype may be responsible for
development of OP in RA [38, 39].
Type I collagen is a constituent major-bone protein, and the genes (COLIA1 and COLIA2) are
believed to be candidates for genetic control of BMD. The COLIA1 gene polymorphism is
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suggested to be implicated in reduced BMD and increased fracture incidence [40]. Mutations
in the two genes for type I collagen have been confirmed to cause osteogenesis imperfecta, and
are associated with OP in postmenopausal women [41, 42]. Population-based studies have
indicated that COL1A1 Sp1 polymorphism may contribute to the development of OP such that
Sp1 polymorphic variants of COL1A1 gene are associated with BMD values [43-46]. The “ss”
and “TT” genotypes possess lower lumbar-spine BMD [46].
The oestrogen-receptor gene encodes an oestrogen receptor (ESR), a member of the super‐
family of nuclear receptors that are involved in DNA and hormone binding and activation of
transcription. The ESR can interact with oestrogen and transcription factors including SP-1,
AP-1 and NF-κB. As oestrogens are important endocrine regulators in skeletal growth and
maintenance, oestrogen-deficient animals exhibit reduced BMD and oestrogen substitution
shows restored bone compartments [47-49]. One case of OP in a male patient was reported to
show an inactivating mutation of the ESR gene, which was parallel with the male knockout
mice with null alleles at the ESR locus [50]. However, inactivation of ESR alpha, specifically in
nervous tissue, the main ER for oestrogenic bone effects, causes increased BMD in mouse
trabecular and cortical bone [51]. Interestingly, ER alpha in osteocytes has been shown to play
an osteoprotective role in the trabecular bone formation, confirmed by tests on ER alpha-
deletion mice [52].
Although many genes have been identified in monogenic skeletal disorders connected to OP,
the linkage data have not been sufficiently robust due to sample size and significance. Studies
in OP genetics need to facilitate more powerful and more sophisticated approaches, such as
GWAS studies, to achieve the identification of OP heritable factors.
4. Genome-wide association study and BMD
Genome-wide association study (GWAS) aims to identify disease-associated loci called single
nucleotide polymorphisms (SNPs), which contribute to small variations of BMD in the
genome. If an allele of an SNP occurs significantly more or less frequently in people with a
particular disease than in people without the disease, the allele is associated with the disease
traits. Although previous linkage and candidate-gene studies have provided few replicated
loci for OP, genome-wide association approaches have produced clear and reproducible
findings.
Two SNPs, rs3736228 on chromosome 11 in the LRP5 gene and rs4355801 on chromosome 8
near the TNFRSF11B gene, were reported to cause risk of OP and osteoporotic fracture in 2,094
British women [53]. The rs3736228 in the LRP5 gene was identified to correlate with decreased
BMD in lumbar spine and femoral neck. The rs4355801 near the TNFRSF11B gene correlated
with decreased BMD for lumbar spine and femoral neck [53]. In a study of 583 postmenopausal
women, the polymorphism of three variants TNFRSF11B (rs4355801, rs2073618, and
rs6993813) and one of LRP5 (rs3736228) was further confirmed to be associated with BMD
variations [54]. In a prospective study of 37,534 subjects in Europe and North America, variants
of LRP5 (rs3736228, rs4988321) and one variant of LRP6 (rs2302685) were examined in terms
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of their effect on BMD and contribution to risk of fracture. The rs3736228 and rs4988321
variants of LRP5 were associated with reduced lumbar-spine BMD, femoral-neck BMD, and
fractures. The rs2302685 of LRP6 polymorphism was not associated with any OP phenotype,
including reduced BMD and fracture [55, 56]. This was further confirmed in a study of 944
postmenopausal Spanish women, where the rs2302685 variant of the LRP6 polymorphism was
not significantly associated with lumbar-spine or femoral-neck BMD [57]. LRP4 was also
analysed for SNP in cohort studies of European populations. One associated SNP of LRP4
(rs6485702) was significant in hip and whole-body BMD, modulated through the Wnt and
BMP signalling pathways [58, 59].
Other gene polymorphisms associated with changes in BMD included the Cerberus 1 (CER1)
gene, ADAM metallopeptidase with thrombospondin type 1 motif 18 (ADAMTS18), trans‐
forming growth factor beta receptor III (TGFBR3), high-mobility group (HMG), signal
transducer and activator of transcription 1 (STAT1), aldehyde dehydrogenase (ALDH), PTH,
and sperm-ion channel gene CatSper channel auxiliary subunit beta (CATSPERB). In a cohort
of 1,083 human subjects, one SNP (rs3747532) in human CER1 gene was reported to play a role
in the increased risk of low BMD in women prior to menopause and a vertebral fractures cohort
[60]. In an association test of 379,319 SNPs in 1,000 unrelated American white individuals,
ADAMTS18 and TGFBR3 were reported as BMD candidate genes in meta-analyses [61].
Additionally, individuals with normal skeletal fractures were different to individuals with
non-union skeletal fracture in the expression of both genes [61]. In two cohorts of 1,548
Caucasian American men and 1,680 Afro-Caribbean men, the rs1042725 of the HMGA2
polymorphism was reported to be associated with decreased tibia trabecular volumetric BMD
[62]. In a GWAS of 1,000 unrelated Caucasians, the STAT1 gene was significantly associated
with BMD variation and was upregulated in the low BMD group rather than the high BMD
group variation [63]. In a study of 700 elderly Chinese Han individuals (350 with hip osteo‐
porotic fracture and 350 healthy controls), one SNP, rs13182402, within the ALDH7A1 gene
on chromosome 5q31, was significantly associated with osteoporotic fractures [64]. This was
further examined in relation to the relevance of hip BMD in Caucasian and Chinese popula‐
tions (n=9,962), finding a consistent association with hip BMD [64]. The Interleukin 21 receptor
(IL21R) encodes a cytokine receptor for interleukin 21 that activates multiple downstream
signalling molecules, including STAT1, STAT3, JAK1 and JAK3. In a GWAS of 983 unrelated
white subjects, the polymorphisms of the PTH gene (rs9630182, rs2036417, and rs7125774) and
the polymorphisms of the IL21R gene (rs7199138, rs8061992 and rs8057551) were associated
with changed femoral-neck BMD [65]. The polymorphisms of CATSPERB (rs1298989,
rs1285635) were reported to be associated with femoral-neck BMD in 1,524 European-
American premenopausal women and 669 African-American premenopausal women [66]. In
particular, the rs1285635 in the European-American women was consistent with that in the
African-American women [66].
Furthermore, meta-analysis of GWAS has shown more candidate genes and BMD loci reaching
genome-wide significance. A meta-analysis of 19,195 Northern European subjects from five
GWAS revealed nine genes from 150 identified genes associated with changed BMD: TNFSF11,
TNFRSF11A, TNFRSF11B, LRP4, LRP5, ESR1, SPP1, ITGA1, and SOST [67]. Additionally, 13
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Furthermore, meta-analysis of GWAS has shown more candidate genes and BMD loci reaching
genome-wide significance. A meta-analysis of 19,195 Northern European subjects from five
GWAS revealed nine genes from 150 identified genes associated with changed BMD: TNFSF11,
TNFRSF11A, TNFRSF11B, LRP4, LRP5, ESR1, SPP1, ITGA1, and SOST [67]. Additionally, 13
Advances in Osteoporosis26
new BMD loci were identified and included: 1p31.3 (GPR177), 2p21 (SPTBN1), 3p22
(CTNNB1), 4q21.1 (MEPE), 5q14 (MEF2C), 7p14 (STARD3NL), 7q21.3 (FLJ42280), 11p11.2
(LRP4, ARHGAP1, F2), 11p14.1 (DCDC5), 11p15 (SOX6), 16q24 (FOXL1), 17q21 (HDAC5) and
17q12 (CRHR1) [68]. In a meta-analysis of 18,098 subjects from six European-descent popula‐
tions and an Asian population, rs2273061 of the Jagged1 (JAG1) gene was identified to be
associated with BMD for lumbar spine and for femoral neck. The JAG1 gene therefore becomes
a new candidate gene in the regulation of BMD and a new risk factor for bone-fracture
pathogenesis [69]. In a meta-analysis of GWAS based on 3,657 Caucasian men and 7,633
Caucasian women, two genes and three new loci were identified as associated with OP-related
traits and BMD in women, including SOX6, GPR177 gene, 2q11.2 (TBC1D8), chromosome
1p13.2 and 18q11.2 (OSBPL1A) [70]. A meta-analysis of GWAS data from European and
Chinese individuals identified further genes associated with changed BMD located at 1q21.3,
9q22, 9q33.2, 20p13, and 20q12. This significantly correlates with the development and
functionality of muscle, skeleton and connective tissue [71]. In a meta-analysis of 17 GWAS
based on 32,961 subjects of East-Asian and European ancestry, 32 new loci were associated
with BMD at genome-wide significance and were localized in 1q24.3, 2p21, 2q13, 2q14.2,
3q13.2, 3q25.31, 4p16.3, 6p21.1, 6p22.3, 7q31.31, 7q31.31, 7q36.1, 8q13.3, 9q34.11, 10p11.23,
10q21.1, 10q22.3_1, 10q24.2, 11p14.1_1, 12p11.22, 12p13.33, 12q13.12, 12q23.3, 14q32.12,
16p13.11, 16p13.3_1, 16p13.3_2, 16q12.1, 17p13.3, 17q24.3, 18p11.21, 19q13.11 and Xp22.31 [72].
Moreover, in a meta-analysis of 27,061 individuals, two new loci were of genome-wide
significance: 14q24.2 (rs227425, SMOC1) in the whole sample and 21q22.13 (rs170183,
CLDN14) in the female-specific sample. These were also shown to be significant in the results
of the GEnetic Factors for Osteoporosis Consortium (GEFOS, n = 32,960) [73].
Thus, GWAS has been successfully used in uncovering key genes or markers associated with
OP in humans and animals. Although it has confirmed the existence of relevant SNPs associ‐
ated with changed BMD and the risk of OP, GWAS still cannot be absolutely accurate in the
prediction of OP.
5. Genome-wide copy-number variants study and BMD
The first large-scale genome-wide studies of copy-number variants (CNVs) in humans were
performed about a decade ago, and CNVs now make a larger contribution to genome varia‐
tions than SNPs [74, 75]. Recent studies have focused on CNVs that may modulate gene
function and affect disease risk. CNVs are structural genetic variants in the genome that alter
the number of copies of one or more sections of DNA. This corresponds to large regions of the
genome with deletion or duplication on certain chromosomes, and results in phenotypic
variation.
Although CNV has been reported to correlate with many complex human diseases, the
contribution of CNV to OP has not been revealed yet. A Chinese study of 700 elderly patients,
comprising 350 individuals with homogeneous hip osteoporostic fracture and 350 control
individuals, reported that CNV 4q13.2 significantly correlated with osteoporostic fracture
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(P<0.0002). Additionally, a variant of UGT2B17 in CNV 4q13.2 was further proven to correlate
with hip osteoporostic fracture in both white (1000 individuals) and Chinese (689 individuals),
with consistently significant results (P=0.0005-0.021) [76].
Another genome-wide study of 1,000 Caucasian individuals found that a CNV in VPS13B gene,
encoding a potential transmembrane protein involved in vesicle-mediated transport, was
significantly associated with hip, spine and femoral-neck BMD. Interestingly, individuals with
two copies of the CNV in the genome exhibited a higher level of BMD in the hip, spine and
femoral neck, compared with one-copy subjects [77].
Another genome-wide CNV study tested 5,178 subjects in a prospective cohort in the Neth‐
erlands. It identified 210 kb deletion located on chromosome 6p25.1 that correlated with the
risk of fracture (P=0.0000869). This deletion has geographic specificity, not affecting the
populations of Australia, Canada, Poland, Iceland, Denmark, or Sweden. It has been found
and is prevalent in Ireland (0.06%), England (0.15%), USA (0.23%), Scotland (0.10%), and Spain
(0.33%), with insufficient significance of fracture risk. However, the role of the 6p25.1 locus in
the prediction of risk of bone fracture needs to be tested in a larger and more diverse population
to confirm the findings [78].
A study on 2,286 Caucasian individuals, and replicated in 1,627 Chinese individuals, identified
two CNVs (CNV2580 and CNV1191) that correlated with appendicular lean mass (ALM), the
main component of skeletal muscle. CNV1191 resides in the gene encoding GTPase of the
immunity-associated protein family (GIMAP1), and is significantly associated with ALM
(P=0.0226). CNV2580 is localized in the serine hydrolase-like protein (SERHL) gene and is also
significantly associated with ALM (P=0.00334). Both genes are important for skeletal-muscle
growth and may be relevant to OP. Although the two new CNVs are responsible for variation
in ALM, more evidence is required to confirm their significance in relation to OP [79].
Therefore, the use of CNV-based GWAS in relation to OP is a cutting-edge technology and
strongly supports the importance of CNV in the pathogenesis of OP. Although the results in
this area are well established, it is necessary to focus on the association between classical
genotypes, and actual experimentation is needed for validation. Additionally, high-through‐
put, sophisticated genotyping approaches for CNVs need to be optimized for further genetic
screening.
6. Conclusion
OP is one of the most common diseases and is becoming more prevalent with the ageing of
the world’s population. BMD is the hallmark of OP and exhibits high heritability; efforts to
understand OP genetic determinants have therefore been increased. OP represents a paradigm
where the effects of multiple genetic factors dominate the phenotype. Although monogenic
approaches that identify genes by rare mutations have contributed to the understanding of
OP, the genetic background of OP is characterized by polymorphisms and variations in
multiple genes; more-powerful and high-throughput technologies are needed to analyse these
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(P<0.0002). Additionally, a variant of UGT2B17 in CNV 4q13.2 was further proven to correlate
with hip osteoporostic fracture in both white (1000 individuals) and Chinese (689 individuals),
with consistently significant results (P=0.0005-0.021) [76].
Another genome-wide study of 1,000 Caucasian individuals found that a CNV in VPS13B gene,
encoding a potential transmembrane protein involved in vesicle-mediated transport, was
significantly associated with hip, spine and femoral-neck BMD. Interestingly, individuals with
two copies of the CNV in the genome exhibited a higher level of BMD in the hip, spine and
femoral neck, compared with one-copy subjects [77].
Another genome-wide CNV study tested 5,178 subjects in a prospective cohort in the Neth‐
erlands. It identified 210 kb deletion located on chromosome 6p25.1 that correlated with the
risk of fracture (P=0.0000869). This deletion has geographic specificity, not affecting the
populations of Australia, Canada, Poland, Iceland, Denmark, or Sweden. It has been found
and is prevalent in Ireland (0.06%), England (0.15%), USA (0.23%), Scotland (0.10%), and Spain
(0.33%), with insufficient significance of fracture risk. However, the role of the 6p25.1 locus in
the prediction of risk of bone fracture needs to be tested in a larger and more diverse population
to confirm the findings [78].
A study on 2,286 Caucasian individuals, and replicated in 1,627 Chinese individuals, identified
two CNVs (CNV2580 and CNV1191) that correlated with appendicular lean mass (ALM), the
main component of skeletal muscle. CNV1191 resides in the gene encoding GTPase of the
immunity-associated protein family (GIMAP1), and is significantly associated with ALM
(P=0.0226). CNV2580 is localized in the serine hydrolase-like protein (SERHL) gene and is also
significantly associated with ALM (P=0.00334). Both genes are important for skeletal-muscle
growth and may be relevant to OP. Although the two new CNVs are responsible for variation
in ALM, more evidence is required to confirm their significance in relation to OP [79].
Therefore, the use of CNV-based GWAS in relation to OP is a cutting-edge technology and
strongly supports the importance of CNV in the pathogenesis of OP. Although the results in
this area are well established, it is necessary to focus on the association between classical
genotypes, and actual experimentation is needed for validation. Additionally, high-through‐
put, sophisticated genotyping approaches for CNVs need to be optimized for further genetic
screening.
6. Conclusion
OP is one of the most common diseases and is becoming more prevalent with the ageing of
the world’s population. BMD is the hallmark of OP and exhibits high heritability; efforts to
understand OP genetic determinants have therefore been increased. OP represents a paradigm
where the effects of multiple genetic factors dominate the phenotype. Although monogenic
approaches that identify genes by rare mutations have contributed to the understanding of
OP, the genetic background of OP is characterized by polymorphisms and variations in
multiple genes; more-powerful and high-throughput technologies are needed to analyse these
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aspects. Recent genetic studies in OP have facilitated the understanding of the aetiology of OP.
The discovery of novel genetic factors through the use of genome sequencing will contribute
to understanding the modulation of BMD and bone fragility with potential therapeutic targets.
Combined with behavioural and environmental factors, findings in genetic studies can be
validated and used in the development of clinical treatments of OP worldwide. There is no
doubt that genetic tests have achieved significant progress in bone biology and are likely to
become even more important within the next decade. To optimize accuracy, we should
highlight elements including careful phenotyping, sophisticated study design, adequately
powered cohorts, and multi-collaboration in future research.
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1. Introduction
1.1. Homocysteine and leptin in the pathogenesis of osteoporosis: evidences, conflicts and
expectations
1.1.1. Osteoporosis
Osteoporosis is a metabolic bone problem, also recognized as “the silent thief” because there
is slow bone loss, generally occurs over the years, and without any symptoms until the bone
becomes so brittle that suddenly fracture occurs. Osteoporosis is the most common disorder
related to age [1]. It is a leading cause of fractures in old age: causing pain, affliction, hospi‐
talization, financial burden, poor life quality leading to early death [2]. Osteoporosis is usually
considered a normal part of the ageing process and an unavoidable consequence of growing
older. However, osteoporosis is a detectable, preventable, and treatable disease.
1.1.2. Types of osteoporosis
Two types have been identified
• Primary osteoporosis.
◦ Type I also called postmenopausal osteoporosis, occurs after menopause when the
estrogen levels drop in the body. It typically involves the trabecular bone.
◦ Type II also called senile osteoporosis, takes place after 70 years of age, involving both
trabecular and cortical bone.
• Secondary osteoporosis.
◦ It is due to the effect of medications like steroids or certain medical conditions.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
1.1.3. Epidemiology
In postmenopausal females, osteoporosis has an enormous social and economic burden. With
increasing age, the risk of osteoporotic fractures increases. There are about two million cases
of fractures in the USA per year and out of them, there are about three hundred thousand hip
fractures. The fractures and resultant health consequences have led to mortality rate up to 24%
in women [3].
International osteoporosis foundation has estimated that globally osteoporosis affects one in
three women and one in eight men above 50 years of age [4].
1.1.4. Pathogenesis
Osteoporosis develops when there is imbalance between the processes of bone resorption and
bone formation. Osteoclasts (bone resorbing cells) eradicate bone by acidification and proteo‐
lytic digestion and osteoblasts (bone forming cells) secrete osteoid into the resorption cavity
[5]. The normal cycle of bone turnover is needed for bone and maintenance of proper bodily
functions. Each year 10 to 30% of the skeleton is remodeled in this way, and many hormones
and chemical factors regulate this process and any change in these factors can manipulate the
progress of osteoporosis. These influencing factors are estrogen, vitamin D, leptin, homocys‐
teine, parathyroid hormone, testosterone, and blood factors involved in cell growth [6].
The bone turnover is perfectly balanced until the age of forty years. Nevertheless, old age,
many diseases and medicines can disturb the balance, ultimately the breakdown process
exceeds the bone formation, and as a result, trabecular plates of bone are destroyed causing
weakness of the structure of bone with greatly reduced bone mass. Bone strength is a sign of
the integration of bone quality (rate of bone remodeling, trabecular connectivity, degree of
mineralization, and damage accumulation) and bone mineral density (BMD) [7]. There is
doubling in the bone remodeling rate at menopause, becomes triple within 13 years of
development of menopause and remains high till the development of osteoporosis. In
osteoporosis, the trabecular bone loss is more as compared to cortical bone (50% as compared
to 5%) and it occurs more swiftly in first 3-4 years after menopause [6].
1.1.5. Risk factors
It is a multifactorial disease including both modifiable and non-modifiable risk factors.
Numerous factors are involved and augment the risk of developing osteoporosis [8-10].
• Non-modifiable risk factors
◦ Increasing age
◦ Female gender
◦ Caucasian and Asian women and men
◦ Small, thin-boned women
◦ Maternal history of osteoporotic fracture
◦ Deficiency of estrogen
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• Modifiable risk factors
◦ Smoking
◦ Excessive alcohol consumption
◦ Sedentary lifestyle over many years
◦ Diet deficient in calcium




Homocysteine (Hcy) is produced from the methionine metabolism, it is a sulfur-containing,
nonproteinogenic amino acid (figure 1) [11]. Methionine, itself is a sulfur containing amino
acid obtained from proteins of animal origin. It is metabolized in the body by either remethy‐
lation or transsulfuration pathway as shown in the figure 2. Both genetic (methylene tetrahy‐
drofolate reductase or cystathionine β synthase polymorphisms) and environmental (age,
renal function, B vitamins status) factors affect the plasma homocysteine concentration [12].
Figure 1. Structure of Homocysteine
2. Hcy and bone metabolism
Hyperhomocysteinemia (HHcy) is the elevated levels of total plasma Hcy. Generally, the Hcy
level <15 μmol/L is considered normal but an increased plasma Hcy level (>15 μmol/L) is
common in about 30–50% of elderly people (>60 years)[13]. There are multifactorial contribu‐
ting factors like, a combination of genetic and environmental factors, lifestyle, diet, and
hormonal factors might play a key role [14]. In addition, of being a known potent thrombogenic
compound, [15] it has been proposed as a new risk factor for primary osteoporosis [16-18].
Like osteoporosis, HHcy is a frequent age related issue in aged people [19-20]. In old age,
deficiency of vitamin B-12 and folate is common, and the prevalence of both vitamin deficien‐
cies increases with age. Deficiency of either folate or vitamin B-12 results in increased tHcy
levels because vit B12 acts as a cofactor for methionine synthase, the enzyme that remethylates
homocysteine to methionine by using 5methyltetrahydrofolate as a methyl donor [20].
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Ozdem  et  al.,  (2007)  reported  that  experimental  hyperhomocysteinemia  disturbs  bone
metabolism  in  rats.  They  found  that  rats  fed  with  a  methionine‐enriched  diet  had  in‐
creased bone resorption markers (hydroxyproline & N‐terminal collagen I telopeptides) and
decreased bone formation marker (osteocalcin) [21]. Additionally, chronic HHcy may take
part  an  imperative  role  in  the  development  of  arterial  and  venous  thrombosis,  senile
osteoporosis,  presbyopia  and  cognitive  decline.  These  diseases  are  usually  common  in
elderly [22]. An inverse correlation of total homocysteine (tHcy) concentrations with BMD
has been documented by several reports, especially in postmenopausal women, and HHcy
has been labeled as a modifiable risk factor for osteoporotic hip fracture [16-17, 23-26], while
several other studies could not establish any correlation [27-29]. Similarly, an Italian study
showed an inverse association of plasma concentration of tHcy with BMD of the total femur
in  post-menopausal  women  and  the  study  concluded  that  it  is  independent  of  other
recognized reasons of bone mineral loss, such as reduced BMI and old age [30]. Recently, in
Pakistan, we investigated correlation of serum Hcy with BMD in postmenopausal osteopor‐
otic females but could not find any correlation [31]. It has been reported that increased Hcy
levels, decreased vitamin B12, and folate status have been related with reduced BMD and
increased  fracture  risk  and  thus  serum  Hcy  level  can  be  used  as  an  indicator  of  such
micronutrient insufficiencies [16-17, 25, 27].
Herrmann et al., (2007) provided the first evidence regarding effects of chronic HHcy on bone
quality in rats. In this study, healthy adult rats displayed reduction in bone strength in
BHMT: betaine-homocysteine methyltransferase DMG: dimethylglycine vitamin B6: pyridoxyl phosphate CBS: cysta‐
thionine beta-synthase vitamin B12: cobalamine MS: methionine synthase THF: tetrahydrofolate MTHFR: 5,10-meth‐
ylenetetrahydrofolate-reductase
Figure 2. Homocysteine metabolism
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cancellous bone as reflected by biomechanical testing and histomorphometry, after 3 months
of HHcy. The study did not explain the main mechanism behind this result [32]. Few mecha‐
nistic studies recommended that Hcy excites osteoclasts and causes disproportion between
osteoclasts and osteoblasts in support of the osteoclasts, which are the main bone resorbing
cells [33-36]. Furthermore, it appears that a number of extracellular mechanisms are also
implicated. A study exhibited a reduced level of enzymatic cross-links in the bones of hyper‐
homocysteinemic female fracture patients that indicates impaired collagen cross-linking [37].
A study reported that in hyperhomocysteinemic animals, Hcy is deposited in bone tissue that
causes considerable bone loss and consequently decreased bone strength [38].
3. Hcy and bone interaction: conflicts and evidences
During last few years, abundant literature has been published about the interaction of HHcy
and bone. Up till now, several mechanisms have been proposed about the involvement of Hcy
in bone pathology. HHcy is an emerging, but still non established, modifiable risk factor for
osteoporotic fractures [39].
An elevated level of Hcy has been proposed as a new threat for primary osteoporosis [16-17].
Tyagi et al., 2011 in their study concluded that Hcy may cause reduced blood flow in bone as
it stimulates the atherogenic process, promotes platelet adhesion and has also been recognized
as a potent thrombogenic compound that might contribute to compromised bone biomechan‐
ical properties [40].
A prospective population-based study, reported that the highest quartile of tHcy was related
with a two-fold augmented risk of fracture, and the relationship was continuous and there was
30% increased fracture risk with each standard deviation raise in tHcy [17]. Recently, a study
by Enneman (2014) reported inverse correlation of plasma homocysteine levels with BMD [41].
In the early years of Hcy and bone research, it seemed that Hcy directly affects biomechanical
properties because deposition of Hcy in bone coupled with a decrease in cancellous bone. A
study suggested that deficiency of B12, folate and vitamin B6 elevates the plasma level of tHcy
[35]. Another study found that the interaction of tHcy molecule with protein (collagen) in bone
matrix takes place through thiol group and an amino group. This study also demonstrated
that bone strength is reduced because most of the tHcy (65%) attaches with collagen [38].
A study proposed four mechanisms by which modification in bone remodeling takes place by
tHcy: (i) enhancement in osteoclastic activity, (ii) reduction in osteoblastic activity, (iii)
reduction in blood flow in bone, (iv) direct interaction of Hcy and bone matrix [42].
A study illustrated that tHcy inhibits lysyl oxidase, thus interferes with post-translational
changes of collagen and this leads to decrease in bone quality [43]. The tHcy stimulated
interleukin-6 (IL-6) production in osteoblasts, affects metabolism of bone by osteoclast. Janus
kinase 2 (JAK2), DNA (cytosine-5) – methyltransferase 1 (DNMT1) stimulate IL-6, which affects
bone matrix formation [44]. A study documented that the skeleton and muscles movements
reduce tHcy level and this link was not dependent on vitamin supplements, vegetables and
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fruits intake. Thus, it was suggested that levels of tHcy are also mainly affected by physical
activity, though, nutritional condition also contribute significantly [16]. Thus, it seems that,
regular exercise may decrease the Hcy level in HHcy individuals while it may help in main‐
taining Hcy level in normal subjects.
A study observed that the maximum tertile of tHcy was related with a higher hip BMD loss
over 4 years (-2.8%) compared to middle (-1.6%) and lowest tertiles (-1.2%) in elderly women
(age ranges from 70 to 85 years). It was stated that the incidence and prevalence of fractures
were not affected by elevated tHcy levels, but the augmented tHcy level is related with
considerable hipbone loss in aged subject [45].
No association of fracture risk with tHcy in the highest quartile was shown in a study after
adjustment for age but without adjustment of age risk was higher. They described that tHcy
level could be modulated by nutritional conditions, renal failure and physical activity [46]. An
animal study demonstrated that HHcy causes impairment in fracture repair. In their study, a
closed femoral fracture was induced in mice after feeding them Hcy for 3 weeks, and biomechan‐
ical parameters were monitored after 4 weeks of healing. They found that hyperhomocysteine‐
mic rats with fracture have reduced bending rigidity of femora and smaller callus diameter with
no change in tissue composition and consequently it impaired fracture repair and reduced bone
quality [47].
First clinical evidence about the relationship of HHcy and fracture risk came from the longi‐
tudinal study in healthy participants of different age groups of both genders [48]. The results
showed that HHcy levels are the independent risk factor for the future worsening of bone mass
in premenopausal women and men. Conversely, they could not find same results in postme‐
nopausal women (PMW). It was suggested that, even if a high serum tHcy level in postme‐
nopausal women is not a factor related to the reduction in BMD, so it is likely that HHcy may
be implicated in the fractures risk in PMW via some other method not involving BMD.
It is known that in the regulation of osteoblasts function, estrogen receptors play important
role and this phenomenon is particularly important after menopause in women [49]. Aaron et
al., (2009) probed the link of tHcy levels and methylation of estrogen receptor α. Their data
pointed out that tHcy can support hypermethylation of promoter A region, by this means
decreases transcription of estrogen receptor α mRNA. It was anticipated that in the patho‐
genesis of postmenopausal osteoporosis it could be a probable mechanism. Therefore, an
estrogen receptor mediated role of tHcy may cause worsening in biomechanical bone charac‐
teristics. Additionally, higher levels of Hcy lead to down regulation of estrogen receptor
transcription in bone and other useful osteogenic effects turn out to be down regulated [50].
A study tried to devise some likely therapeutic options for reducing increased plasma levels
of tHcy that may cause damaging effect on bone. They used strontium ranelate 2 g/day to
lessen increased plasma levels of tHcy because such material found to extensively reduce tHcy
concentrations in osteoporotic women and was suggested to be employed as a mean to lessen
fracture risk by reducing tHcy levels [51]. Strontium ranelate was selected because of its
recognized positive outcome of lessening resorption of bone and supporting bone construc‐
tion. It is not unlikely that decrease in levels of tHcy is accountable for permitting the recog‐
nized effects of strontium ranelate to happen [52].
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It  is  suggested that if  changed bone biomechanical characteristics are result of increased
Hcy and hormone replacement therapy (HRT) is recognized to ameliorate quality of bone,
it was assumed that HRT would ameliorate quality of bone by reducing tHcy concentra‐
tion. But the researcher could not confirm this effect of HRT on Hcy in postmenopausal
osteoporotic women [53].
A study in hip arthroplasty patients because of osteoarthritis, tried to investigate the link of
serum tHcy levels with osteoarthritis. But this study could not establish any noteworthy
association of tHcy levels with biomechanical or morphological bone characteristics as
evaluated by histomorphometry and DEXA [54]. Bayhan et al., (2009) demonstrated that
elevated tHcy levels appear to influence bone quality and fracture risk, but there have been
no distinguishing alterations in bone density [51].
The Hcy impairs the cross-linking of collagen and for the solidity and potency of the collagen
network, these cross-links are essential. Any meddling in cross-link formation would there‐
fore, affect the quality of bone matrix, which in turn causes the fragility of bones due to
defective collagen formation but would not affect BMD, which is the representative of bone
mineralization only [37]. It was found in an animal study that elevated levels of Hcy for three
months increase femoral neck fragility by 18% in methionine-fed rats, and two-fold in Hcy-
fed rats. Lumbar spine and femoral neck also demonstrated reduce biomechanical character‐
istics, however, more in methionine- versus Hcy-fed rats [32].
Recently, a meta-analysis by Zhong et al., (2014) suggested that vitamin B12 and Hcy levels
were considerably elevated in postmenopausal osteoporotic (PMOP) group compared to
controls and these were linked with BMD in PMOP [55].




Reducing OPG and elevating RANKL production in osteoblast [58]
Moderate stimulation of osteoblast activity but predominant effect on
osteoclast [35]
Osteoclast Increase activity
Shift the OPG:RANKL ratio in favour of elevated osteoclast activity
and reduced bone quality by altering the redox regulatory system in
the osteoblast [40, 58]
Bone matrix Degradation
Reduction in bone blood flow [40]
Activation and amplification in matrix metallo-proteinases through
generation of ROS [59].
By inhibiting enzyme of collagen cross-linking (lysyl hydroxylase and
lysyl oxidase) thus directly manipulate the stable bone matrix
formation [44, 60].
Osteocalcin Inhibit secretion Suppress the expression of OC mRNA [61]
Osteopontin Activated By enhancing the expression of osteopontin mRNA (6).
OPG osteoprotegrin, RANKL receptor activator of nuclear factor-κB ligand, Hcy Homocysteine, ROS reactive oxygen
species, MAPK Mitogen-activated protein kinases, OC osteocalcin mRNA messenger ribonucleic acid.
Table 1. Effect of Homocysteine on different Bone components
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A meta-analysis provided a proof on homocysteine and fracture risk, displaying that HHcy
augments the fracture risk [56]. A very important evidence of effect of HHcy on fracture risk
was provided by another meta-analysis including more than ten thousand subjects, demon‐
strated 4% augmented risk of fracture by per μmol/L raise in Hcy level [57].
3.1. Expectations
In spite of substantial evidence that indicating the direct damaging role of HHcy on bone
metabolism, the role of serum tHcy in bone loss is still unclear. HHcy can be reduced by vit
B12, and folate therapy, so by designing randomized controlled trials (RCTs) of B-vitamins vs.
placebo, it is quite likely to establish whether tHcy is a contributory risk factor for bone fracture
or not [62].There are few RCTs available in literature but because of various reasons these are
not up to the mark.
Based on evidences, provided in the literature, it seems that HHcy may have negative role in
bone metabolism generally and in the process of osteoporosis particularly. However, more
interventional studies are required to confirm the unfavorable role of HHcy, particularly in
subjects who are at the risk of developing low bone mass. It is suggested that there is a need
to develop several multicenter, well-designed trials on determining the effects of Hcy-lowering
treatment on the prevention and/or management of osteoporosis. These longitudinal trials
would determine the accurate nature of Hcy and bone interaction and that will establish the
outcome of different bisphosphonate therapies on Hcy levels in treating osteoporosis.
4. Leptin
Adipose tissue is the largest endocrine organ in the human body; it serves considerable role
in the energy homeostasis and several metabolic processes. It also has a multifaceted associa‐
tion with the bone. It is a general phenomenon that with increasing age the fat tissue in the
bone marrow increased while the bone mass decreased. It is because both the osteoblast and
adipocyte are developed from the same cell lineage the mesenchymal stromal cells (MSCs).
The segregation tendency to preadipocytes or preosteoblasts is competitive and being
inhibited by each other. Nevertheless, published literature advocates that through adipokines,
adipose tissue have intricate effects on bone metabolism [63]. The family of adipokines,
including leptin, adiponectin, chemerin, resistin, omentin, visfatin and vaspin, take part in
several physiological, biochemical and pathological processes, including, the glucose and lipid
oxidation, energy expenditure, immunity, reproduction, inflammation, and others. Because of
growing evidences regarding interaction of adipokines and bone metabolism, the researchers
are paying special attention to their relationship.
Leptin is a diverse 16 kDa peptide hormone, which belong to the family of helical cytokine
with lengthy chain (figure 3) [64]. Leptin is an important member of adipokine family that
helps in regulation of food intake, energy homeostasis, reproduction, metabolism, immune
function, bone physiology, tissue remodeling, neuroendocrine function and others [65].
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Research has shown that leptin plays significant role in the regulation of body weight and
BMD. Experimental evidence in mice showed that they appeared obese and have increased
bone density when they were congenitally absent in leptin (ob/ob), indicating that leptin has
a role in loss of bone density as well as fatty tissue [66].
Figure 3. Leptin structure [64]
In a study, leptin replacement demonstrated the improvement of abnormalities in ob/ob mice
in the form of decreasing food intake, energy loss, and temperature of body, infertility and
immune function [67]. Since then, the knowledge which has been obtained from various
studies indicating that leptin is not only important in control of body weight but also play
imperative role in angiogenesis, hematopoiesis, blood pressure, immune function, lymphoid
organ homeostasis, T lymphocyte systems, fertility, and bone formation [68].
Leptin is produced primarily from adipocytes according to adipose tissues quantity in the
body. Brown fat tissue, stomach, placenta, ovary, bone marrow, liver, pituitary and mammary
epithelial cells also secrete leptin [69]. Researchers observed that leptin is encoded by ob gene
(LEP) (ob - obese and LEP - Leptin), according to the name that was first proposed, ‘leptos’,
derived from the Greek word meaning thin, as ob protein is considered to be one of the
molecules that regulates energy balance in mice [70].
4.1. Leptin receptor
Leptin’s receptors were first isolated by cloning from mouse choroid plexus, these receptors
belong to the cytokine family. There are six leptin receptors, which are divided into secretory
(ob-Re), long (ob-Rb), and short forms (four short form receptors) [71-72]. The molecular
receptor structure of the leptin and helical cytokine (class I) is similar. These homodimer
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receptors are able to activate the Janus kinase (JAK), and JAK is capable of starting as an
activator of STAT – signal transducer and activator of transcription (Figure 4) [73]. Leptin
signals through the activator system of JAK transcription, are associated with the form obRb
(isoform long form) that would alter the expression of hypothalamic neuropeptides [74-75].
The ob-Rb is found in high levels in the hypothalamic nuclei [71] and its activity helps in
mediating signal transduction by leptin in the hypothalamus, while the other leptin receptor
activity (short form) is not strong enough in the functioning of leptin [72].
Figure 4. Leptin receptor [73]
4.2. Leptin and bone interaction: conflicts and evidences
Bone mass has been said to be regulated by leptin. The interaction of leptin with bone is
multifaceted, related with location of bone. It also depends on the fact that whether leptin
has  a  direct  action  on  osteoblasts  through  receptors  or  it  acts  indirectly  through  the
hypothalamus,  it  has  the  ability  to  both  stimulate  and  inhibit  bone  formation  [76-79].
Reduction in serum leptin levels are linked with decreased intake of food that might results
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in reduction in formation of bone and growth especially in children and adolescence [80-81].
In mice, lack of leptin also causes loss of bone and increased adiposity in bone marrow [82].
Leptin’s enhanced levels and bone mass are associated with each other in obesity [83]. Leptin
instead of  supporting adipocyte  phenotype of  bone marrow stromal  cells  (BMSCs)  sup‐
ports osteoblast demonstrated by in vitro studies [78, 84-85]. Similarly, in vitro studies have
demonstrated that  in  ovariectomized rats  there was reduction in bone loss  and suspen‐
sion of tail after leptin treatment [86-87].
A study in Caucasian woman demonstrated that serum leptin had an inverse relationship with
BMD, another study observed a positive connection [88-89]. A large-scale study established
that serum leptin has no association with BMD [90]. Similarly, in another study no relation
established between leptin and BMD [91]. Furthermore, it was suggested that leptin might be
a forecaster of BMD in females with low BMD [92]. Recently, in Pakistan, we investigated
correlation of serum leptin with BMD in postmenopausal osteoporotic females but no rela‐
tionship was found [31].
In vitro data shows that serum leptin supports the segregation and development of the
osteoblast lineage cells and controls development of osteoclast [92-93]. Some clinical data have
shown an inverse relationship between bone resorption markers and serum leptin concentra‐
tions in postmenopausal women [89, 94] while other found a negative relationship [95-96].
Recently, Scotece et al., (2014) described that leptin level could be a valuable risk marker for
osteoporosis [97]. A study by Suh et al., (2013) found that changes in serum osteocalcin were
linked with leptin levels. It seems that there is connection between adipose tissue and bone
[98]. On the other hand, Mohiti-Ardekani et al., (2014) reported that there is no correlation of
circulating leptin concentrations with BMD and bone biochemical markers including osteo‐
calcin [99].
4.3. Indirect role of leptin in bone metabolism
Leptin has both direct and indirect effects on bone. Indirect mechanisms have been revealed
by experimental studies in mutant rats and mice that cannot synthesize leptin or do not have
receptors for it. Leptin is carried across the blood brain barrier (BBB) by special receptors, which
are located on the endothelial cells, the obRa receptors. In the brain leptin binds with obRb
receptors which are located in hypothalamus and activates them. Binding of leptin with its
receptors stimulate the expression of a hypothalamic osteoblast inhibitory factor (HOBIF) that
lowers the ability of osteoblast to make bone matrix [76-77, 100-101]. And because of this
mechanism, obese ob (Lep)–/– mice, due to lack of leptin have an unusually elevated bone
mass.
Leptin stimulates bone formation via beta-1-adrenergic receptors and stimulation of the
somatotropin-IGF-1 system [102]. Leptin inhibits activity of osteo-catabolic neuropeptide Y
(NPY) and stimulates activity of osteo-anabolic systems, such as cocain and amphetamine-
regulating transcript, via hypothalamic relays [103]. Moreover, leptin suppresses bone
formation through beta-2-adrenergic receptors located in bone and inhibits serotonin produc‐
tion in the brain that result in loss of trabecular bone formation [104].
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4.4. Direct role of leptin in bone metabolism
This is achieved by directly inhibiting the BMSCs to generate osteoclast while stimulating them
to differentiate into osteoblasts [84, 93]. The BMSCs can be discriminated mainly into adipo‐
cytes or osteoblast cell family. These adipocytes in bone marrow provide leptin, which is able
to inhibit adipogenesis discrimination of BMSC. It can excite discrimination of osteoblasts [84]
while another study have pointed out that extremely elevated level of leptin causes apoptosis
of BMSCs. A study reported that human osteoblasts, can begin producing and secreting leptin
in the delayed matrix-mineralizing stage or shifting to osteocytes [85]. Proliferation of cultured
human osteoblasts is also stimulated with leptin and it causes human BMSCs to express
collagen-I, osteocalcin & alkaline phosphatase, and matrix mineralization [84,105]. These in
vitro studies demonstrated that effects of leptin are dual in the microenvironment of bone and
it also depends on presence of the leptin levels locally.
In the last decade, researchers proposed leptin to be a strong inhibitor of synthesis of bone
because they could not find that osteoblast have long isoforms of the leptin receptors (ob-R)
[76, 100]. In hypothalamus, and in many peripheral tissues expression of a large number of
long isoform of ob-R have been confirmed [69].
Leptin receptors are also expressed by BMSCs, osteoblasts, osteoclasts and chondrocytes [84].
The signaling pathway in osteoblast, by which leptin acts, is osteoprotegerin (OPG)/RANKL
(Receptor Activator for Nuclear factor κB Ligand). There was alteration found in the OPG/
RANKL expression profile after treatment with leptin [93]. Burguera et al., (2001) have also
established that bone loss in ovariectomized rats is reduced by elevating osteoprotegerin
mRNA in osteoblasts [87].
For verifying the central effect, infusion of leptin was given into the brain and it was found
that leptin also inhibits the bone formation through central nervous system. One important
finding was that the lower doses inhibited the bone formation as compared to the doses which
was essential for the loss of body weight [100-101]. It was observed in the experimental ob/ob
mice that this central effect is due to activation of sympathetic part of autonomic nervous
system. This activation of sympathetic system by leptin is very important in controlling energy
homeostasis and numerous physiological functions [100].
In mice, food restriction decreased longitudinal growth and bone mass, but administration of
leptin restored skeletal growth, in spite of low energy intake and raised serum osteocalcin, that
is a bone formation marker [106].
In patients of hypothalamic amenorrhea, who have relative leptin deficiency, recombinant
leptin treatment improves markers of bone formation [107]. It seems that leptin affects bone
centrally through the sympathetic nervous system, which is a main downstream mediator
[108]. Leptin deficiency seems to reduce adrenergic tone [109] and to influence the discharge
of noradrenaline from sympathetic nerve fibers [110]. Noradrenaline binds to α -adrenergic
receptors on osteoblasts and restrains formation of bone [108-109,111].
For observing direct and indirect or central and peripheral effects in vitro/in vivo, many
researchers used supraphysiological doses of leptin in their studies [78,84,85,87], so it’s difficult
to draw accurate conclusion from these studies.
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The mechanism of leptin function is highly intricate, because of the several receptor isoforms,
localized expression and activation of leptin. Still, the role of leptin is not completely under‐
stood and the heterogeneity in its functions and its involvement in several body systems make
its role challenging, particularly in the field of metabolism and endocrinology, and generally
in medicine. Further studies are essentially needed for better understanding the role of leptin
in several metabolic and non-metabolic functions that may also elucidate its role in health and
disease and particularly in the pathophysiology of osteoporosis.
Bone component Effect Mechanism
Osteoblast Increase directly
By inhibiting GSK-3β and thus promote differentiation of osteoblast and




By binding and activating obRb receptors, in hypothalamus. It stimulates
the expression of a HOBIF that lowers the ability of osteoblast to make bone
matrix [76-77, 100-101]
Osteoclast Decrease By inhibiting osteoclast generation by RANKL/RANK/OPG system [93]
Bone Matrix Decrease
By inhibiting matrix mineralization. Endochondral ossification at the
growth plate mediated by the leptin signaling[113]
Osteocalcin Increase
By elevating osteoblast-specific osteocalcin release through a hypothalamic
relay [114]
Osteopontin Increase
By increasing up regulation of osteopontin by stimulating OPN mRNA and
protein expression in these cells [115]
GSK glycogen synthase kinase, VSMC vascular smooth muscle cells BBB Blood Brain Barrier, HOBIF Hypothalamic
osteoblast inhibitory factor, OPG osteoprotegrin, RANKL receptor activator of nuclear factor-κB ligand, OPN Osteo‐
pontin
Table 2. Effects of leptin on different Bone components
4.5. Expectations
Leptin replacement therapy in animals and humans has shown promising results, but, whether
in postmenopausal osteoporotic patients, its use as a drug or drug target may give some
therapeutic benefits; it’s a basic question that is yet to be explored.
Therefore, in future, it could be expected that administration of some therapeutic agents that
target the leptin secretion would contribute in decreasing the severity of the disease in
postmenopausal women. Future studies may elucidate such agents and their role in alleviating
progression and spread of osteoporosis. Serum leptin effects on bone metabolism are incon‐
sistent and intricate, so there is still need to investigate the precise effects of leptin on bone by
designing some clinical trials and longitudinal studies. Such studies would improve our
understanding regarding the mechanisms underlying leptin role in bone metabolism and how
it could be targeted particularly to treat osteoporosis or other bone disorders. Still, several
venues need to be explored to explicate its undiscovered functions in human body especially,
its role in terms of agonist and/or antagonist for the bone forming cells.




Evidences, shown by the results of several studies have clearly exhibited the role and involve‐
ment of leptin and Hcy in pathophysiology of osteoporosis at various levels but still their exact
role, generally in bone metabolism and particularly in osteoporosis is not clear. We still need
well designed experimental and clinical studies to validate the specific involvement of these
two biochemical agents in bone pathophysiology or as a diagnostic & therapeutic markers,
and also their precise involvement in osteoporosis and their synergistic, antagonists and/or
agonists’ influences on bone forming or destroying cells and other bone proteins.
It seems in future, leptin and Hcy could be the emerging therapies and new targets for
treatment of osteoporosis. However, it would be too early to validate the role of Hcy and leptin
in osteoporosis before addressing some important queries: like identifying their actual
mechanism of action, site/s of their targets in the body for influencing bone metabolism, the
effects of presently available anti-resorptive treatment on Hcy and leptin levels. Although,
various studies have revealed mechanism of Hcy and leptin action, still further clarification
regarding bone specific receptors, peripheral or central or both actions and their interaction
with osteoporotic risk factors need to be investigated.
Numerous basic and clinical studies are available which are helping us to understand their
role in health and diseases but still these are far from completion. Our future research should
be focused on these important questions that whether bringing change in their level and/or
activity may help us in preventing and treating osteoporosis, and interaction of Hcy and leptin
with several other hormones and peptides and consequences of their increased/decreased
levels at various tissues and organs level. Such questions require to be addressed for estab‐
lishing their precise role in bone metabolism. Therefore, further studies are needed to reveal
their character as novel therapeutic agents and/or targets.
6. Few key points
• Homocysteine (Hcy) and leptin are new risk factor for primary osteoporosis.
• Hcy interacts with bone by enhancing osteoclastic and reducing osteoblastic activity,
reducing bone blood supply and directly interacting with bone matrix.
• Hcy level could be modulated by nutritional conditions, and physical activity.
• Each μmol/L raise in Hcy level augments 4% fracture risk.
• Serum leptin supports the segregation and development of the osteoblast lineage cells and
control development of osteoclast.
• Leptin stimulates bone formation via beta-1-adrenergic receptors and stimulation of the
somatotropin-IGF-1 system




Evidences, shown by the results of several studies have clearly exhibited the role and involve‐
ment of leptin and Hcy in pathophysiology of osteoporosis at various levels but still their exact
role, generally in bone metabolism and particularly in osteoporosis is not clear. We still need
well designed experimental and clinical studies to validate the specific involvement of these
two biochemical agents in bone pathophysiology or as a diagnostic & therapeutic markers,
and also their precise involvement in osteoporosis and their synergistic, antagonists and/or
agonists’ influences on bone forming or destroying cells and other bone proteins.
It seems in future, leptin and Hcy could be the emerging therapies and new targets for
treatment of osteoporosis. However, it would be too early to validate the role of Hcy and leptin
in osteoporosis before addressing some important queries: like identifying their actual
mechanism of action, site/s of their targets in the body for influencing bone metabolism, the
effects of presently available anti-resorptive treatment on Hcy and leptin levels. Although,
various studies have revealed mechanism of Hcy and leptin action, still further clarification
regarding bone specific receptors, peripheral or central or both actions and their interaction
with osteoporotic risk factors need to be investigated.
Numerous basic and clinical studies are available which are helping us to understand their
role in health and diseases but still these are far from completion. Our future research should
be focused on these important questions that whether bringing change in their level and/or
activity may help us in preventing and treating osteoporosis, and interaction of Hcy and leptin
with several other hormones and peptides and consequences of their increased/decreased
levels at various tissues and organs level. Such questions require to be addressed for estab‐
lishing their precise role in bone metabolism. Therefore, further studies are needed to reveal
their character as novel therapeutic agents and/or targets.
6. Few key points
• Homocysteine (Hcy) and leptin are new risk factor for primary osteoporosis.
• Hcy interacts with bone by enhancing osteoclastic and reducing osteoblastic activity,
reducing bone blood supply and directly interacting with bone matrix.
• Hcy level could be modulated by nutritional conditions, and physical activity.
• Each μmol/L raise in Hcy level augments 4% fracture risk.
• Serum leptin supports the segregation and development of the osteoblast lineage cells and
control development of osteoclast.
• Leptin stimulates bone formation via beta-1-adrenergic receptors and stimulation of the
somatotropin-IGF-1 system
• Leptin directly inhibits the BMSCs to generate osteoclast and stimulate them to differentiate
into osteoblasts.
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• BMSCs, osteoblasts, osteoclasts and chondrocytes have leptin receptors.
• The mechanism of leptin function is highly intricate, because of the several receptor
isoforms, localized expression and activation of leptin.
• Leptin and Hcy role as diagnostic & therapeutic markers in osteoporosis needs further
exploration.
• Further well-designed experimental and clinical studies are needed to validate the specific
involvement of these two biochemical agents in bone pathophysiology.
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1. Introduction
1.1. Classical renin-angiotensin system
The renin–angiotensin system (RAS) is an endocrine system that governs body fluid, electro‐
lyte balance and blood pressure. Within the classical RAS, angiotensinogen (AGT) secreted by
liver is enzymatically cleaved to angiotensin (ANG) I by kidney-derived renin. ANG I is,
hereafter, cleaved by angiotensin-converting enzyme (ACE) to generate the effector hormone
ANG II, which exerts various biological actions through its receptors, ANG II type 1 receptor
(AT1) and ANG II type 2 receptor (AT2). The initial reaction between the enzyme renin and
the substrate AGT is the rate-limiting step of the RAS [1].
As the RAS is a hormonal cascade that is thought to act as a master controller of blood pressure
and fluid balance within the body [2], the systematic RAS has been an important target of
antihypertensive medications. There are several groups of drugs in this category that affect
different parts of the RAS axis, including ACE inhibitors (ACEI) and angiotensin receptor
blockers (ARB), both of which are widely used for anti-hypertension treatment [3]. Addition‐
ally, Aliskiren, the first orally active direct renin inhibitor approved for clinical use, is a small
molecule competitive inhibitor that specifically inhibits the enzymatic activity of renin [4, 5],
consequently it could effectively suppress the rate-limiting step within RAS cascade to reduce
the production of ANG II. The recent evidences have shown the effective blood pressure
control of Aliskiren, generally well tolerated as monotherapy or in combination with other
antihypertensive drugs [3, 6].
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
2. Tissue renin–angiotensin system
From an evolutionary point of view, it is cost-effective to have a common system to potentiate
and effect the actions of the regulating hormones. Interestingly, the RAS is also found in
primitive animals without a closed circulatory system, which indicates that the system is far
more than a mediator of vasoconstriction [7]. It is now evident that the components of RAS,
in addition to the classical pathway, are produced and acting locally in multiple tissues, a
concept known as tissue RAS [7]. The local effects of tissue RAS are diverse and depend on
the specific tissues involved.
The  functional  tissue  RAS  is  postulated  to  participate  in  various  physiological  and
pathological processes such as insulin secretion [8], glomerular sclerosis [9], renal inflamma‐
tion [10], atherosclerosis [11], cardiac hypertrophy [12], brain ischemia [13] and follicular
development and endometrial cancer in female reproductive tract [14]. A growing body of
studies has demonstrated that the diabetic complications,  such as cardiovascular disease
[15], nephropathy [16] and retinopathy [17], are caused by the high activity of tissue RAS
and the increased production of ANG II in local tissues, and the clinical practice has revealed
that these pathological alterations associated with diabetes were significantly improved in
response to the treatment with RAS inhibitors [15-17]. Additionally, hyperglycemia, obesity,
hypertension,  and cortisol,  well-known risk factors of  metabolic  disease,  are all  stimula‐
tors on tissue RAS, whereas glucagon-like peptide-1, vitamin D, and aerobic exercise could,
to some extent, prevent metabolic disease through inhibiting tissue RAS [7]. Thus, the factors
and drugs suppressing tissue RAS activity have potential in improving RAS-involved tissue
injuries.
Recent in vivo studies showed that the components of RAS, such as renin, ACE, and ANG II
receptors, were expressed in the local milieu of bone [1, 18-20], and in vitro study identified
the expression of ANG II receptors in primary osteoblasts derived from newborn mouse
calvaria [1], indicating the components of RAS are expressed locally in bone microenviron‐
ment. Our further animal studies demonstrated that the local RAS in bone was involved in
age-related osteoporosis of aging mice [21], and bone deteriorations of mice with either
obstructive nephropathy [22] or type 1 diabetes [23]. Other groups elucidated the involvement
of skeletal RAS in the process of fracture healing in a mouse femur fracture model [24], and
the steroid-induced osteonecrosis in rabbits [20] as well as the development of postmenopausal
osteoporosis in ovariectomized (OVX) animal models [25, 26] and glucocorticoid-induced
osteoporosis [19]. Therefore, it concludes that the local RAS exists in bone tissue and plays an
important role in local bone metabolism.
3. Action of angiotensin II on bone
ANG II has been postulated to be able to act upon the cells involved in bone metabolism
through receptors  located in  osteoblasts  and osteoclasts  or  regulate  blood flow in  bone
marrow capillaries. At the end of last century, the studies showed that ANG II stimulat‐
Advances in Osteoporosis62
2. Tissue renin–angiotensin system
From an evolutionary point of view, it is cost-effective to have a common system to potentiate
and effect the actions of the regulating hormones. Interestingly, the RAS is also found in
primitive animals without a closed circulatory system, which indicates that the system is far
more than a mediator of vasoconstriction [7]. It is now evident that the components of RAS,
in addition to the classical pathway, are produced and acting locally in multiple tissues, a
concept known as tissue RAS [7]. The local effects of tissue RAS are diverse and depend on
the specific tissues involved.
The  functional  tissue  RAS  is  postulated  to  participate  in  various  physiological  and
pathological processes such as insulin secretion [8], glomerular sclerosis [9], renal inflamma‐
tion [10], atherosclerosis [11], cardiac hypertrophy [12], brain ischemia [13] and follicular
development and endometrial cancer in female reproductive tract [14]. A growing body of
studies has demonstrated that the diabetic complications,  such as cardiovascular disease
[15], nephropathy [16] and retinopathy [17], are caused by the high activity of tissue RAS
and the increased production of ANG II in local tissues, and the clinical practice has revealed
that these pathological alterations associated with diabetes were significantly improved in
response to the treatment with RAS inhibitors [15-17]. Additionally, hyperglycemia, obesity,
hypertension,  and cortisol,  well-known risk factors of  metabolic  disease,  are all  stimula‐
tors on tissue RAS, whereas glucagon-like peptide-1, vitamin D, and aerobic exercise could,
to some extent, prevent metabolic disease through inhibiting tissue RAS [7]. Thus, the factors
and drugs suppressing tissue RAS activity have potential in improving RAS-involved tissue
injuries.
Recent in vivo studies showed that the components of RAS, such as renin, ACE, and ANG II
receptors, were expressed in the local milieu of bone [1, 18-20], and in vitro study identified
the expression of ANG II receptors in primary osteoblasts derived from newborn mouse
calvaria [1], indicating the components of RAS are expressed locally in bone microenviron‐
ment. Our further animal studies demonstrated that the local RAS in bone was involved in
age-related osteoporosis of aging mice [21], and bone deteriorations of mice with either
obstructive nephropathy [22] or type 1 diabetes [23]. Other groups elucidated the involvement
of skeletal RAS in the process of fracture healing in a mouse femur fracture model [24], and
the steroid-induced osteonecrosis in rabbits [20] as well as the development of postmenopausal
osteoporosis in ovariectomized (OVX) animal models [25, 26] and glucocorticoid-induced
osteoporosis [19]. Therefore, it concludes that the local RAS exists in bone tissue and plays an
important role in local bone metabolism.
3. Action of angiotensin II on bone
ANG II has been postulated to be able to act upon the cells involved in bone metabolism
through receptors  located in  osteoblasts  and osteoclasts  or  regulate  blood flow in  bone
marrow capillaries. At the end of last century, the studies showed that ANG II stimulat‐
Advances in Osteoporosis62
ed DNA and collagen synthesis and decreased alkaline phosphatase (ALP) activity in bone
cell populations derived from calvariae of fetal rat [27] and newborn rat [28]. Similar effects
of ANG II were observed in osteoblastic ROS17/2.8 cells [29] and human adult bone cells
obtained  by  collagenase  digestion  from  trabecular  bone  [27].  The  clonal  cell  analysis,
autoradiographic studies, and receptor subtype analysis suggested that ANG II might be
intimately involved in the proliferation of the osteoblast-rich populations of cells through
the AT1 receptor [27, 28], which also plays one of the essential roles in bone metabolism
as a mechanoreceptor of osteoblasts [30].
When investigating the direct effects of ANG II on matured osteoblasts, the results revealed
that ANG II inhibited the expression of mRNA for osteocalcin, which is a protein that is
specifically expressed during maturation of osteoblastic cells, decreased the activity of ALP,
the number and the total area of mineralized nodules as well as reduced the accumulation of
calcium in cells and the matrix layer [31]. Besides, the ANG II-involved impairment of bone
formation may be attributed that it altered the expression of Cbfa1 by activating the cAMP
signaling pathway and subsequently reduced osteoblast number and osteoblastic function
[32]. SOST, which encodes sclerostin, is a secretory product of osteocytes that counters Wnt
signaling, thereby negatively regulates bone formation [33]. The AT1-involved inhibition on
bone formation was highly correlated with its regulation on downstream factor SOST, as the
decreased SOST expression in osteocytes was observed in AT1-deficient mice [34]. Further‐
more, the treatment with ANG II strikingly increased the expressions of matrix metallopro‐
teinase (MMP)-3 and-13 through MAPK signaling pathways via the AT1 in osteoblastic
ROS17/2.8 cells, suggesting that ANG II stimulated the degradation process that occurs during
extracellular matrix (ECM) turnover in osteoid by increasing the production of MMP-3 and-13
in osteoblasts [29]. Additionally, ANG II induced mitochondrial dysfunction and promoted
apoptosis via JNK signaling pathway in primary mouse calvaria osteoblast [35]. Taken
together, the target genes including Cbfa1, SOST, MMP-3 and MMP-13, and the signaling
pathways like MAPK and JNK are involved in the mediation of ANG II on osteoblastic function
and bone formation.
Osteoblast modulates osteoclast differentiation by producing both positive and negative
regulators, most notably receptor activator of NF-κB ligand (RANKL) and osteoprotegerin
(OPG), respectively [36]. Of note, it has been recently found that ANG II could induce the
differentiation of bone marrow mononuclear cells to multinuclear cells and the number of
multinuclear cells in osteoclasts as well as increase tartrate-resistant acid phosphatase (TRAP)-
positive multinuclear osteoclasts due to its stimulation on the expression of osteoclastogenesis-
supporting cytokine, RANKL in osteoblasts, leading to the activation of osteoclasts [1, 25],
whereas these effects were completely blocked by either ANG II type 1 receptor blockade
(olmesartan) or mitogen-activated protein kinase kinase inhibitors (U0126) [25]. Importantly,
ANG II itself had no capacity to induce osteoclast differentiation and did not potentiate
osteoclast formation triggered by RANKL, while it stimulated the formation of osteoclasts in
the co-culture system of primary osteoblasts and bone marrow macrophages in a dose-
dependent manner [1, 32]. Taken together, these results suggested that ANG II stimulates
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osteoclastogenesis by acting on osteoblastic cells (i.e., ‘the soil cells’), but not through a direct
action on hematopoietic ‘seed cells’ [1].
It was found that the TRAP activity and the TRAP-positive stained area were significantly
increased in the tibia of OVX rats with systemic administration of ANG II at a subpresser dose
(200 ng/kg/min), and the treatment with ANG II significantly induced the ovariectomy-
induced increase in urinary level of deoxypyridinoline [25]. The ratio of ALP to TRAP was
significantly decreased in the tibia of OVX rats upon to ANG II treatment. These results
suggested that ANG II accelerated the turnover of bone metabolism, which is similar to the
typical pattern in elderly postmenopausal women who are at high risk for osteoporosis [25].
Of importance, the bone density as assessed by double energy X ray absorptiometry (DEXA)
was significantly decreased in the tibia of OVX rats by ANG II. These results suggested that
ANG II directly accelerated estrogen deficiency-induced osteoporosis.
4. Interaction of AT1 and AT2 on bone
Previous studies have focused on the ANG II–AT1 interactions since these are the best
described and considered the most important. However, the system is complex and several
other components probably play significant roles as well [7]. Several publications raise the
possibility that AT1 and AT2 carry out negative cross-talk within fibroblasts and vascular
endothelial cells with respect to each other’s signaling pathways and responses [37]. This may
be of particular importance when the AT1 are pharmacologically blocked.
Asaba  et al. determined the relative contribution of the two receptors for transducing the
osteoclastogenesis-supporting  function  of  ANG  II  in  osteoblasts  by  knocking  down  the
expression of  each of  the receptors with siRNA in primary osteoblasts  in culture [1].  In
AT1-knockdown osteoblasts, the stimulatory effect of ANG II on osteoclast formation was
somewhat  enhanced.  In  AT2-knockdown  osteoblasts,  in  contrast,  the  osteoclastogenic
potential  was  markedly  attenuated  [1],  which  was  consistent  with  that  AT2  deficiency
increased  bone  mass  of  distal  metaphyseal  regions  of  femoral  in  mice  as  well  as  the
treatment with AT2 blocker PD123319 suppressed ANG II-induced increase in the num‐
ber of  osteoclasts  in organ cultures of  bone [18].  Asaba  et  al.’s  study suggested that  the
action  of  ANG  II  on  osteoblasts  in  terms  of  stimulating  osteoclastogenesis  was  mainly
mediated through the AT2 and AT1 might exert an inhibitory effect on AT2. These findings
in osteoblasts are consistent with the notion that the functions of AT1 and AT2 are in many
cases counter-regulatory to each other [7].  However,  they are contrary to the conclusion
that  AT2  is  the  protective  arm of  RAS and counterbalances  pathological  processes  and
enable recovery from disease [38]. Thus, further studies are needed to dissect the signal‐
ing pathways downstream of each receptor in osteoblasts.
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5. ACE inhibitors and osteoporosis
Osteoporosis, hypertension, diabetes are major chronic diseases in older subjects and the latter
two are well known to be high risk factors for osteoporosis. As ACE inhibitors are usually
prescribed for hypertension, cardiac failure, and diabetic nephropathy [23, 39], it is important
to know the prospective effects of ACEI on bones of these patients taking ACEI treatment.
Previously, most of clinical studies demonstrated that patients treated with ACEI showed an
increased bone mineral density (BMD) and a reduced fracture risk [40-45]. The menopausal
and hypertensive women who followed treatment with ACEI fosinopril did not present the
physiological loss of bone mass that affected to menopausal women without treatment [43].
A large case–control analysis carried out in the UK, suggested a possibly decreased fracture
risk associated with longer-term use of ACE inhibitors [40], and in an open prospective study
including 134 patients with low to moderate hypertension and stable BMD, the plasma calcium
and 25-hydroxyvitamin D levels were both increased in patients treated with the ACEI
quinapril [41]. It also significantly increased BMD of lumbar spine in female subjects with ACE
DD genotype, which could induce a higher level of ANG II [41]. The research group from Hong
Kong performed two large scale cohort studies which investigated the risk factors for osteo‐
porotic fractures in Hong Kong-dwelling elderly Chinese, and their data concluded that male
ACEI users had higher BMD at the total hip, female neck and lumbar spine than non-users.
Likewise, female ACEI users also had higher BMD than non-users, although only significant
at the femoral neck [42].
While, in the contrary to the above mentioned beneficial effects of ACEI on bone health, the
recent emerging evidences indicated that ACEI use did not change the rate and risk of fracture
[46], and even led to greater bone loss [39, 47, 48]. The same research group from Hong Kong
recently also stated that female continuous users of ACEI had increased bone loss both in total
hip and femur neck [47]. A large sample size study in American men also supported this theory
by showing that ACEI use was associated with increased bone loss [39], moreover, another
prospective study-a cohort study of atomic bomb survivors in Japan, demonstrated that ACEI
use was associated with increased bone loss of femoral neck in older Japanese [48].
Similarly in animal studies, the use of ACEI enalapril (10-20 mg/kg, i.g.) did not show positive
effects on bone function of OVX mice [49] or OVX spontaneously hypertensive rats (SHR) [50],
and the administration of enalapril (0.4 mg/kg, i.p.) in a dose recommended for the treatment
of hypertension did not cause significant changes in bone density, the ash and mineral content
or morphometric parameters of the femur in female Wistar rats [51]. Another ACEI moexipril,
when given alone at oral dose of 10 mg/kg, had no effect on the cancellous bone site in either
OVX or sham-operated rats and did not hamper the osteoprotective effects of 17beta-estradiol
[52]. Even though the treatment of Tsukuba hypertensive mouse with enalapril improved
osteoporosis [1] as well as the OVX rats in response to the treatment with ACEI captopril (1 or
5 mg/kg) showed the increased trabecular area of lumbar vertebrae (L4) and the improved
biomechanical properties by increasing L5 break stress and elastic modulus [26], our recent
published article elucidated that the treatment with captopril (10 mg/kg, i.g.) significantly
elevated serum level of TRAP 5b, and had a trend to decrease BMD of trabecular bone and
Biological Effects of Skeletal Renin-Angiotensin System in Osteoporosis
http://dx.doi.org/10.5772/59299
65
damage micro-architecture of proximal tibial head and distal femoral end in type 1 diabetic
mice [23].
Based on the facts that ANG II locally in bone tissue has detrimental effects to bone function
and ACE is the major enzyme producing ANG II, it is surprising that ACEI could not improve
even accelerate bone loss in both humans and animals. Since the modest changes in ACE level
affect the levels of its substrates much more than its products, indicating that relatively small
changes in the levels of ACE affect kinin level more than ANG II level [53], a possible reason
comes from the regulation of ACE on kinin-kallikrein system within which bradykinin can
stimulate bone resorption and reduce BMD [47]. Another possible explanation we should
consider is that although short-term ACEI therapy was associated with decreased ANG II level,
there were some evidences that long-term ACE inhibition resulted in a return of ANG II
towards baseline level, so-called ‘ACE escape’ [47]. The complete mechanisms have not yet
been fully demonstrated. More research needs to be carried out to clarify the influence of the
ACEI treatment on bone health as this might be of clinical relevance when antihypertensive
therapy is initiated, particularly in hypertensive women who typically suffer from a concom‐
itant rapid onset of osteoporosis after menopause [52].
6. Angiotensin receptor blockers and osteoporosis
The clinical profiles of users of ACEI and ARB were very similar. In the USA, ARB was usually
prescribed when ACEI was not tolerated, thus explaining the smaller number of ARB users
[39] and limited human studies of ARB and BMD or fracture risk in the literatures [46]. The
completed studies on the affections of ARB on bone function in human and animals have
shown contradictory results.
The recent population-based, retrospective cohort study with propensity score-matching
using administrative databases in Ontario, Canada to examine the risk of osteoporosis-related
fractures in hypertensive elderly patients treated with ARBs versus ACEIs, showed that there
was no significant difference between the effects of ARBs and ACE inhibitors on hip and other
osteoporotic fractures [54]. A large cohort study on Medicare beneficiaries with a diagnosis of
hypertension initiating single-drug therapy for anti-hypertension treatment suggested the
increasingly protective effect of ARB on relative fracture risk over time [46]. While, the study
with large sample size of community-dwelling older adults from six different geographic
regions demonstrated that the use of ARBs did not have any significant overall effect on bone
loss in older men [39].
The contradictory results about the actions of ARBs on bone metabolism were also shown
among  animal  studies.  The  treatment  with  telmisartan,  olmesartan,  and  losartan,  could
reduce bone loss of OVX mice [49], attenuate the ovariectomy-induced decrease in BMD
[25], and increase bone strength, mass and trabecular connections of OVX rats femur [55,
56],  respectively.  Moreover,  telmisartan  partially  protected  from  thiazolidinedione-in‐
duced bone loss  by actively  blocking thiazolidinedione-induced anti-osteoblastic  activity
via maintaining PPARγ serine 112 phosphorylation [57], and promoted fracture healing in
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a mice model [58]. However, some studies reported ARBs did not cause significant changes
of bone properties in normal female rats [51], type 2 diabetic mice [57], OVX rats [59] or
orchiectomized rats [60]. Importantly, it was noted that in some animal models ARBs may
lead to more bone injuries [1, 61]. The treatment of transgenic Tsukuba hypertensive mouse
with losartan resulted in exacerbation of the low bone mass phenotype [1]. The study in
our  group demonstrated a  trend of  losartan to  promote  the  loss  of  bone mass  and the
deteriorations  of  trabecular  bone  micro-architecture  in  type  1  diabetic  mice  due  to  the
compensatory stimulation of bone RAS activation as shown by the up-regulation of renin
and ANG II expression in bone tissue [61].
7. Perspective
It has been argued that neither ACEIs nor ARBs completely block the RAS cascade due to the
disruption of the feedback inhibition of renin production [62]. The increase in renin activity
stimulates the conversion of ANG I and ultimately ANG II, which largely limits the efficacy
of RAS inhibition [63]. The increased renin can also act through the prorenin/renin receptor,
which may cause tissue damages independent of ANG II [64]. Thus, as compared to single
treatment with RAS inhibitors, whether combining renin inhibitor, like Aliskiren, with ARB
or ACEI could generate better therapeutic effects on tissue injuries, such as osteoporosis,
should be further clarified.
As discussed in this chapter, RAS locally plays a key role in the modulation of bone metabo‐
lism. However, over the past 10 years, several studies have presented evidences for the
existence of a new arm of the RAS, namely the ACE2/ANG-(1–7)/Mas axis [65]. The identifi‐
cation of the ACE homolog, ACE2 as a key ANG-(1–7)-forming enzyme, unravels the existence
of a distinct enzymatic pathway for the production of ANG-(1-7), which has a broad range of
effects in different organs and tissues that goes beyond its initially described cardiovascular
and renal actions [66]. This heptapeptide exerts its actions through binding to a G protein-
coupled receptor Mas, distinct from AT1 and AT2 [67]. It is now accepted that the ACE2/ANG-
(1–7)/Mas axis is able to counteract most of the deleterious actions of the ACE/ANG II/AT1
axis, especially in pathological conditions [68] such as cardiac dysfunction, increased blood
pressure, decreased baroreflex function, endothelial dysfunction, reduced reproductive
function, increased thrombogenesis [66]. Thus, how the cross-talk and the interaction between
the dual axis systems of RAS contribute to the maintainance of bone metabolism needs to be
further investigated and elucidated for better understanding the molecular mechanism of bone
metabolic diseases.
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1. Introduction
Osteoporosis can be divided into two principle strands, clinical osteoporosis and densitometric
osteoporosis. Clinical osteoporosis involves the identification of a fragility fracture and does
not need densitometry for treatment to begin. Densitometric osteoporosis is identified via an
assessment of bone mineral density. Approaches to treatment depend on the global fracture
risk and the outcomes of densitometric tests.
The initial stage of the pharmacological treatment of osteoporosis is to identify the pathology
of the primary condition or to determine whether the loss of bone density is a secondary
symptom of a separate condition. Where secondary osteoporosis is identified, priority is given
to the treatment of the primary condition. The option of pharmacological therapy must only
be contemplated if the risk of fracture is too elevated, given that the intention behind phar‐
macological treatment in osteoporosis is to reduce the fracture risk. Based on World Health
Organization figures, less than half of patients presenting a fragility fracture have been
diagnosed with densitometric osteoporosis [1]. Once a course of medication has begun, long-
term management must address improvements to lifestyle and take aspects of, security, cost,
and compliance into account. As such, it is absolutely necessary to assess and make determi‐




Calcitonin binds to osteoclasts and hinders bone resorption. The use of salmon calcitonin has
previously been widespread as a result of its extreme potency in humans, a result of its greater
affinity for the human calcitonin receptor.
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and eproduction in any medium, provided the original work is properly cited.
Calcitonin is now no longer a treatment for osteoporosis, having been supplanted by other
treatments. Following a European risk-benefit analysis, the scientific committee of the Europe‐
an Medicines Agency (CHMP) advised that treatments using calcitonin should only be deployed
in short-term scenarios.. Treatments using injectable calcitonin should be confined to the short-
term in Paget's disease, the prevention of acute bone loss as a result of sudden immobiliza‐
tion and hypercalcemia resulting from cancer. In addition to this, calcitonin has been proven to
be effective in treating pain resulting from fractures of the vertebral column. [2-4]
2.2. Hormonal Replacement Therapy (HRT)
HRT is a form of treatment which deploys varying doses of estrogen, sometimes on its own,
sometimes in combination with progestagens. The calculated risk of fracture, based on
principal cohort trials of postmenopausal women treated with HRT over the long term,
indicate an appreciable lowering of the likelihood of both vertebral fracture (RR=0.6; CI 95%:
0.36 to 0.99) and wrist fracture (RR=0.39; CI 95%: 0.24 to 0.64), but a non-significant lowering
of the likelihood of hip fracture (RR=0.64; CI 95%: 0.32 to 1.04). The WHI trial (Women's Health
Initiative), a randomised clinical trial (RCT) that assessed postmenopausal women randomly
assigned to combined HRT (combined equine estrogen 0.625mg daily plus medroxyproges‐
terone 2.5mg daily) or a placebo, recorded, following 5.2 years of treatment, a decrease in hip
fracture risk of 34% (hazard ratio [HR]=0.66; CI 95%: 0.45 to 0.98), in clinical vertebral fractures
of 34% (HR=0.66; CI 95%: 0.44 to 0.98) and in any fracture of 24% (HR=0.76; CI 95%: 0.69 to
0.85) [5,6]. In the same investigation, the cohort taking estrogen on its own demonstrated
comparable outcomes, however the treatment was put on hold as a result of an adverse risk-
benefit ratio. In two meta-analyses of RCT’s, a decrease of 27% (RR=0.73; CI 95%: 0.56 to 0.94)
in non-vertebral fractures and a trend towards a reduction of vertebral fractures (RR=0.66; CI
95%: 0.41 to 1.07) was recorded [7]. Nonetheless, neither the HERS (The Heart and Estrogen +
Progestin Replacement Study) RCT nor the subsequent group, the HERS II study (Hulley et
al., 1998), were able to register a decrease of the risk of hip fractures or of other locations
(RR=1.04; CI 95%: 0.87 to 1.25) in patients with a history of cardiovascular disease [8].
The British National Institute of Health and Clinical Excellence published a meta-analysis of
RCTs on HRT efficacy (with estrogen alone or combined) compared with placebo/non-
treatment in postmenopausal women or those with surgical menopause [9]. The outcomes
were organised according to the location of the fracture and the RCT used as the basis for the
calculation of the relative risk was also identified. The outcomes are outlined in table 1.
Fracture Location Nr of RCTs n RESULTS References
Vertebral fracture 4 RCTs 11,842 RR=0.55; CI 95%: 0.46 to 0.66 [10-13]
Non-vertebral fracture 3 RCTs 11,774 RR=0.73; CI 95%: 0.65 to 0.81 [10, 11,14]
Hip fracture 2 RCTs 11,745 RR=0.63; CI 95%: 0.42 to 0.93 [11,14]
Any type of fracture 3 RCTs 11,556 RR=0.70; CI 95%: 0.63 to 0.78 [14-16]
Table 1. Relative fracture risk in NICE meta-analysis
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A thorough and methodical review of five RCTs looking at HRT with estrogen and two looking
at combined HRT estrogen plus progesterone, failed to display compelling variance in the
occurrence of acute coronary events (including acute myocardial infarction) between the
cohort subject to intervention and the control cohort [7]. A combination of the outcomes of
three studies contrasting estrogenic therapy to a placebo [11, 17] reported an odds ratio (OR)
of 1.34 (IC 95%: 1.07 to 1.68) for cerebral vascular events. The combined outcomes of the studies
that contrasted estrogen plus progesterone combined treatment with a placebo [5, 18],
indicated an elevated risk of ictus (OR=1.28; CI 95%: 1.05 to 1.57) in the cohort subject to
intervention. Out of four thorough and methodical reviews of observational trials looking at
women treated with HRT [19-22], three of these indicated a significant decrease in the global
mortality risk for acute coronary events. A recently published, thorough and methodical
review, that compensated for selection bias of inclusion and analysis, did not reveal any link
between the THS and the incidence, and mortality of acute coronary events [22].
The WHI primary prevention trial indicated a distinct elevation of the risk of acute coronary
events (41%), starting the second year of treatment (29 instances in the treatment cohort,
compared with 21 instances for 10,000 women per year in the general population) [5]. This
elevated risk was greater in non-mortal coronary incidents (RR=1.50; CI 95%: 1.08 to 2.08) than
in the mortal coronary incidents (RR=1.20; CI 95%: 0.58 to 2.50). The RCTs of HRT with
estrogens alone, in both primary and secondary prevention, failed to indicate any positive
impact on cerebrovascular illness [23]. In addition, the WHI study cohort with estrogen
indicated an elevated risk of cerebrovascular incidents.
2.2.1.2. Venous thrombotic events
In a thorough and methodical review, McLean et al. indicated that estrogen patients treated
with estrogen demonstrate an elevated risk of major venous thromboembolic incidents
(OR=1.36; CI 95%: 1.01 to 1.86) compared to the placebo cohort [7]. A further thorough and
methodical review assessing the impact of HRT (estrogen with or without progestagens)
encompassed 12 studies (3 RCTs, 8 case-control studies and 1 cohort study) and indicated an
elevated risk of thromboembolism (RR=2.14; CI 95%: 1.64 to 2.81). This risk was elevated in
the first two years of the therapy and it varied according to the dose [24].
2.2.1.3. Breast cancer
A thorough and methodical review of 4 RCTs proved that patients treated with estrogens alone
have a lower risk of breast cancer (OR=0.79; CI 95%: 0.66 to 0.93) than those treated with the
placebo [7]. On the other hand, patients treated with estrogen and progestin have a higher risk
of breast cancer (OR=1.28; CI 95%: 1.03 to 1.60) than those treated with the placebo [5, 18, 24].
Nonetheless the combined HRT cohort of the WHI study presented an elevated risk of invasive
breast cancer [5]. This elevated risk occurred following the fourth year of treatment (RR=1.26;
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CI 95 %: 1.0 to 1.59), with a propensity to rise in line with the treatment’s longevity (38 instances
compared with 30 for 10,000 women per year).
2.2.1.4. Endometrial cancer
The treatment of estrogen alone elevates the risk of subsequent endometrial hyperplasia and
cancer [25,26]. A meta-analysis including 29 observational studies reported a demonstrable
elevation of the risk of endometrial cancer, with or without combined estrogens (RR=2.3; CI
95%: 2.1 to 2.5) [20]. This risk is directly related to the treatment’s longevity and continues to
be raised for a maximum of 5 years or more following the termination of treatment.
2.2.1.5. Ovarian cancer
Recently published thorough and methodical reviews of observational trials indicate an
elevated incidence of ovarian cancer amongst women undergoing treatment, particularly long-
term therapies (more than 10 years) [28,28]. Two cohort trials of postmenopausal women who
underwent treatment for a period of more than 10 years corroborate this elevated risk of
ovarian cancer (RR=2.2; CI 95%: 1.53 to 3.17), as well as an elevated mortality risk (RR=1.59; CI
95%: 1.13 to 2.25) [29, 30].
We can conclude that HRT is an effective therapy both for postmenopausal osteoporosis and
for the management of fracture risk. Nevertheless, even taking this conclusion into account,
the use of combined HRT is not recommeneded for periods greater than 5 years, given the
possible risk factors linked with treatments using a daily dose equivalent to 50 pg of estradiol.
When HRT treatment is indicated, it should be prescribed at a low dosage (equivalent to
estrogen transdermal patches of 25 mcg), only using higher doses if it is absolutely essential
to do so. Estrogens and progestagens are only advised for the treatment of women with intact
uteri. The level of the progestagen dose should be determined on the basis of the estrogen dose.
In instances where a hysterectomy was carried out as a result of endometrial cancer, HRT
should not involve combined estrogen and progestagens. Continuous combined HRT treat‐
ment should only commence following one whole year of menopause.
2.3. Selective Estrogen Receptor Modulators (SERMs)
Selective estrogen receptor modulators are medications with a selective impact on the estrogen
receptor. They can function as estrogen receptor (ER) agonists in some tissues while in other
tissues functioning as estrogen receptor antagonists. As a result of their selective estrogen-
agonist behaviour within a variety of tissues, SERMs may be indicated as an alternative option
for the prevention or treatment of conditions like osteoporosis, which are the result of a
deficiency of estrogen, where avoiding the negatives effects of estrogens is a priority.
2.3.1. Differences between SERMs
At present there are two forms of SERM, which are distinguished by their chemical structure:
triphenylethylene derivatives, for example tamoxifen and toremifene, and benzothiophene
derivatives, for example raloxifene and bazedoxifene. Tamoxifen and toremifene on the one
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hand are indicated for use in the treatment of breast cancer. Raloxifene on the other hand is
used for the prevention and treatment of osteoporosis and in addition the prevention of breast
cancer. All SERMs have been linked with an elevated occurrence of pulmonary thromboemb‐
olism and with the start of hot flushes, however they also impact in a positive manner on the
lipid profile.
The SERMs vary distinctively with regards to tissue specificity. Bazedoxifene appears to have
a lower impact on the uterus than estradiol jointly with raloxifene in animal experiments as a
result of reduced estrogen receptor alpha agonistic effects.
2.3.2. Raloxifene
Raloxifene acts as estrogen agonist in bone and other systems but not in reproductive tissue.
Many trials have proved the effectiveness of raloxifene for preserving bone in the early
postmenopausal phase. In a meta-analysis of seven studies (four treatment and three preven‐
tion studies) which looked at the impact of raloxifene versus a placebo on bone mineral density,
raloxifene augmented bone mineral density within the lumbar spine following a two year
period of treatment [31]. A trial of 601 women, five years following the menopause, who were
given a daily dose of 30, 60 or 150mg of raloxifene over two years, indicated an augmentation
of their bone mineral density in spine and hip, whereas those subjected to the placebo
presented reduced bone mineral density in the same locations [32]. In contrast with the results
from the placebo, the average alteration in BMD with 60mg of raloxifene was 2.4% in the spine
and 2.4% at the total hip (p<0.001 versus placebo). Postmenopausal women presenting low
bone mass and osteoporosis were monitored over eight years in the study entitled ‘Multiple
Outcomes of Raloxifene Evaluation’ (MORE, n=7,705) and its sister trial entitled ‘Continuing
Outcomes Relevant to Evista’ (CORE, n=4,011) [33]. In relation to fractures, whilst raloxifene
treatment led to a decreased risk of vertebral fracture, it failed to demonstrate a reduced risk
of non-vertebral fractures. Nevertheless, in a meta-analysis of RCTs contrasting the effects of
raloxifene with those of a placebo, raloxifene typically led to a decreased risk of vertebral
fractures in postmenopausal women (OR=0.6; CI 95%: 0.5-0.7).
The results of the MORE trial indicated that, following a raloxifene treatment period of four
years, at 60mg per day, the cumulative relative risk of one or more vertebral fractures was 0.64
(IC 95%: 0.53 - 0.76), compared with treatment using a placebo.
Verus placebo, treatment with 60mg of raloxifene was also linked to a decrease of 65% to 78%
in occurrences of invasive breast cancer and invasive breast cancer with positive estrogen
receptor (both p <0.05).
2.3.2.1. Adverse Effects
The MORE and CORE studies reported a link between raloxifene and an elevated incidence
(1.7 times) of thromboembolism (TE), versus treatment using a placebo (95% CI: 0.93-3.14; risk
difference total of 0.9/1,000 women-years) [34]. In a meta-analysis of nine trials, raloxifene
treatment was linked with an elevated incidence of deep venous thrombosis and pulmonary
embolism (OR=1.5; CI 95%: 1.1-2.1 and OR=1.9; 95% CI: 1.0-3.5, respectively) [35]. The RUTH
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trial (‘Raloxifene Use for The Heart’), which studied 10,101 postmenopausal women with an
average age of 68 and presenting with coronary heart disease, indicated a link between
raloxifene and an elevated incidence of fatal stroke (HR=1.49; 95% CI: 1.00-2.24, a rise in the
absolute risk of 0.7/1,000 women-years) as well as an elevated risk of thromboembolism
(HR=1.44; 95% CI: 1.06-1.95, a rise in the absolute risk of 1.2/1,000 women-years) in comparison
with the placebo results. No elevated risk of myocardial infarction or other coronary events
was indicated in the RUTH trial. Nevertheless, in line with the observations regarding
thromboembolism and pulmonary embolism, the outcomes of a recent review of a sub-cohort
of the trial indicated that age had an impact on the occurrence of coronary events. For women
of 60 years or under, the rate of occurrence of coronary events was distinctly reduced with
raloxifene (50 cases), compared with the placebo group (84 cases; HR=0.59; 95% CI: 0.41 to 0.83,
p=0.003). Raloxifene was also linked with an elevated occurrence of hot flushes, especially
amongst women with recent menopause onset [36].
We can conclude that raloxifene provides an alternative option within osteoporosis therapies
for specific patients. The drug’s profile relating to heart disease and breast cancer is sound but
its links to an elevated risk of venous thrombosis should be taken into account in its use as a
treatment.
2.3.2.2. Bazedoxifene
Bazedoxifene is a third-generation SERM. Some key differences have been demonstrated
between the generations regarding their impact on the uterus and on breast tissue in particular
[37]. The drug was developed with raloxifene as a template and by replacing the benzothio‐
phene core with an indole ring [38].
In a phase II trial of healthy postmenopausal women, oral doses of bazedoxifene 2.5, 5, 10, 20,
30, or 40mg per day were as a rule well-tolerated and did not aggravate the endometrium. In
addition, bazedoxifene 30 and 40 mg resulted in a notably reduced increase in the thickness
of the endometrium and distinctly lowered the occurrence of uterine bleeding versus results
from the placebo. In a two-year phase III trial of postmenopausal women at risk of osteoporosis,
bazedoxifene 10, 20, and 40mg were proven to prevent bone loss and decrease bone turnover
and were linked with a positive endometrial, ovarian, and breast security profile [39, 40].
A phase III, multi-centre, double-blind, randomised, controlled trial was formulated with the
sole purpose of assessing the effectiveness of bazedoxifene in fracture prevention. The trial
looked at 7,492 healthy postmenopausal women presenting with osteoporosis both with or
without prevalent vertebral fractures. The women were randomly assigned to 20 or 40mg per
day of bazedoxifene, 60mg of raloxifene, or to a placebo plus 1200mg of calcium and 400IU of
vitamin D. The primary outcome was the occurrence of new vertebral fractures following a
three-year treatment period. Secondary indicators included clinical vertebral fractures,
worsening of vertebral fractures, non-vertebral fractures, breast cancer incidence, and varia‐
tions in height. Both bazedoxifene 20 and 40mg reduced the occurrence of vertebral fractures
to a similar extent as raloxifene versus the placebo. The occurrence at 36 months of new
vertebral fractures was 2.3%, 2.5%, 2.3%, and 4.1% in the bazedoxifene 20mg, bazedoxifene
40mg, raloxifene 60mg, and placebo cohorts, respectively, with a distinct lowering of the
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relative incidence for new vertebral fractures of 42%, 37%, and 42%, respectively, versus
placebo. There was no overall impact on non-vertebral fractures, with incidence rates of 5.7%
and 5.6% for the bazedoxifene 20 and 40mg cohorts, respectively, versus 5.9% for the raloxifene
cohort and 6.3% for the placebo cohort. Nevertheless, in a later review of women with elevated
fracture risk (poor femoral neck T-score and multiple vertebral fractures, n=1,772), bazedoxi‐
fene 20mg reduced the incidence of non-vertebral fracture by 50% and 44% reduction relative
to the placebo (HR=0.50; 95% CI: 0.28–0.90; p=0.02) and raloxifene 60mg (HR=0.56; 95% CI:
0.31–1.01; p=0.05), respectively [41].
2.3.2.3. Safety
Miller et al. demonstrated that deep venous thromboembolism was uncommon with baze‐
doxifene (0% to 0.6% with varying dosage levels after two years) and similar to the placebo
(0.3%). The rate of occurrence and the intensity of hot flushes were comparable with raloxifene,
but slightly elevated versus placebo [40]. In the trial by Silverman et al., leg cramps (10.9% to
11.7% with varying dosage after three years) and deep venous thromboembolism (0.4% to 0.5%
with varying dosage after three years) were decidedly more prevalent with bazedoxifene
compared with the placebo (8.2% for leg cramps and 0.2% for deep venous thromboembolism),
while fibrocystic breast disease was markedly less frequent. No distinction in risk levels
between bazedoxifene and placebo was noted for myocardial infarction, strokes (ischemic or
hemorraghic), or retinal vein thrombosis [40-43].
We can conclude that bazedoxifene appears to have improved selectivity in contrast with other
SERMs. The impact of bazedoxifene on the skeleton is not dissimilar to raloxifene, and
bazedoxifene may be employed in the same way as raloxifene. The usefulness of bazedoxifene
possibly lies in its risk profile being distinct to that of raloxifene, particularly with regards to
uterine safety, and bazedoxifene may therefore present another option for the prevention and
treatment of osteoporosis.
2.3.3. Lasofoxifene
Lasofoxifene is a powerful third-generation SERM. It has a distinct structure compared to first-
and second-generation SERMs (raloxifene, tamoxifen and clomiphene or idoxifene). Lasofox‐
ifene displays powerful estrogenic and anti-estrogenic activity in vitro and in vivo, targeting
any areas with estrogens receptors, including bone, uterus, breast, blood vessels, and liver.
Lasofoxifene has been analysed in postmenopausal women with regards to the prevention and
treatment of osteoporosis. Security and tolerance levels of lasofoxifene is similar to that of
raloxifene, however nonadherence rates as a result of adverse events are greater with lasofox‐
ifene. Despite these indications, results demonstrate that lasofoxifene treatment may lead to
greater endometrial thickness versus the placebo, despite there being no evidence of an
elevated incidence of endometrial hyperplasia or cancer.
The PEARL study, a three-year pivotal fracture study, showed that lasofoxifene elevated
lumbar spine and femoral neck BMD by approximately 3%. Furthermore, vertebral fractures
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saw a decrease of 42%, and non-vertebral fractures of 27%, with a decrease in markers of bone
turnover. Nevertheless, lasofoxifene did not reduce the risk of hip fractures [43].
2.4. Bisphosphonates
2.4.1. Analysis and mode of action
Bisphosphonates are a member of a class of antiresorptive agents whose antifracture action is
well-documented through randomised controlled studies. There have been no studies to
compare different bisphosphonates, a fact which has prevented the identification of a definite
order of effectiveness for treatment.
Bisphosphonates lower fracture risk as a result of its inhibitory action of osteoclasts, which
enables the osteoblasts to synthesize bone in the resorption spaces and some bone lacunae.
This produces an augmentation in bone mass. However, the bisphosphonates also increase
bone quality, by conserving the bone architecture, as demonstrated in studies which have
analysed the biopsies of treated patients and control subjects.
Bisphosphonates comprise pyrophosphate analogs in which the central oxygen has been
replaced by a carbon atom and two side chains (R1 and R2). Two phosphate chains are vital
to enable the drug to bind to bone and to have an antiresorptive effect.
2.4.2. Etidronate
Etidronate was the original bisphosphonate used in osteoporosis therapy. It is no longer used
in current practice. Its greatest asset is most likely its cost. It augments bone mass in the spine
and femur and lowers the risk of vertebral fractures, however it has not demonstrated a
reduction in the incidence of femoral fractures [44,45].
2.4.3. Clodronate
Clodronate has been deployed in postmenopausal osteoporosis therapy in oral and intrave‐
nous treatments. The trials indicate that it reduces the risk of bone loss in the vertebral spine
in comparison to control subjects, and it presents similar results to estrogens after two years.
In a six-year long study, it was also demonstrated to lower the incidence rate of vertebral
fractures. McCloskey et al. carried out a three-year, double-blind, controlled study to observe
the impact of oral clodronate (800mg per day) on fracture rates. In this study, clodronate was
linked with a distinct improvement in the mean lumbar spine and hip BMD. Furthermore, it
significantly lowered the risk of vertebral fracture (relative risk, 0,54; 95% CI, 0,37-0,80;
p<0,0001). Despite these outcomes, subsequent to the introduction of powerful nitrogen
bisphosphonates, the first-generation bisphosphonates have been reduced to a therapy of last
resort [46].
2.4.4. Alendronate (alendronic acid)
Alendronate is one of the most commonly deployed bisphosphonates. It augments vertebral
bone mass approximately 6-8% and 3-6% at the hip in postmenopausal osteoporotic women
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after a three-year treatment. It demonstrates a reduction in vertebral and non-vertebral
fractures of around 50% in this time period. In male osteoporosis, it has demonstrated
improvements in bone mass of 5% after two years of treatment.
Alendronate is given orally, in doses of 70mg/week, fasting with 200 ml of water. The patient
is prohibited from consuming solids or liquids for 30 minutes after treatment and must remain
standing for this time.
The decisive study of alendronate, the FIT (Fracture Intervention Trial), demonstrated that the
incidence of clinical fracture was reduced for the alendronate cohort compared to the control
cohort (139 (13.6%) versus 183 (18.2%); relative hazard=0.72 (0.58-0.90)). The corresponding
risk of hip and wrist fracture for the alendronate cohort when compared to the placebo cohort
were 0.49 (0.23-0.99) and 0.52 (0.31-0.87) [47]. Ensrud et al. provided an assessment of a subset
of FIT subjects who were patients with an elevated risk of fracture. The outcomes of this
analysis demonstrate a decisive 47% lowering of the risk of new vertebral fractures in the
alendronate cohort when set against the control cohort. A number of other papers have been
generated from the FIT study, addressing multiple symptomatic fractures, bone mineral
density, biochemical markers of formation and resorption, fracture prevention in osteopenic
women, impact of alendronate continuation versus discontinuation, and the impact on women
who lost bone over the course of treatment [48-51].
We can conclude that alendronate is a well-tolerated, secure and efficacious treatment method
for postmenopausal osteoporosis, male osteoporosis, and glucocorticoid induced osteoporosis
(GIOP).
2.4.5. Risedronate
This treatment has been proven to improve bone mass in spine and hip and to considerably
lower the incidence of fracture in postmenopausal women. Treatment of postmenopausal
women with osteoporosis with risedronate over a three-year period has produced a reduction
in the risk of vertebral fractures in roughly 50% and non-vertebral fractures in 39% of subjects.
At the hip, the fracture reduction rate is between 40 and 60%. After a five-year period, the
outcomes are comparable. The treatment has demonstrated its anti-fracture efficacy after a six-
month course. In other trials it has been proven that this reduction in risk was still present
following a seven-year period of treatment, and was accompanied by a positive security
profile. One of the principal studies of risedronate [52] looked at 5,445 women aged 70 to 79
years with osteoporosis (T-score at the femoral neck greater than -4 SD below the mean or
lower than -3 plus a non-skeletal risk factor for hip fracture, such as poor gait or a tendency to
fall) and 3,886 women aged at least 80 years with a minimum of one non-skeletal risk factor
for hip fracture or poor BMD at the femoral neck (T-score below -4 or below -3 plus a hip-axis
length of 11.1cm or greater). The subjects were given a treatment at random of either oral
risedronate (2.5 or 5.0mg per day) or a placebo, over a three-year period. The outcomes
indicated that the risk of hip fracture among subjects given risedronate was 2.8%, versus 3.9%
among those given the placebo (relative risk, 0.7; 95% CI, 0.6 to 0.9; p=0.02). In the cohort of
women with osteoporosis (70 to 79 years old), the risk of hip fracture among subjects given
risedronate was 1.9%, versus 3.2% among subjects given the placebo (relative risk, 0.6; 95% CI,
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0.4 to 0.9; p=0.009). In the cohort of subjects chosen principally for non-skeletal risk factors
(those at least 80 years old), the risk of hip fracture was 4.2% for subjects given risedronate and
5.1% for those given the placebo (p=0.35) [52].
To assess the impact on vertebral fracture risk, Reginster et al. carried out a randomised,
double-blind, controlled trial to evaluate the effectiveness and security of risedronate for
reducing the risk of vertebral fractures in postmenopausal women with established osteopo‐
rosis. The trial was carried out at 80 locations in Europe and Australia. In total, 1,226 postme‐
nopausal women with two or more prevalent vertebral fractures were given risedronate 2.5mg
or 5mg per day or a placebo. Whilst the trial was carried out over three years, the 2.5mg cohort
was ended by protocol amendment after two years. Risedronate 5mg lowered the incidence
of new vertebral fractures by 49% over three years in comparison with the placebo (p<0.001).
A distinct decrease of 61% was witnessed over the initial year alone (p=0.001). The decreased
incidence of fracture was comparable in both cohorts after two years. The incidences of non-
vertebral fracture saw a decrease of 33% in relation to the placebo figures over three years
(p=0.06). Risedronate produced a distinct elevation in BMD at the spine and hip within a six-
month period. We can conclude that risedronate 5mg was an efficacious and well-tolerated
treatment for severe postmenopausal osteoporosis, decreasing the risk of vertebral fractures
and increasing bone density in women with chronic osteoporosis [53].
2.4.6. Ibandronate
In trials lasting three years, ibandronate has been proven to decrease the risk of vertebral
fractures (52%) and improve vertebral BMD (6.5%) whilst not having a substantial negative
impact on bone histology. It has also shown to be very efficacious in reducing bone loss in
GIOP (glucocorticoid induced osteoporosis). In women with severe osteoporosis T scores (<-3),
it decreases the risk of non-vertebral fractures up to 69% [54].
Randomised clinical studies such as MOPS (Monthly Oral Pilot Study) or MOBILE (Monthly
Oral Ibandronate in Ladies) have indicated that the ibandronate monthly dosage is just as
efficacious and safe as the daily dosage. Amongst the general population of the pivotal trial
(BONE,  Oral  Ibandronate  Osteoporosis  Vertebral  Fracture  Trial  in  North  America  and
Europe), the likelihood of adverse incidents of the gastrointestinal tract in both the daily
and the intermittent treatment cohorts was similar to the control cohort. Dyspepsia was the
only adverse incident with a marginally greater rate in subjects undergoing therapy with
ibandronate [55].
2.4.7. Zoledronate (zoledronic acid)
Zoledronic acid is a third-generation bisphosphonate. It is roughly as powerful as alendronate,
risedronate and ibandronate, however the application of this drug intravenously prevents any
negative impact and in fact augments the bioavailability, whilst also improving compliance to
100%.
The HORIZON trial (Health Outcomes and Reduced Incidence with Zoledonic Acid Once
Yearly Pivotal Fracture Trial) was a global, multi-centre, double-blind, controlled study of
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postmenopausal women with osteoporosis, whose goal was to demonstrate the increase
efficacy of intravenous zoledronic acid 5mg compared with a control. Subjects presented with
densitometric osteoporosis or densitometric osteopenia with a minimum of 2 mild to moderate
vertebral fractures [56]. Over 7,700 women were involved in the trial and were monitored over
a three-year period; particular scrutiny was made of new fractures, bone remodeling bio‐
chemical markers and densitometric developments. On completion of the trial, subjects that
had been treated with zoledronic acid presented a decrease in the vertebral fracture risk of
70%. The decrease was comparable for the first two years of the trial, varying from 60% to 71%.
In addition, subjects given zoledronate presented a decrease of 41% in hip fracture incidence
and 25% in non-vertebral fracture incidence. The outcomes of bone density and biochemical
bone remodeling markers were also markedly improved for the cohort given zoledronic acid.
Furthermore, bone mineral density was elevated to over 6% in the lumbar spine and total hip,
and to over 5% in the femoral neck. The biochemical markers of bone remodeling, after the
initial transfusion of zoledronic acid, decreased significantly as anticipated, and stayed stable
throughout the remainder of the trial [57].
Many subjects experienced adverse effects over the course of the trial, with a greater occurrence
of these in the zoledronate cohort. This variance was explained by post-infusion syndrome,
which commonly manifested itself 24-48 hours after the zoledronic acid infusion and dissi‐
pated three days after infusion. The syndrome presented with mild fever, myalgias, flu-like
symptoms, headache and/or arthralgias and was dissipated with analgesic, non-steroid anti-
inflammatory drugs or acetaminophen. A few subjects presented with passing renal function
deterioration 9 to 11 days post-infusion, however these instances were of no clinical transcen‐
dence [57].
Perhaps the most significant conclusion in relation to zoledronate therapy is the 28% decrease
in mortality of any cause, which was demonstrated in a cohort of over 2,000 subjects with femur
fracture [56].
We can conclude that zoledronate therapy is extremely efficacious in the reduction of vertebral,
non-vertebral and hip fractures. It reduces mortality, independent of the cause, following a
femur fracture.Moreover, it is a low-risk therapy that avoids the gastrointestinal adverse
events and high nonadherence rates that are commonly encountered with other bisphospho‐
nates, but it should be dispensed and regulated with great caution when treating individuals
with severe renal function impairment.
2.4.8. Safety of bisphosphonates
This class of treatments is usually well-tolerated, provided that they are administered carefully
and that patients adhere to the instructions for their use. Esophageal ulcerations been encoun‐
tered in situations where these treatments are given orally and on a daily basis. They must not
be given to patients with gastric or esophageal ulcerations, or to patients with pyrosis (heart‐
burn) which requires treatment. They must not be administered to pregnant women, or to
individuals with chronic renal impairment. The intravenous bisphosphonates normally give
rise to acute phase reactions with fever, arthromyalgia and flu-like symptoms that commonly
dissipate before the second dosage and which can be mitigated by giving acetaminophen or
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ibuprofen concurrently. Hypocalcaemia can present more frequently, so it is advisable to give
calcium and vitamin D concurrently. The renal function has to be regulated both prior to and
following treatments of intravenous bisphosphonates.
The avascular necrosis of the jaw, also called osteonecrosis of the jaw, is a condition which has
concerned many practitioners since Marx identified it for the first time in 2003 and it ought to
be outlined more completely in another chapter [58].
2.4.9. Long-term impact of bisphosphonate therapies: Atypical hip fractures
Research linking atypical fractures of the femur with longstanding treatments of bisphosph‐
onates caused the American Society for Bone and Mineral Research (ASBMR) to launch an
enquiry to consider the important queries raised by the conclusions of this research. The
enquiry’s committee identified both major and minor features of incomplete and complete
atypical femoral fractures and advised that all significant features, including their location in
the subtrochanteric region and femoral shaft, transverse or short oblique orientation, little or
no associated trauma, a medial spike when the fracture is complete, and lack of comminution,
be discernible in order to designate a femoral fracture as atypical. Minor features include the
fracture’s relationship with cortical thickening, a periosteal reaction of the lateral cortex,
prodromal pain, bilaterality, delayed healing, co-morbid conditions, and concurrent drug
usage, including bisphosphonates, other antiresorptive agents, glucocorticoids, and proton
pump inhibitors. On the strength of published and unpublished information and the wide
application of bisphosphonates, the occurrence of atypical femoral fractures linked with
bisphosphonate use for osteoporosis seems to be decidedly uncommon, especially in relation
to the extent to which vertebral, hip, and other fractures are in turn prevented. Moreover, a
causal link between bisphosphonates and atypical fractures has not been demonstrated.
Nevertheless, new investigations infer that the incidence rate increases with longer periods of
therapy, and there is a feeling of unease that a lack of understanding and underreporting could
be hiding the true extent of the issue.
A 2008 trial of 12,777 Swedish women aged 55 years or more with a fracture of the femur was
made public recently. Radiographs of 1,234 of 1,271 women presenting a subtrochanteric or
shaft fracture were analysed. Fifty-nine subjects with atypical fractures were isolated. The
relative and absolute incidence of atypical fractures linked with bisphosphonate treatment was
calculated using a national cohort analysis. The 59 subjects were also subject to a comparison
with 263 control subjects who presented typical subtrochanteric or shaft fractures. The cohort
analysis indicated an age-adjusted proportional risk of atypical fracture of 47.3. The rise in
global risk was 5 instances per 10,000 patient-years. In total, 78% of the fractured patients and
10% of the controls had been given bisphosphonates (multivariable-adjusted odds ratio of
33.3). The incidence level was independent of coexisting ailments. Following cessation of
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2.5. Biological agents
Conditions that give rise to bone loss, like osteoporosis, are caused by the imbalance in the
cycles of bone remodeling favouring bone resorption. The receptor activator of the nuclear
factor kB (RANK), and its ligand (RANKL) are critical for the differentiation, activation and
survival of osteoclasts and, as a result are the most simple intermediary in the regulating of
bone remodeling (Burgess et al.1999). It has been proven that the signaling of the RANKL is
inherent to the pathophysiology of many bone loss conditions, such as primary and many
secondary forms of osteoporosis.
2.5.1. Denosumab
Denosumab is a fully human monoclonal IgG2 antibody to RANKL that imitates the effects of
osteoprotegerine (OPG), endogenous inhibitor of RANKL that blocks bone resorption.
Comercial denosumab is sold as a sterile, uncolored solution administered via subcutaneous
injection.
2.5.1.1. Denosumab in human clinical studies
Data is accessible from more than 50 clinical studies in healthy adults and patients with
osteoporosis, bone loss linked with hormone-ablation treatments, rheumatoid arthritis,
advanced cancer (multiple myeloma and advanced malignancies that involve bone and giant
cell tumor of the bone collected since June 2001).
In the Denosumab Fortifies Bone Density (DEFEND) trial, a phase III, randomised, controlled
trial of 332 postmenopausal women with osteopenia sorted by the length of menopause (<5
years, >5 years), denosumab showed a distinctive rise in lumbar BMD (6.5%) at the two-year
point, in relation to the control (-0.6%). It also raised BMD in other sites including total hip,
distal third of the radius, and whole body (p>0.001) in the two cohorts. The rate of side effects
was comparable between the control cohort and the denosumab cohort [60].
In a comparative clinical study, the DECIDE (Determining Efficacy: Comparison of Initiating
Denosumab vs. Alendronate) trial of 1,189 postmenopausal women with low BMD (T-score: ≤-2
SD), subjects were randomly allocated 1:1 to two groups, one to be given subcutaneous
denosumab (60mg per 6 months) plus an oral alendronate placebo weekly or oral alendronate
weekly (70mg) plus a subcutaneous denosumab placebo injection every 6 months. Denosumab
raised total hip BMD in relation to alendronate (3.5% versus 2.5%, p<0.00001). A more
significant increase in BMD could be witnessed with denosumab than with alendronate in
other locations, as in the trochanter (4.5% vs. 3.5%), distal radius (1.1% versus 0.6%), lumbar
spine (5.3% versus 4.2%) and femoral neck (2.2% versus 1.6%); p<0.0003. The security profile
was comparable for the two cohorts. No subject in the trial developed antibodies in reaction
to denosumab [61].
Another phase III, multi-centre, double-blind trial, named STAND (Study of transitioning from
Alendronate to Denosumab) was carried out to assess the impact of denosumab in subjects who
were undergoing alendronate treatment. Five hundred and four postmenopausal women ≥ 55
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years old with a BMD T-score of <-2.0 and >-4 SD, who were taking weekly oral alendronate
for a minimum of six months, were randomly assigned to the treatment for 44±33 months.
Alterations to BMD and bone biochemical markers were assessed. After a year, the cohort
taking denosumab (and had been given alendronate before the trial) presented a markedly
elevated total hip BMD in comparison with the cohort which continued to take alendronate
(1.9% versus 1.05%; p<0.00012). Markedly elevated BMD readings with denosumab in
comparison with alendronate were also noted after one year at the lumbar spine, femoral neck,
and distal radius (all p<0.0125). The side effects and serious side effects were comparable in
both cohorts [62].
Lastly, the principal phase III study, the FREEDOM (Fracture Reduction Evaluation of Denosumab
in Osteoporosis every 6 Months) study, involved 7,868 postmenopausal women with osteopo‐
rosis and a BMD T-score between <-2.0 and >-4 SD and assessed the effectiveness in fracture
reduction of denosumab. Subjects were given 60mg subcutaneous denosumab or placebo
every six months for three years. Approximately 23% of the subjects had experienced a prior
vertebral fracture. The trial’s retention rate of subjects was 83%. The decrease in relative risk
of fracture was 68% (2.3% versus 7.2%; p<0.0001) for vertebral fractures, 20% (6.5% versus 8.0%)
for non-vertebral fractures and 40% (0.7% versus 1.2%) for hip fractures. In comparison to
patients in the control cohort, patients in the denosumab cohort saw a proportional elevation
of 9.2% in bone mineral density at the lumbar spine and 6.0% at the total hip at three years.
No distinctive dissimilarities were apparent between patients who were given denosumab and
those who were given a placebo in the overall rate of side effects, serious side effects, or
nonadherence to the trial as a result of side effects. No instances of osteonecrosis of the jaw
were found in either cohort during this decisive study (Cummings et al. 2009). Lastly, the
positive effects of denosumab therapy were generally discernible following the first treatment
and remained so over the course of up to eight years of denosumab therapy in an open-ended
extension trial [63].
We can conclude that denosumab provides an extremely efficacious substitute for osteoporosis
therapy through the reduction of bone resorption and the elevation of bone mineral density
via the inhibition of RANKL. A distinct benefit of denosumab is its route of administration
and dosage. A subcutaneous injection every 6 months is comparatively free of discomfort and
improves the therapy retention levels.
3. Anabolic agents
3.1. Fluoride
A series of observations were published indicating a low occurrence of fracture in subjects
residing in locations with elevated fluoride levels. Fluoride was first employed in osteoporosis
therapy in 1961. It was authorised for the prevention of osteoporosis in several European
countried, but was never given authorisation by the American Federal Drug Administration
(FDA) [64,65].
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The outcomes of studies into the impact of fluoride on the reduction of fracture risk are
ambiguous. Some trials have shown a reduction in the risk of vertebral fractures under
monofluorophosphate, or sodium fluoride treatment, whereas other trials, giving patients the
same preparations and dosage, did not. In addition, one meta-analysis extends these investi‐
gations and identifies an elevated fracture risk with increasing dosages after four years [66-68].
As a result, fluoride is not employed in the treatment of osteoporosis any longer.
3.2. Teriparatide (1-34 parathohormone)
Within the range of treatment options available, teriparatide or recombinant human PTH
(1-34), has a significant role to play. It is a member of the group of anabolic bone-forming drugs
rather than the anti-resorptive or catabolic group. It is a catalyst for fresh bone formation by
accelerating bone turnover in favour of formation. Teriparatide therapy improves trabecular
connectivity and cortical bone thickness [69] and augments the mechanical properties of bone
causing a marked reduction in vertebral and non-vertebral fractures in postmenopausal
women with osteoporosis, male osteoporosis and corticosteroid-induced osteoporosis [70]. For
this reason its application is deemed to be suitable mostly for individuals at high risk of fracture
and for those for whom other drugs have been unsuccessful [71].
The original indication for teriparatide first made public was the treatment of established
osteoporosis in postmenopausal women. Amongst the varying trials which have been carried
out on this treatment, the FPT (Fracture Prevention Trial) is the most significant. It assessed
teriparatide at dosages of 20 or 40μg/day in controlled conditions in 1,637 postmenopausal
women with vertebral fractures. Subjects taking teriparatide presented a marked decrease in
the rate of fresh vertebral and non-vertebral fractures. They also experienced elevated lumbar
and femoral neck bone density. Whilst the 40μg/day dose had a greater impact on BMD, the
risk of fracture did not vary to any marked extent between the two dosage levels, while the
higher dosage was less tolerated (11% nonretention due to adverse events with 40μg/day
compared with 6% with 20 μg/day or with the placebo). The dosage of 20μg/day presented a
decreased risk of vertebral fracture of 65% and a decreased risk of non-hip non-vertebral
fracture risk reduction of 35%. This trial was originally supposed to run over a 36-month
period, but it was terminated when subjects had undergone on average 21 months of treatment
for safety reasons following osteosarcomas witnessed in rats during drug toxicity trials [72].
In other trials it transpired nevertheless that this effect presented only in juvenile rats given
with elevated doses of PTH [73]. In addition, no instances of osteosarcomas have been noted
in humans.
A subset of subjects were monitored for a maximum of 18 months following the termination
of the therapy. This subset, which had been given teriparatide, demonstrated an enduring 40%
decrease in vertebral fracture risk at 18 months versus the control sample. These outcomes
indicate that the drug’s positive impact on the rate of non-vertebral fractures continues beyond
the termination of treatment [74].
3.2.1. Combination therapy: Teriparatide plus antiresorptives.
Despite bisphosphonates being the current benchmark for the treatment of osteoporosis,
several studies exist that have assessed whether the combination of teriparatide and BP can
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produce a positive impact. The trials indicate that, if both treatments are given at the same
time, bisphosphonates reduce rather than increase the anabolic action of teriparatide [75].
Combined teriparatide and denosumab, on the other hand, improves spine and hip BMD to a
greater extent than either treatment does when administered in isolation. In the DATA-
HRpQCT study, subjects underwent high-resolution peripheral QCT assessments at the distal
tibia and radius (postmenopausal osteoporotic women randomly assigned to take teriparatide
20μg daily (n=31), denosumab 60mg every 6 months (n=33), or both (n=30) for 12 months). In
the teriparatide cohort, the overall volumetric BMD (vBMD) did not vary at either anatomic
location but was improved in both other cohorts at both locations. The elevated vBMD at the
tibia showed an increase in the combination cohort (3.1±2.2%) compared with either the
denosumab (2.2±1.9%) or teriparatide cohort (-0.3±1.9%) (p<0.02). Cortical vBMD was reduced
by 1.6±1.9% at the tibia and by 0.9±2.8% at the radius in the teriparatide cohort whilst it was
elevated in both other cohorts at both anatomic locations. Tibia cortical vBMD saw greater
increases in the combination cohort (1.5±1.5%) than in the other two cohorts (p<0.04 for both
comparisons). Cortical thickness was not affected in the teriparatide cohort, but was elevated
in the other cohorts. Elevations in cortical thickness at the tibia was more marked in the
combination cohort (5.4±3.9%) than the other cohorts (p<0.01 for both comparisons). In the
teriparatide cohort, radial cortical porosity was raised by 20.9±37.6% and by 5.6±9.9% at the
tibia but was not affected in the other two cohorts. Bone stiffness and failure load, as calculated
through finite element analysis, was not affected in the teriparatide cohort but was elevated
in the other two cohorts at both locations. These results suggest that the application of
denosumab combined with teriparatide has a positive impact on HR-pQCT indices of bone
quality to a greater extent than either treatment in isolation and may be of significant clinical
benefit in the management of postmenopausal osteoporosis [76].
3.2.2. Teriparatide in individuals formerly given antiresorptives
The EUROFORS study was a prospective, open-label, randomised study of 865 postmeno‐
pausal women with established osteoporosis and aimed to assess a variety of consecutive
applications of teriparatide over a two-year period. Subjects were split into several subsets
based on their former therapies. The outcomes of the BMD variations and biochemical markers
of bone formation indicated that the application of teriparatide has a beneficial impact on bone
mass and osteoblast function in postmenopausal women with established osteoporosis
whatever the extent or type of former long-term exposure to antiresorptive treatments has
been.
The length of the antiresorptive treatment and the length of pause in treatment between the
former therapy and the teriparatide had no impact on BMD levels at any anatomic location.
The skeletal reaction at the lumbar spine was comparable among former antiresorptive
treatment cohorts at every point in time over the course of the trial, however subjects who had
previously been given etidronate presented a greater increase, most likely a factor of its poorer
anti-remodeling action. At six months, overall hip and femoral neck BMD showed a marked
reduction in the former alendronate subset, and total hip BMD showed a marked reduction in
the former risedronate subset. Overall hip and femoral neck BMD was statistically reduced
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from baseline in all other subsets at the six-month point. Nevertheless, this short-term
reduction was contradicted over longer-term teriparatide therapy. All subsets demonstrated
a numerically distinctive rise in BMD versus baseline after 18 and 24 months of therapy, and
without variations between the cohorts at any point in the trial [77].
3.2.3. Sequential treatment
In a further non-randomised trial, 59 postmenopausal women with osteoporosis formerly
given raloxifene or alendronate over an 18-36 month period, were treated with teriparatide
over 18 months. Variations in BMD and bone-turnover markers were analysed. Subjects who
had formerly been given alendronate saw a delayed rise in bone-turnover markers with results
more than a third lower than those of subjects who had formerly been given raloxifene. Over
the initial six-month period there were marked variations in the rise in BMD at the lumbar
spine and hip. Subjects formerly given raloxifene saw more significant rises in BMD at the two
sites. After 18 months of therapy marked variations continued in the lumbar spine, with greater
improvement in subjects previously given raloxifene, however the variations in the hip were
not as decisive. This proves that this application of teriparatide augments bone turnover in
subjects formerly given raloxifene or alendronate, and that this improvement comes sooner
and is more significant with the raloxifene pretreatment cohort [78].
3.2.4. Corticosteroid-induced osteoporosis and male osteoporosis
Studies have also been published which demonstrate the effectiveness of teriparatide in the
management of GIOP. In a randomised, double-blind study, 428 subjects both male and female
from 22 to 89 years old, who had been given corticosteroids for a minimum of three months
were randomly assigned to be treated with either alendronate 10mg/day or teriparatide 20μg/
day over an 18 month period. After a year, the overall femur BMD was greater in the teripara‐
tide cohort and on termination of the trial there were fewer vertebral fractures in the teripara‐
tide cohort [79].
Teriparatide has also been employed as a treatment in men with osteoporosis. The trial
analysed results from men with idiopathic or secondary osteoporosis being treated with
teriparatide in comparison with a control group. The trial indicated elevated results, inde‐
pendent of gonadal status and other influential elements in the teriparatide cohort [80].
3.2.5. Adverse Effects
Overall,  teriparatide  (recombinant  human  PTH  (1-34))  injections  are  well-tolerated.  It
disappears from the bloodstream in less than four hours following subcutaneous adminis‐
tration. Injections on a daily basis are required and a passing reddening at the injection site
has been observed. Headache and nausea have been noted in under 10% of patients treated
with a daily dose of 20μg. Mild, early, short-term hypercalcemia can transpire, but severe
hypercalcemia is uncommon. Higher levels of urinary calcium (up 30μg per day) and serum
uric acid concentrations (up 13%) are witnessed, however these do not seem to have clinical
ramifications.
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We can conclude that teriparatide is an appropriate and effective drug for the management of
osteoporosis. It is efficacious in addressing a variety of clinical conditions, e.g. male osteopo‐
rosis or corticosteroid-induced osteoporosis.
3.3. 1-84 Parathormone
Intact PTH (PTH 1-84) has been reported to have a beneficial impact on bone micro-architecture
and to reduce incidence of fresh fractures as a result of its bone-forming mode of action [81].
PTH 1-84 is not procurable any more due to the withdrawal of its marketing licence at the
behest of the regulating authority.
4. Dual action agents
4.1. Strontium ranelate
The possible clinical applications of strontium were revealed in approximately 1940, when
strontium-89 was deployed as an analgesic treatment for bone metastases caused by prostate
cancer [82,83].
In-vitro, strontium ranelate augments collagen and non-collagen protein synthesis through
mature osteoblasts. The bone-forming action has been demonstrated by the higher levels of
replication amongst pre-osteoblastic cells. This catalytic action on the duplication of pre-
osteoblastic cells and the higher levels of collagen and non-collagen proteins have caused
strontium ranelate to be regarded as a dual effect bone agent, because it does not simply reduce
resorption [84]. The principal tool that can determine bone resorption at a molecular level is
the RANK/RNAKL/OPG system outlined above. Solutions of 0.1mM to 2nM of strontium
ranelate reduce the capacity of human osteoblasts to cause osteoclast differentiation, by
reducing expression of mRNA of RANK-L and boosting mRNA expression of OPG, as
reported in the trials carried out by Brennan et al. in 2006 [85, 86].
4.1.1. Impact of Strontium ranelate in fracture reduction
Studies have shown that the chemical properties of strontium ranelate cause the, densitometric
values of subjects given the compound to be greater than the true values. Complex mathe‐
matical formulas exist to cut out the statistical impact of this from the DMO value, however it
is more straightforward and sufficiently accurate to assume instead that half of the DMO
achieved in the first year of therapy with strontium ranelate is a result of elevations in BMD
and the remainder is a result of the basis caused by the heavier strontium measured by the
DXA [87].
Information from the SOTI (Spinal Osteoporosis Therapeutic Intervention) study and the
TROPOS (Treatment of Peripheral Osteoporosis) study looked at 1,649 postmenopausal
subjects (SOTI trial) and 5,091 subjects (TROPOS trial) [88,89]. The initial three-year outcomes
demonstrated a decrease in vertebral fractures of 41% with a NNT of 9. Moreover, an im‐
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provement in BMD of 12.7% was recorded. The decrease in vertebral fractures at the end of
the four- and five-year periods was 33% and 24% respectively. In relation to non-vertebral
fractures, the reduction in the relative incidence of fracture with strontium ranelate was 16%
at the end of the three-year period and 15% at the end of the five-year period. A later assessment
of these results in a subset of 1,977 subjects with high fracture risk (≥74 years old and a T-score
of ≤-2.4) indicated a decrease in the incidence of vertebral fracture of 36% at the end of the
three-year period and 43% at the end of the five-year period [87, 90].
4.1.2. Security
Strontium ranelate was deployed in a widespread manner across Europe up to February 2014,
when the European Medicines Agency (EMA) advised that the use of the drug be limited to
cases which cannot use other treatments approved for osteoporosis, and that subjects with
high risk for ischemic cardiac disorders should be excluded from this treatment option. This
decision was grounded in a study carried out by the Pharmacovigilance Risk Assessment
Committee (PRAC) that highlighted doubts about cardiovascular security which went beyond
the risk, already known, of venous thromboembolism. On the basis of the PRAC analysis, an
elevated incidence of serious cardiac disorders (including myocardial infarction) was pin‐
pointed and steps were put forward to minimize the risk, specifically targeting the highlighted
issue, in April 2013.
5. Overview of current treatments
As set out in this review, there are several treatment options for osteoporosis. Unfortunately
the choices are more restricted in daily clinical practice as treatments have been removed or
their use restricted. Table 2 provides a summary of those treatments currently available to
practitioners.
Table 2. Current available osteoporosis therapies
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6. Future treatment options
6.1. Cathepsine K (CatK) inhibitors
Cathepsin K is expressed in the main in osteoclasts and a variety of other multinucleated cells
including giant foreign body cells and Langhans cells. To a lesser extent it is present in
macrophages, synovial fibroblasts, and fibroblasts at sites of wound repair or inflammation,
chondrocytes, various epithelial cells of the human fetus, adult lung airway epithelium,
thyroid epithelium, and potentially in low levels within smooth muscle cells. When the enzyme
has been synthesised, it is separated into lysosomes and can be introduced into the extracellular
environment. It is introduced particularly into the resorption lacuna below actively resorbing
osteclasts where it is causes the degradation of the collagen type I dominated organic bone
matrix. Thus, in a similar manner to pycnoidisostosis, removal of cathepsin K from osteoclasts
prevents bone resorption. Inhibitors of cathepsin K are reported to have a less significant
impact on osteoclast–osteoblast interaction, causing a lower inhibition of bone formation than
available bisphosphonate antiresorptive drugs. Human cathepsin K inhibitors have been
proven to stop bone loss in ovariectomized mice without reducing the anabolic effeciveness
of parathyroid hormone (PTH) [91].
Whilst no CatK inhibitor is licensed for osteoporosis treatment or prevention at the present
time, trials of three CatK inhibitors for the management of osteoporosis have been published:
balicatib, relacatib, and odanacatib.
6.1.1. Balicatib
Balicatib is extremely selective for CatK in enzyme potency tests but has a reduced selectivity
in living tissue. Clinical trials of balicatib have shown elevated BMD in postmenopausal
women, but the drug was linked with cutaneous adverse effects. The first presentation of the
efficacy of cathepsin K inhibitors on human bone density was witnessed with balicatib. This
study, released by Adami et al. at an ASBMR meeting in 2009 (Denver, CO, USA), was a multi-
centre, randomised, controlled, 12 month, dose-range identifying trial of 675 postmenopausal
subjects with lumbar spine T-score less than 2.0. In the cohort treated with 50mg of balicatib
daily, markers of bone resorption were reduced by over 55% with no reduction in markers of
bone formation (osteocalcin, bone-specific alkaline phosphatase and N-terminal propeptide
of type I collagen). The lumbar spine BMD was elevated 4.46%, that of the total hip was elevated
2.25%. Cutaneous reactions, including pruritus and morphea-like alterations, were observed
in a low number of subjects. In a limited Japanese study, intact PTH levels were demonstrated
to be elevated by 50% with balicatib treatment [92].
6.1.2. Relacatib
Relacatib is a powerful but nonselective inhibitor of cathepsins K, L, V, and S for which no
clinical data in humans has been made public. The use of relacatib with ovariectomized and
control monkeys caused an acute and rapid decrease in bone markers, and the impact of this
lasted for a maximum of 48 hours, according to the dosage administered [93].
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On the basis of the adverse effects, especially the cutaneous reactions, the production of all
cathepsin K inhibitor drugs has been discontinued or put on hold, with the exception of
odanacatib and, at present, ONO 5334
6.1.3. Odanacatib
Odanacatib is a potent, selective inhibitor with an ability to inhibit cathepsin K in osteoclasts
[91].
Two trials have been undertaken to assess the effectiveness and security of odanacatib, a phase
I study to determine the dosage and a phase II study to assess the security and effectiveness.
In the Phase I study a cohort of 49 women was used to assess a weekly dose. Doses of 5mg,
25mg, 50mg, and 100mg were used and 12 subjects were placed in the control cohort. A cohort
of 30 women was created to enable the evaluation of the daily dosage. Doses of 0.5, 2.5, and
10mg were deployed, with six subjects placed in the control cohort. All treatments were given
under fasting conditions. Odanacatib had an extended half-life of between 66 and 93 hours for
all the treatments and dosages assessed. The effectiveness of both weekly and daily dosages
in altering the markers was assessed. The impact was dose-dependant but not in proportion
to the dosage level. Decreases in resorption markers were highest for weekly doses >50mg and
daily doses ≥2.5mg. The greatest suppression was witnessed between days 3 and 5 with the
weekly dose and this level remained elevated until the subsequent treatment [95].
The Phase II trial presented by Cusick et al. at the ASBMR meeting in 2009 (Denver, Co, USA),
was a double-blind, randomised, controlled study lasting one year, with an expected extension
period of two years. It looked at 399 postmenopausal women (postmenopausal (5yr) or
bilateral oophorectomy) aged 45 to 85 years, presenting a T-score <-2 but not less than -3.5 in
any one location. Subjects were assigned to five different cohorts with differing dosage levels:
placebo, 3mg/week, 10mg/week, 25mg/week and 50mg/week. The variations in BMD at the
lumbar spine were analysed and taken as the main outcome. In addition, variations in bone
remodeling, variations in BMD in other locations and side effects were assessed in turn. The
data indicated a elevation in BMD in all locations, which was related to the dose level. The
more significant improvement was achieved with the highest dose. Weekly treatments of 50mg
of odanacatib augmented bone mass by 5.7% in the lumbar spine, 4.1% in the total hip, 4.7%
in the femoral neck, 5.2% in the trochanter and 2.9% in the distal third of the radius at the two-
year point. Resorption markers dropped relative to the dose from the start of the therapy and
stayed lower over the initial six-month period, at which point they increased to a similar level
as those in the control group.
The data from the extension period of the phase II study to the three-year point (reported by
Eisman et al. at the ASBMR meeting 2009 in Denver), looked at 169 women randomly assigned
to weekly doses of odanacatib 50mg or a placebo. In the odanacatib cohort, BMD continued to
rise (lumbar spine 7.5%, total hip 5.5%, femoral neck 5.5% and trochanter 7.4%). The urine NTX
resorption marker was reduced by 50% versus the placebo, while the BSAP (bone specific
alkaline phosphatase) formation marker remained unchanged. At the three-year point,
formation markers had not only not decreased, but had in fact risen by 18% above baseline
values.




ONO5334 is a new cathepsin K inhibitor. An initial trial has been carried out to assess its
effectiveness and security in the treatment of postmenopausal osteoporosis. This was a year-
long, randomised, double-blind, placebo and active-controlled parallel-group trial carried out
across 13 locations in six European states. The study looked at 285 postmenopausal women
from 55 to 75 years old with osteoporosis. Patients were randomly assigned to one of five
dosage groups: placebo; 50mg twice daily, 100mg once daily, or 300mg once daily of
ONO-5334; or alendronate 70mg once a week. After 12 months of monitoring all ONO-5334
doses and alendronate demonstrated a marked elevation of BMD at the lumbar spine, total
hip (except the 100mg/day cohort), and femoral neck. There was little or no evidence that
ONO-5334 suppressed bone-formation markers versus the alendronate, however the sup‐
pressive action on bone-resorption markers were comparable. There were no security issues
of any clinic consequence. With a marked elevation in BMD, ONO-5334 also heralds a new
mechanism in the treatment of osteoporosis. This new agent increases the range of treatments
available both in the class of cathepsin K inhibitors as the second apparently available agent,
and also across the full range of osteoporosis treatment [94].
We can conclude that Cathepsine K inhibitors are a new class of treatment that adds to the
range of therapies available for the treatment and prevention of fractures, the most hazardous
consequence of osteoporosis. Being able treat this condition at a variety of points along the
resorption pathway is an asset and it provides clinicians with the opportunity to reduce the
risk of fractures more effectively than before.
6.2. Sclerostin
Sclerostin is a protein encoded by the SOST gene [96, 97]. It is identified as an important
inhibitor of osteoblast-mediated bone formation [98, 99]. Loss-of-function mutations in this
gene are linked with sclerosteosis, which results in progressive bone overgrowth and elevated
bone mass and BMD.
A similar condition is van Buchem disease, a less severe form of sclerostosis resulting from by
a deletion downstream of this gene, and leading to reduced sclerostin expression. SOST gene
knockout mice no longer produce sclerostin and have an elevated bone mass, which demon‐
strates the impact this protein has on bone mass and BMD levels. In addition to elevated bone
mass and BMD levels resulting from sclerostin deficiency, it is notable that no fractures have
been reported in patients with either sclerosteosis or van Buchem disease [99, 100].
Sclerostin binds to low-density lipoprotein receptor-related protein (LRP) 5/6 and intercepts
Wnt-signaling, governing bone formation in a negative manner and preventing osteoblast
differentiation, proliferation, and activity [101].
6.2.1. Anti-sclerostin monoclonal antibodies
At the present there are three separate humanized sclerostin antibodies under investigation:
romosozumab (AMGEN & UCB), blozosumab (Eli Lilly) and BPS804 (Novartis). Romosozu‐
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mab is a high affinity immunoglobulin G2 (IgG2) monoclonal antibody. It is produced through
the humanisation of a mouse sclerostin monoclonal antibody that neutralizes sclerostin. The
first-in-human single-dose trial in healthy men and postmenopausal women was carried out
to assess pharmacokinetics, pharmacodynamics, tolerance and security of romosozumab
doses of 0.1, 0.3, 1, 3, 5 or 10mg/kg delivered sub-cutaneously and 1 or 10mg/kg delivered
intravenously. Seventy-two subjects in total took part in the trial and were subsequently
monitored for a maximum of 85 days. The pharmacokinetics of this agent were not relative to
the dosage levels. Dose-related rises in bone formation markers and falls in bone resorption
markers were noted. A small proportion of subjects presented anti-investigational product
bodies however the majority of these were non-neutralizing antibodies. The data indicated
that the agent was well-tolerated [102].
In a phase II, multi-centre, multi-dose, controlled, parallel groups clinical study, 419 postme‐
nopausal women with poor BMD were randomly assigned to the treatment to assess the
effectiveness of romosozumab versus alendronate, teriparatide and a placebo, over a one year
course of therapy. The main outcome was BMD change. All the dosage levels of romosozumab
causes a marked elevation in the BMD at the lumbar spine, femoral neck and total hip together
with a short-term rise in the bone formation markers and a durable fall in the bone resorption
markers [103]. Data from the phase III studies is to be published soon.
A randomised, double-blind, controlled phase II clinical study of blosozumab in postmeno‐
pausal women with poor BMD was recently made available. Subjects were given subcutane‐
ously administered blosozumab 180mg Q4W, 180mg Q2W, 270mg Q2W or equivalent placebo
over a period of one year. In total, 120 women took part. Dosage levels across the range of
blosozumab augmented lumbar spine and total hip BMD. Bone formation markers rose rapidly
during the therapy while bone resorption markers fell at an early point in the therapy and
continued at low level through to the end of the trial [104].
A comparable study was carried out using BPS804 with a similar cohort, however no data is
yet published from this trial.
We can conclude that anti-sclerostin antibodies may be the most efficacious agent in the
treatment of osteoporosis and bone defect related conditions.
7. Conclusion
Over the last decade, new drugs have come forward as potential pharmacological treatments
for osteoporosis. More recent options are part of new classes of agent which present optimised
modes of action, allowing practioners to replace patients’ lost bone mass more quickly and
efficaciously than with older treatments. Nonetheless, it is important to be aware that all drugs
have their appropriate uses and also a wide range of side effects, factors which must be
considered in any clinical decision-making process. Furthermore, it is vital that practitioners
ensure that, as required by the majority of therapies, treatments for osteoporosis are admin‐
istered alongside adjustments in a patient’s lifestyle and/or calcium and vitamin D supple‐
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mentation. New treatments are now coming into use that are likely to enable practitioners to
opt for shorter courses of therapy which result in better outcomes for patients.
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1. Introduction
1.1. Chronic kidney disease (CKD)
Chronic kidney disease (CKD) is an international public health problem affecting 5–10% of the
world population, as it is responsible for high morbidity and mortality particularly affecting
population over 60 years of age. [1]. CKD is defined as abnormal renal function or structure [1].
GFR category GFR (ml/min/1.73 m 2 ) Terms
G1 >90 Normal or high
G2 60–89 Mildly decreased*
G3a 45–59 Mildly to moderately decreased
G3b 30–44 Moderately to severely decreased
G4 15–29 Severely decreased
G5 <15 Kidney failure
* Relative to young adult level
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate
Reprinted with permission from Kidney Disease: Improving Global Outcomes (KDIGO) CKD
Work Group (2013) KDIGO 2012 clinical practice guideline for the evaluation and
management of chronic kidney disease. Kidney International (Suppl. 3): 1–150
Table 1. Stages in CKD
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
As classified by National Kidney Foundation [1] and Kidney disease improving global
outcome (KDIGO) [2] CKD has 5 stages based on e GFR (estimated glomerular filtration rate)
(Table 1) and markers of kidney damage. CKD is diagnosed when e GFR is consistently <60ml/
min/1.732 on at least two separate occasion separated by a period of more than 3 months. Stage
3 is further sub classified into 3a (45 to 59ml/min) and 3b (30 to 44ml/min) and includes
albuminuria in the classification. eGFR ≥30-60ml/min/1.732 or stage 3 is referred as “early CKD”
and eGFR <30 or stage 4-5 is referred as “late CKD”. Stage 5 or e GFR <15 is also referred as
end stage renal disease (ESRD).
1.2. Bone mineral disruption in CKD
As kidney function declines, there is a progressive deterioration in mineral homeostasis, with
a disruption of normal serum concentrations of calcium and phosphorus. The disturbance in
mineral homeostasis is due to changes in circulating levels of hormones such as parathyroid
hormone (PTH), 25-hydroxyvitamin D [25 (OH) D), 1,25-dihydroxyvitamin D [1,25 (OH) D)or
calcitriol and fibroblast growth factor (FGF-23] [3].
Beginning in CKD stage 3 or early CKD, the ability of the kidney to appropriately excrete a
phosphate load is diminished. However, serum calcium and phosphorous levels remain
within the reference range with PTH either within the reference range or slightly elevated. Rise
in FGF-23appears much earlier than changes in serum phosphate or PTH [4,5]. FGF-23 is
produced by osteocytes and osteoblasts. It has phosphaturic action where by it reduces the
renal tubular reabsorption of phosphate by reducing the expression of sodium phosphate
cotransporters in renal tubule through Klotho-FGF receptor. Therefore, FGF-23 production is
stimulated by impaired renal excretion of phosphate and elevated 1,25 (OH)D.FGF-23
indirectly stimulates PTH secretion by decreasing the synthesis of 1,25 (OH)D. Studies have
shown the effect of this raised FGF-23 on mortality in dialysis patients [6].
As CKD progresses further, hyperphosphatemia stimulates the secretion of PTH, leading to
secondary hyperparathyroidism. Additionally, hyperphosphatemia itself has direct posttrans‐
lational effect on PTH synthesis [7]. Further deterioration in kidney function results in
impaired conversion of 25 (OH) D) to 1,25 (OH) D, reducing 1,25 (OH)Dsynthesis. This
reducesintestinal calcium absorption and ensuing hypocalcaemia further stimulates PTH
secretion aggravating secondary hyperparathyroidism. FGF-23 also down regulates the
synthesis of 1,25 (OH)D through 1-alfa hydroxylase, which exacerbates the secondary hyper‐
parathyroidism. In addition, there is evidence at the tissue level of a down regulation of vitamin
D receptor and of resistance to the actions of PTH. Due to target tissue resistance to PTH action,
kidney fails to respond adequately toPTH, aggravating secondary hyperparathyroidism.
Thus there is continuous secretion of PTH due to hyperphosphatemia, hypocalcaemia, reduced
synthesis of 1,25 (OH)D resulting in parathyroid hyperplasia [8]. This is commonly seen in late
CKD, which presents with mineral and hormonal disturbances such as hypocalcaemia,
hyperphosphatemia, raised PTH, raised FGF-23 and low vitamin D status.
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The disruption in mineral and endocrine functions in CKD has significant effect on bone
remodeling as secondary hyperparathyroidism stimulates the bone resorption. Vitamin D
deficiency disrupts mineralization of bone leading to overall deterioration in bone quali‐
ty.Hence a wide spectrum of bone metabolic disorders is seen in patients with CKD stage 3-5
and those on dialysis (stage 5D). This mineral and hormonal disruption in CKD alters the bone
morphology and constitutes renal osteodystrophy of CKD.PTH and vitamin D are the major
hormones, which, are involved in renal osteodystrophy. Besides this recent studies have
shown that FGF-23 also contributes to vitamin D deficiency [10].More recently, there has been
an increasing concern for extra skeletal calcification that may result from the deranged mineral
and bone metabolism of CKD. Extra skeletal calcification or vascular calcifications is major risk
for cardiovascular disease in CKD patients contributing to high morbidity and mortality in
this sub population group.
1.3. Bone metabolic disorders in CKD
CKD can present with wide spectrum of bone metabolic disorders, includingrenal osteodys‐
trophy and osteoporosis. The manifestation of bone metabolic disorders is influenced by the
severity of CKD. Osteoporosis is predominant in early CKD where it is potentiated by risk
factors such as ageing, gender (post menopausal women), poor calcium and vitamin D intake,
premature menopause, medications and chronic inflammatory disorders. These risk factors
reduces the bone mass and results in osteoporosis. Renal osteodystrophy is predominant in
late CKD where impaired bone and mineral homeostasis associated with hormonal distur‐
bances affects the bone quality and mineralization. Both types of bone metabolic disorders
increase the risk of bone fragility fractures thereby contributing to high morbidity and
mortality in CKD patients.
1.3.1. Osteoporosis
Osteoporosis, which is characterized by low bone mass, is traditionally diagnosed as low bone
mineral density (BMD). Osteoporosis as defined by WHO is the measurement of bone density
at lumbar spine or hip which is equal to or less than 2.5 standard below the bone density of
young adult reference population.DEXA or dual energy X ray absorptiometry is recommended
as a diagnostic tool for measuring BMD. Osteoporosis is more common in postmenopausal
women particularly Caucasian women [11].Pathologically, osteoporosis is associated with
high bone turnover due to increased osteoclastic activity, increasing the bone resorption.
Since osteoporosis disrupts bone quality, patients with osteoporosis are at increased risk of
fractures. The BMD provides information on the likelihood of fracture risk in patients as lower
is the BMD, higher is the risk of fracture and vice versa. Besides BMD, several factors identify
the risk of fracture in an individual such as ageing, gender (post menopausal women), low
body mass index, smoking, alcohol intake, parental history of hip fracture, previous fracture,
steroid intake, rheumatoid arthritis and inflammatory bowel diseases.The risk of osteoporosis
in general population is being assessed by fracture risk assessment tool (FRAX) provided by
WHO [12].
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Since osteoporosis is commonly seen in postmenopausal women or men above 50 years of age,
this population group also has a high incidence of early CKD. Where as patients with late CKD
have renal osteodystrophy, which is,characterized by abnormal bone quality with normal or
high bone mineral content. Hence osteoporosis in CKD is most appropriate only for early CKD.
Where as in CKD 4-5 or 5D stages (late CKD), low BMD should be designated as having ‘CKD
with low BMD.’ The prevalence of osteoporosis is high in early CKD where as in late CKD it
coexists with renal osteodystrophy.
1.3.2. CKD–MBD
KDIGO introduced a clear defined terminology for renal osteodystrophy in CKD patients,
which is based on diagnostic tools [1].The wide spectrum of bone metabolic disorders, which,
encompasses renal osteodystrophy is now defined as CKD associated mineral and bone
disorder or CKD-MBD. This includes:
• Disruption in mineral homeostasis such as calcium, phosphorous
• Hormonal disturbances involving PTH, vitamin D and FGF-23
• Bone metabolic disorders characterized by high or low bone turnover affecting bone quality
and strength
• Extra skeletal calcification (vascular or soft tissue) increasing the cardiovascular risk
Three types of bone metabolic disorders are seen in CKD-MBD as classified by bone histo‐
morphometry:
• Osteitis fibrosa (OF): characterized by increased bone turnover and bone resorption due to
secondary hyperparathyroidism
• Osteomalacia (OM): defective bone mineralization due to low vitamin D status
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Thus secondary hyperparathyroidism, which accompanies CKD, has a significant effect on the
bone metabolism. Over the years, several approaches have been used to manage secondary
hyperparathyroidism such as calcium salts to bind phosphate, vitamin D analogues to correct
hypocalcaemia and vitamin D deficiency, parathyroidectomy in tertiary hyperparathyroidism
to correct hypercalcaemia, calcimimetic drugs are used as an alternative to parathyroidectomy.
All these therapies are given to reduce the effect of PTH on bone and therefore over-suppres‐
sion of PTH over a prolonged time reduces the bone turnover and leads to adynamic bone
disease (ABD) [14]. Studies have shown that 30% patients in CKD 4 and between 15 and 60%
patients in CKD 5 or 5D has ABD [9]. ABD in CKD-MBD is characterized by subnormal osteoid
tissue, mineralization, reduced osteoclast and osteoblast activity.Thus a large proportion of
patients with CKD-MBD presents more frequently with ABD than OM or OF.
The prevalence of ABD has been increasing in CKD population. The exact mechanisms
contributing to this type of bone disorders is largely unknown. Nevertheless, several factors
are thought to be aggravating this type of low bone turnover renal osteodystrophy. Dialysis
fluid containing aluminum is deposited in bone and can impair bone mineralization and
reduce bone turnover. However aluminimum is no longer used in dialysis now. ABD is
commonly seen in patients with diabetic nephropathy than in non-diabetics. Iron load is also
thought to contribute to ABD. Patients with ABD are also susceptible to develop hypercalcae‐
mia. Therisk of hypercalcaemia is exacerbated with administration of calcium carbonate in the
CKD patients where it used as a phosphate binder. Patients with ABD have impaired ability
to buffer calcium loads, a tendency to hypercalcaemia, as well as increased fracture rates and
prevalence of extra-skeletal calcification.
1.3.3. Bone fragility fractures
Both osteoporosis and renal osteodystrophy in CKD-MBD can lead to increased bone fragility
and fractures as both conditions are associated with low bone quality and poor bone micro‐
architecture. However both these diseases have different pathophysiological backgrounds.
Bone fragility is due to varying combinations of low bone mineral content and abnormal bone
quality. The fracture risk in CKD is magnified in elderly patients, women, diabetic, those using
glucocorticoids, and in those with a longer exposure to dialysis. Patients in CKD are at higher
risk of bone fragility fractures than those without CKD. FRAX (fracture risk assessment tool
by WHO), which is used to estimate fracture risk in patients without CKD, is not applicable
to patients with CKD as it will underestimate fracture risk.
The low impact fractures such as vertebral, non-vertebral and hip fractures are usually
associated with osteoporosis as well as seen in CKD-MBD. The bone fragility fractures usually
present with back pain leading to disability and death in these patients [15]. Hip fractures are
common in CKD patients due to secondary hyperparathyroidism as PTH affects the cortical
bone leading to high morbidity and mortality in these patients [16,17].
Patients with CKD-MBD have an increased risk of fracture compared with the general
population, which can be due to osteomalacia, secondary hyperparathyroidism or adynamic
Management of Osteoporosis in Chronic Kidney Diseases
http://dx.doi.org/10.5772/59607
113
bone.In CKD-MBD secondary hyperparathyroidism potentiates the risk of bone fractures by
increasing the bone turnover as seen in OF and OM. ABD is presumed to increase the risk of
bone fractures due to impair ability of bone to repair micro fractures due to low bone turnover.
2. Management of osteoporosis in CKD
Since CKD involves wide spectrum of bone metabolic disorders, the identification of osteo‐
porosis from other bone metabolic disorders is essential particularly in late CKD stage.
2.1. Investigations
2.1.1. Bone Mineral density (BMD)
Patients in early CKD are diagnosed by bone mineral density measured by DEXA scan. BMD
measurement is indicated in early CKD provided they do not have manifestations of CKD-
MBD. Since CKD-MBD encompasses a wide spectrum of bone metabolic dystrophy, which
varies from renal osteodystrophy to osteoporosis, BMD measurement by DEXA is unable to
differentiate between the types of bone metabolic disorders. More importantly there is no
evidence that BMD in CKD-MBD predict the fracture risk in this subpopulation unlike in
patients with early CKD. The risk of fractures is high in CKD-MBD as compared to early CKD
as both renal osteodystrophy and osteoporosis increases the risk of fractures.Thus, the routine
use of BMD in patients with late CKDhas not been recommended. In patients with late CKD,
the relationship between BMD and fractures is not as strong as that in the general population.
2.1.2. Biochemical markers
The biochemical markers are useful in assessing the bone metabolic status in CKD. These
include:
• Hormones regulating the bone turnover
• Markers of bone collagen breakdown or formation
• Indicators of bone mineralization
The biochemical markers, help in differentiating the high bone turnover from low bone
turnoverparticularly in CKD-MBD. Studies have shown that 40% CKD-MBD patients have
high bone turnover compatible with OF and mixed bone disease where as 60% have low or
normal bone turnover as seen in OM and AD.
Since these biochemical markers are non-specific they cannot help with the diagnosis of the
type of bone metabolic disorder in CKD. They are helpful in monitoring the management of
bone metabolic disorders in CKD patients.
• Hormones regulating the bone turnover
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PTH regulates bone physiology. Serum PTH levels have been used as a surrogate indicator of
bone turnover in the absence of bone biopsy.Raised PTH indicates vitamin D deficiency in
early CKD where as late CKD it suggests high turnover bone metabolic disorders.PTH which
is usually six times above the reference range, is associated with high bone turnover which
can be seen in osteitis fibrosa cystica or osteomalacia but do not conclusively predict high
turnover bone metabolic disease.The presence of low PTH (<15.9pmol/L or 150pg/ml) is
consistent with low bone turnover osteodystrophy such as ABD. Thus raised PTH excludes
the ABD in CKD-MBD.
• Biochemical markers of bone turnover
The markers of bone turnover help in the biochemical monitoring of bone metabolism. These
markers include enzymes and proteins released during bone formation and degradation or
resorption. The markers are not recommended for the diagnosis of osteoporosis. Nevertheless,
they are useful in monitoring the treatment of osteoporosis in patients. The markers of bone
turnover along with BMD are helpful in predicting the fracture risk in osteoporotic patients
[18]. The markers are classified as formation markers, which are produced by osteoblasts or
from pro collagen metabolism where as resorption markers are derived from degradation of
osteoclasts or collagen tissue.
The markers of bone turnover includes:
a. Bone formation markers
1. Bone Alkaline phosphatase (BALP)
2. Type 1 N terminal procollagen peptide (P1NP)
3. Type 1 C-terminal procollagen peptide (P1CP)
4. Osteocalcin (OC)
b. Bone resorption markers
1. C terminal telopeptide (CTX)
2. N terminal telopeptide (NTX)
3. Pyridinolines (PYR)
4. Deoxypyridinolines (DPYR)
5. Tartrate resistant acid phosphatase (TRACP)
Role of bone turnover markers in early CKD
In patients with early CKD, markers of bone turnover predict the status of bone metabo‐
lism.The biochemical status of bone turnover is monitored by release of proteins and enzymes
during bone formation and degradation products during bone resoprtion. The bone turnover
markers are associated with bone loss and this is more significant with bone resorption than
formation markers [19]. Large observational studies have shown that bone turnover markers
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predict the fracture risk in osteoporotic patients and this is independent of BMD [20]. This
relationship is again stronger for bone resorption than formation markers [21,22].
The bone turnover markers are not recommended for the diagnosis of osteoporosis as they
have low specificity but high sensitivity in predicting the bone remodeling status. The bone
turnover markers are recommended for the monitoring of therapy as they predict the response
to treatment as early as 3-6months of starting therapy. Therefore bone turnover markers
predict the changes in bone remodeling status much earlier than BMD. IOF (International
Osteoporosis Foundation) and IFCC (International Federation of clinical chemistry) has
produced the recommendation for using bone turnover markers in fracture risk prediction and
monitoring of osteoporosis.
Among markers of bone resorption, CTX in blood is commonly used for predicting the bone
resorption status where as serum P1NP is used commonly as marker of bone formation.
Urinary markers such as PYR, DPYR are not used routinely due to problems associated with
urine collection and is influenced by creatinine excretion.
In early CKD raised bone turnover markers suggest the presence of bone metabolic disorders
such as osteoporosis, pagets, osteomalacia, recent fracture or bone metastasis. Besides this rise
in bone resorption markers in osteoporoticpatients suggests:
• Risk of fractures
• Other bone metabolic diseases such as malignancy
• To initiate the treatment where BMD and clinical risk factors are not sufficient to make
treatment decision
Osteoporotic patients on anti-resorptive therapy need repeat BMD every 2-3 years to assess
the response to treatment. However, bone markers have the ability to assess the short-term
response to anti-resorptive treatment every 6 monthly. Hence bone markers have a great value
in monitoring ant-resorptive therapy in osteoporotic patients.
Among the markers of bone turnover, serum CTX or P1NP are preferred in monitoring the
anti-resorptive treatment in osteoporotic patients with early CKD. The patients starting on
anti-resorptive should have baseline serum CTX, treatment is monitored by evaluating the
change in CTX at 6 month and reduction of >30% from baseline suggest efficacy and compli‐
ance to therapy [23].
Role of bone turnover markers in late CKD
Serum markers of bone remodeling can be useful to evaluate renal osteodystrophy in CKD-
MBD.Most bone makers have renal metabolism and/or excretion and accumulate in renal
failure.CTX, NTX, PYR and DPYR are influenced by renal function and its concentration in
blood increases with deterioration in renal excretion. Among bone markers BALP, P1NP, P1CP
and TRACP do not undergo renal metabolism or excretion and hence not influenced by renal
functions.
The biochemical markers such as PTH and BALPare recommended for assessing the bone
turnover in CKD-MBD. Further KDIGO does not suggest the use of markers of collagen
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degradation such as CTX/NTX or PYR/DPYR in late CKD. BALP is preferred over cross linked
telopeptides (CTX/NTX) as it is not excreted or metabolized by kidney, assess the rate of bone
formation and increased levels exclude the ABD [24]. Nevertheless, BALP is a non-specific
marker of high bone turnover as raised BALP reflects bone metabolic disorders such as vitamin
D deficiency, secondary hyperparathyroidism and recent fracture. BALP has emerged as one
of the most sensitive marker of bone turnover and correlates with bone histomorphometry and
BMD. Studies have shown that BALP is a useful bone marker in the diagnosis of ABD and low
BALP has a high sensitivity and specificity in excluding ABD as compared to PTH [25].
Similarly raised PTH also reflects the high bone turnover, which predicts OF, OM and excludes
ABD. BALP is a better predictor of bone turnover than PTH. Hence normal bone ALP with
normal or elevated PTH excludes high bone turnover in CKD-MBD. Studies have shown that
BALP ≥20U/L alone or with PTH ≥21pmol/L has the highest sensitivity, specificity, positive
and negative predictive value for the diagnosis of high bone turnover and excludes patients
with normal or low bone turnover [26].
There is minimal data on the bone turnover markers in predicting fracture risk in CKD-MBD
patients. Several studies have shown that PTH and BALP are better markers of bone turnover
in CKD-MBD patients [25,27].
Based on evidence available, raised BALP with or without raised PTH excludes ABD in CKD-
MBD patients. This has been further endorsed by KDIGO, which recommends the use of BALP
and PTH in assessing the bone status in CKD-MBD patients [28].
Recommendations:
i. Markers of bone turnover are non-specific markers of bone metabolism and therefore
not to be used for the diagnosis of bone metabolic disorders in CKD.
ii. Markers of bone turnover are used in monitoring the efficacy of therapy in CKD.
iii. Serum CTX or P1NP are preferred makers for monitoring the therapy in osteoporotic
patients in early CKD.
iv. Since BALP is not excreted by kidney, it is a useful marker of bone turnover in CKD-
MBD
v. Low BALP indicates low bone turnover and ABD
vi. BALP above the reference range excludes ABD
vii. Besides BALP, TRACP is also not excreted by kidney and is a marker of increase bone
resorption.
viii. PINP which is a marker of bone formation and not affected by reduced e GFR has not
been investigated in CKD-MBD
ix. Bone resorption markers such as CTX are affected by reduced e GFR and thus not
useful in evaluating the bone turnover status in CKD-MBD
x. BALP and PTH together increases the predictive value of identifying ABD in CKD-
MBD
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xi. Serum measurements of PTH and BALP are related to clinical outcomes, including
relative risk of mortality. They also correlate with some of the bone histomorpho‐
metric measurements.
xii. The biochemical markers of bone turnover are non-invasive and convenient to
measure unlike bone biopsy and can be used to assess the bone status in CKD-MBD
• Indicators of bone mineralization
The measurement of serum calcium, phosphorous and 25 (OH) vitamin D predict the status
of bone mineralization in patients with CKD.
Serum calcium and phosphorous
The serum calcium is a poor predictor of total body calcium status as only 1% of calcium is
extracellular and rest is in bone. The serum corrected calcium (after correcting serum calcium
with albumin) is measured to assess the calcium status in clinical practice. Inorganic phos‐
phorous plays a role in skeletal development. Serum phosphorous measures the inorganic
phosphorous in blood. Both calcium and phosphorous are bound to hydroxyapatite crystals
in bone, which helps with bone mineralization. Low serum calcium and phosphorous suggests
vitamin D deficiency or secondary hyperparathyroidism. On the contrary, raised serum
calcium or phosphorous in CKD patients suggest vitamin D over-replacement. The raised
calcium and phosphorous in blood increases the risk of extra-skeletal calcification which
further potentiates the cardiovascular risk in these patients. Thus monitoring of serum calcium
and phosphorous is recommended in CKD patients particular in CKD-MBD patients.
Serum 25 (OH)vitamin D
Vitamin D deficiency is common in CKD patients due to impaired synthesis of active 1,25
(OH)D [29]. Low 25 (OH) vitamin D levels are seen in approximately 80% of patients with late
CKD [26]. Studies have shown that 25 (OH) D has significant positive effect on PTH and BMD
[30] as vitamin D deficiency aggravates the risk of secondary hyperparathyroidism, which
further increases the bone resorption and bone metabolic disorders. Thus correction of vitamin
D status has been recommended which will improve the bone mineralization.The serum 25
(OH) D above 75nmmol/L levels is recommended in CKD patients that will reduce the risk of
secondary hyperparathyroidism and improve bone mineralization.
Recommendations:
• 25 (OH)D to be measured in patients with CKD to assess the bone mineral status
• 25 (OH)D should be above 75nmol/L in CKD patients
• Serum corrected calcium and phosphorous should be within the reference range
2.1.3. Bone biopsy
CKD–MBD can lead to an abnormal bone quality even in the setting of a normal or high bone-
mineral content. Bone biopsy provides measurements of bone turnover, mineralization, and
volume. These help to assess bone quality and the underlying bone physiology. Bone biopsy
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is a gold standard test for diagnosing the bone metabolic disorders in CKD-MBD. Nevertheless,
it cannot be used in routine practice as it is a invasive procedure, painful to patient and can be
carried out by an expert.Bone histomorphometery is studied by taking a biopsy from iliac crest
of the bone. Since it is invasive procedure it cannot be carried routinely.
Recommendations:
• Bone biopsy is considered as the gold standard test for the diagnosis and classification of
CKD-MBD.
• Not available routinely as it needs to be carried by a trained doctor.
• Bone biopsy is helpful if there is a history of unexplained bone pain or fracture in CKD-
MBD patients to identify the type of bone metabolic disorder.
2.2. Treatment of bone metabolic disorders in CKD
Osteoporosis is a predominant bone metabolic disorder in early CKD where as its prevalence
reduces in late CKD.
An osteoporotic patient in early CKD benefit with anti-resorptive treatment as it increases
BMD and reduces fracture risk. Since CKD-MBD has wide spectrum of bone metabolic
disorders, bisphosphonates may not be beneficial as seen in early CKD.The presence of ABD
is a contraindication to bisphosphonates. In addition there is limited evidence regarding
efficacy of treatments in reducing fracture risk in those patients with late CKD who have low
BMD and biochemical abnormalities of CKD–MBD.
There are two types of therapies for treating osteoporosis in CKD: anti-resorptive which
inhibits the osteoclastic induced bone resorption and anabolic therapy, which stimulates the
osteoblastic induced bone formation.
Anti-resorptive is a first line therapy in the treatment of osteoporosis in postmenopausal
women in whom it increases BMD both at cortical and trabecular site and reduces the fracture
risk at vertebral, non-vertebral and hip.
Bisphosphonates (BP)
BP is the synthetic analogue of inorganic pyrophosphate, which inhibit the osteoclastic induced
bone resorption and causes apoptosis of osteoclast. Thus BP reduces the bone turnover in
osteoporosis. Alendronic acid is the commonly used BP and is recommended as first line
therapy [31] for treating osteoporosis in post-menopausal women with osteoporosis. It has
been shown to increase BMD and reduces the vertebral, non-vertebral and hip fractures.In
early CKD patients with osteoporosis, BP is recommended as first line therapy. Recently
continued use of BP in osteoporotic patients has been discouraged due to adverse affects
associated with its long-term use. The risk of osteonecrosis of jaw and atypical fracture have
been shown to be associated with prolonged use of BP. Hence it has been recommended to
administer BP for 5 years in osteoporotic patients [32].
FDA and MHRA do not recommend the use of BP in patients with e GFR <30ml/min. Since BP
have renal excretion, it may affect kidney function. Moreover, low BMD in CKD-MBD can be
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either due to renal osteodystrophy or osteoporosis, and therefore suggesting a cautious use of
BP in this subpopulation of CKD.
Adminstration of BP in CKD-MBD patients with low bone turnover can have adverse conse‐
quences in the form of over-suppression leading to ABD. This will further increase the risk of
fractures and extra-skeletal calcification increasing the morbidity in this group of patient.
2.2.1. Nephrotoxic effect of BP
There is a concern regarding nephrotoxic effect of BP. There is substantial evidence, which
state that BP increases serum creatinine and this has been seen in cancer patients receiving
intravenous bisphosphonate therapy.
BP administered intravenously does have nephrotoxic effect and intravenous zolendronic acid
increases serum creatinine levels.Ibandronic acid may be less problematic in this respect.
Approximately 50% of oral bisphosphonate is renally eliminated and the pharmacokinetics in
renal impairment has not been fully elucidated.
Despite several reports, nephrotoxicity is uncommon and rarely of clinical significance when
lower (osteoporotic range) doses of BP are used. Renal toxicity with BP appears to be associated
with both dose and infusion time. Some experts recommend lower dose of BP to prevent
nephrotoxicity. However there is lack of evidence related to effect of BP on fracture risk and
BMD in CKD-MBD. Very few studies have assessed the effect of BP on renal function and have
shown no difference in serum creatinine in patients administered BP over a period of three
years in CKD 2-4 [33].Nevertheless, manufacturers do not recommend administration of BP
in patients with e GFR less than 35ml/min in view of safety issues.
2.2.2. Effect of BP on bone turnover in CKD
The second area of concern relates to the skeleton itself. BP binds to hydroxyapatite and
powerfully impairs resorptive activity, and thus reducing bone turnover rate. Since there are
very few clinical trials involving small which have assessed the effect of BP on fracture risk in
CKD-MBD, there is no clear evidence regarding its efficacy in this group of CKD. Therefore it
is reasonable to administer BP only in those patients who have high bone turnover in CKD-
MBD. However, BP need to be given cautiously in this group as they can reduce serum calcium
levels by inhibiting bone resorption, thereby leading to secondary hyperparathyroidism which
can be detrimental to bone. Additionally BP has a long retention time in bone, which can further
induce parathyroid hyperplasia and can lead to adynamic bone. The incidence of ABD has
increased in CKD patients particularly those on dialysis and BP administration can have
deleterious effect. The risk of extra-skeletal calcification is high in ABD as it is associated with
impaired ability of bone to buffer calcium. Moreover there is a increased risk of fracture in
ABD which gets further aggravated by BP impairing the bone strength and quality.
Therefore patients with reduced bone turnover in CKD-MBD may benefit with anabolic
therapy which will increase the bone formation. This will be a more logical approach in
managing the bone metabolic disorder in CKD-MBD.
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BMD in CKD-MBD. Very few studies have assessed the effect of BP on renal function and have
shown no difference in serum creatinine in patients administered BP over a period of three
years in CKD 2-4 [33].Nevertheless, manufacturers do not recommend administration of BP
in patients with e GFR less than 35ml/min in view of safety issues.
2.2.2. Effect of BP on bone turnover in CKD
The second area of concern relates to the skeleton itself. BP binds to hydroxyapatite and
powerfully impairs resorptive activity, and thus reducing bone turnover rate. Since there are
very few clinical trials involving small which have assessed the effect of BP on fracture risk in
CKD-MBD, there is no clear evidence regarding its efficacy in this group of CKD. Therefore it
is reasonable to administer BP only in those patients who have high bone turnover in CKD-
MBD. However, BP need to be given cautiously in this group as they can reduce serum calcium
levels by inhibiting bone resorption, thereby leading to secondary hyperparathyroidism which
can be detrimental to bone. Additionally BP has a long retention time in bone, which can further
induce parathyroid hyperplasia and can lead to adynamic bone. The incidence of ABD has
increased in CKD patients particularly those on dialysis and BP administration can have
deleterious effect. The risk of extra-skeletal calcification is high in ABD as it is associated with
impaired ability of bone to buffer calcium. Moreover there is a increased risk of fracture in
ABD which gets further aggravated by BP impairing the bone strength and quality.
Therefore patients with reduced bone turnover in CKD-MBD may benefit with anabolic
therapy which will increase the bone formation. This will be a more logical approach in
managing the bone metabolic disorder in CKD-MBD.
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Hence the theoretical hypothesis does not favour the administration of BP in low bone turnover
CKD-MBD.This implies that ideally bone biopsy should be performed before administration
of BP in late CKD patients. However similar benefit might be obtained more simply by using
indirect measures of biochemical markers of bone turnover such as BALP and PTH.
2.2.3. Extra-skeletal calcification
Vascular calcifications are a serious problem in patients with CKD-MBD. There has been
suggestion that BP by reducing the bone turnover in CKD-MBD can exacerbate the risk of
vascular calcification. The interaction between BP and vascular calcification is complexwhich
is related to low bone turnover effect of BP. Several studies have shown that low bone turnover
is unable to buffer calcium and phosphate load increasing the risk of vascular calcification [34]
2.2.4. Effect of BP on fracture risk
The patients with early CKD with no biochemical abnormalities will benefit from BP as shown
in general population in terms of fracture prevention and risk [35,36].
The decision regarding BP use is more difficult in late CKD who present with bone mineral
disorder and have been having fractures. Studies so far carried in late CKD are confined to
stage 4, are post hoc analysis and have small sample size and thus difficult to interpret their
results with regards to fracture risk in this sub-population [37].There are no published data
for the safety and efficacy of BP in patients with CKD 5/5D.
Recommendations
• BP is recommended for the treatment of osteoporosis in early CKD
• BP use in late CKD can be detrimental than beneficial due to concerns, around its appro‐
priateness and safety
• There is no reliable evidence regarding the efficacy of BP in late CKD
• Since BP have longer bone retention, it may exacerbate the risk of vascular calcification and
atypical fractures in late CKD patients
Role of Denosumab (DN)
Denosumab, a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor, is not
cleared by the kidney and may be safe in patients with CKD. DN inhibits the bone resorption
by reducing the production of osteoclasts, thereby increasing the BMD at both lumbar and hip
and reducing the vertebral and hip fractures [38].
DN unlike BP is not metabolized or excreted by the kidney and does not affect kidney function
[39].DN is recommended by FDA in patients with low eGFR. Since DN is metabolized by
reticuloendothelial cells, it has a shorter duration of action lasting 3-6months and therefore
shorter retention time in bone. Efficacy and safety of DN in reducing fracture risk has been
demonstrated in post hoc studies in CKD stage 4 [40].Besides this it has a shorter retention
time in bone [41]. Study by Jamal et al showed that DN significantly increased BMD and
reduced fracture risk in postmenopausal women with CKD 1-4 [40].
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Nonetheless, severe hypocalcaemia has been reported post DN in patients with late CKD or
on dialysis [42]. It has been suggested that post DN therapy in CKD-MBD simulates the hungry
bone syndrome. CKD-MBD is characterized by secondary hyperparathyroidism resulting in
increased bone resorption. By giving DN in such patients there is inhibition of bone resorption,
which promotes the bone uptake of calcium thereby causing severe hypocalcaemia. Thus
patients with severe hyperparathyroidism with concomitant vitamin D deficiency are at
potential risk of severe hypocalcaemia following DN [42].Recent MHRAalert Oct 2012, has
reported the risk of hypocalcaemia in patients with e GFR<30ml/min.Therefore MHRA
recommends the supplementation of calcium and vitamin D in such patients to avoid hypo‐
calcaemia.
DN is considered to be safe in late CKD as it does not affect renal functions and has shorter
bone retention time. There is no evidence that DN over suppresses the bone turnover and
potentiates the risk of ABD in late CKD. However, it has been suggested to carry out bone
biopsy before administration of DN in CKD 5/5D.
Recommendation
• DN is recommended for the management of osteoporosis in early CKD
• DN is safe to administer in late CKD as it neither affects kidney function nor metabolized
by kidney
• It has a shorter duration of action and has shorter retention time in bone, therefore its affect
on bone turnover will reverse after an interval of 6 months
• Post hoc studies have shown that it increases BMD and reduces the fracture risk in CKD 4,
nevertheless there is no evidence regarding its efficacy on bone in CKD 5/5D
Strontium Ranelate in CKD
The mode of action of SR is thought to be dual with both anti-resorptive and mild anabolic. It
is approved for the treatment of postmenopausal osteoporosis as it reduces the risk of vertebral
and hip fractures. Nevertheless, it is not recommended for the treatment of osteoporosis in
patients with late CKD. Its use in early CKD for the management of osteoporosis is contrain‐
dicated in patients with cardiovascular diseases, uncontrolled hypertension and deep venous
thrombosis.
Raloxifene
Raloxifene is a selective estrogen receptor modulator and is approved for the management of
osteoporosis in postmenopausal women. It reduces the risk of vertebral fractures but has not
been shown to reduce the hip fractures. Its use is contraindicated in patients with late CKD.
Teriparatide
Teriparatide is a human recombinant hormone that contains amino acid residues 1-34 of the
84 amino acid sequence of human PTH. It is an anabolic agent that has been shown to improve
the spine and hip BMD and reduces the vertebral and non-vertebral fracture [43]. It is approved
for the treatment of postmenopausal osteoporosis in women and in men. It has been recom‐
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mended to treat patients with severe osteoporosis with teriparatide who have been having
recurrent fractures in spite of being on anti-resorptive treatment.
The safety and efficacy of teriparatide have been demonstrated in patients with early CKD
(eGFR >30 mL/min), but there are no data on the use of this agent in patients with eGFR <30
mL/min. Teriparatide is contraindicated in patients with early CKD who have hypercalcaemia,
elevated PTH, bone metabolic disorders other than osteoporosis and malignancy.
Calcium and vitamin D
In CKD patients with osteoporosis, calcium and vitamin D supplementation is recommended
at the same dose as it is used for individuals with postmenopausal osteoporosis. Optimal
calcium intake of 1200mg daily and optimal 25 (OH) D levels ≥75nmol/L are suggested by
various guidelines. Vitamin D supplementation in the form of cholecalciferol or vitamin D
analogues is approved for the treatment of postmenopausal osteoporosis. It has been shown
to reduce the risk of vertebral fractures in postmenopausal women with osteoporosis.
2.2.5. Recommendations on the treatment of osteoporosis in CKD
• BP is the first line of osteoporosis treatmentin early CKD whereas it is not recommended
for the treatment of low BMD in late CKD
• DN is safe to administer in late CKD
• DN should be given cautiously in late CKD as there is risk of hypocalcaemia and adynamic
bone with its administration
• Adequate intake of calcium and vitamin D is important in patients with late CKD before
DN therapy
• Before administration of DN, serum calcium should be within the reference range and 25
(OH) D levels should be ≥75nmol/L in late CKD
3. Critical appraisal of evidence
3.1. Kidney Disease – Improving Global Outcomes (KDIGO) published the
recommendations for the management of osteoporosis and CKD-MBD in CKD patients
KDIGO Clinical Practice Guidelines for the diagnosis, evaluation, prevention and treatment
of Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD) (Kidney Int. 2009; vol
76 suppl 113, s1-132]
Following are the recommendations made by KDIGO 2009 guideline in managing CKD-MBD
• The bone biopsy and histological/histomorphometric diagnosis is helpful in classification
of CKD-MBD
• It is reasonable to perform a bone biopsy in various settings including: unexplained
fractures, persistent bone pain, unexplained hypercalcaemia, unexplained hypophospha‐
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temia, possible aluminum toxicity, and prior to anti-resorptive therapy in patients with
osteoporosis
• BMD does not predict fracture in CKD-MBDand should not be used routinely
• Serum 25 (OH) D should be measured routinelyand corrected
• Monitor serum levels of calcium, phosphorus, PTH, and alkaline phosphatase activity
• Measurements of serum PTH or BALP can be used to evaluate bone disease because
markedly high or low values predict underlying bone turnover
• Routine measurement of bone-derived turnover markers of collagen synthesis such as
P1CP/P1NP and breakdown such as CTX, NTX, PDY, DPYD is not recommended
• Patients with levels of intact PTH above the upper normal limit of the assay need to be
evaluated for hyperphosphatemia, hypocalcaemia, and vitamin D deficiency
• It is reasonable to correct these abnormalities with any or all of the following: reducing
dietary phosphate intake and administering phosphate binders, calcium supplements,
vitamin D supplements and calcimimetics
• In patients with persistently high serum PTH, treatment with calcitriol or vitamin D analogs
is suggested
• In patients with CKD stage 5D, maintaining PTH levels in the range of approximately two
to nine times the upper normal limit for the assay
3.2. Suggested protocol for management of osteoporosis in CKD
CKD 1-3 (early CKD)
• DEXA: T scores suggest osteoporosis
• Treat as postmenopausal osteoporosis
CKD 4-5 /dialysis (e GFR ≤30 or late CKD)
• DEXA not helpful in predicting osteoporosis and does not predict fracture risk
• Bone fragility fracture can be due to renal osteodystrophy/ osteoporosis
• Biochemical markers: BALP and PTH may be used to assess the bone turnover
Increased bone turnover
Raised BALP and PTH
• Exclude other causes of raised bone markers before treating high bone turnover:
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If any of THE above present than correct and recheck BALP and PTH
• If vitamin D sufficiency (≥75nmol/L) WITH serum adjusted calcium and serum phosphate
levels within the reference range
◦ Administer Denosumab 60mg subcutaneous
◦ Monitor BALP after therapy every 6 months
◦ Administer further Denosumab only if there is a rise in BALP
Reduced bone turnover
Normal BALP and normal PTH/mildly elevated PTH
• No treatment with anti-resorptive therapy
4. Summary
Osteoporosis in early CKD is treated similar to general population. In late CKD or CKD-MBD,
it is difficult to identify the type of bone metabolic disorder. Moreover, treatment of bone
metabolic disorders is complicated by mineral and hormonal disturbances seen in late CKD.
Also, there is a high prevalence of ABD in CKD-MBD and administration of anti-resorptive
potentiates the risk of ABD or vascular calcification. Hence judicious use of anti-resorptive
therapy is required in late CKD.
Following protocol can be followed for the management of Osteoporosis in late CKD or CKD-
MBD:
• There are no published data on the safety and efficacy of any approved agent for osteopo‐
rosis among men and women with eGFR <30 or in late CKD
• In clinical practice, at the current time and with current limited knowledge, treatment of
osteoporosis in stage 4-5/D CKD or late CKD is opinion based
• A reasonable clinical approach would be to consider therapy only in those with bone
fragility fractures
• After exclusion of ABD (low bone turnover) and osteomalacia (vitamin D deficiency); high
bone turnover should be considered for treatment with anti-resorptive therapy
• Osteoporosis in CKD-MBD is a diagnosis of exclusion
• Correct the biochemical abnormalities associated with CKD-MBD i.e. calcium and phos‐
phate within the reference range; optimal vitamin D levels (≥75nmol/L)
• Increased bone turnover is indicated by: raised BALP after correction of calcium, phosphate
and vitamin D levels (as mentioned above)
• Avoid DEXA: poor association of BMD with fracture risk
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• Low BMD is not an indicator of treatment with anti-resorptive therapy
• Denosumab is the preferred treatment and should be administered after correcting calcium
and vitamin D status
• Avoid Denosumab in severe hyperparathyroidism (>30pmol/L) as there is a risk of hypo‐
calcaemia
• Post Denosumab therapy: check BALP every 6 monthly to assess the response to treatment
• Administer Denosumab only if there is rise in BALP
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1. Introduction
Sodium alendronate (hereinafter, AL-Na) is one of the most important drug substances of the
bisphosphonate class administered orally for the treatment of all types of osteoporosis.
Alendronate has a positive influence on all symptoms of osteoporosis by increasing bone
mineral density and pacient mobility, reducing the risk of osteoporotic fractures in all
vulnerabilities (vertebrae, hip, arm and femoral neck) and having an analgesic effect in bone
pain. The anti-resorptive mechanism of action of AL-Na is complex and involves effects at both
the molecular and the cellular level. Osteoclasts and their precursors are the target cells of AL-
Na and, by internalization, they absorb the AL-Na molecule from the surface of bone. At the
molecular level, AL-Na prevents the conversion of dimethyl-allyl pyrophosphate to geranyl -
geranyl - pyrophosphate. Besides the biochemical effects described above, AL-Na also
produces a number of effects at the cellular level, among which loss of brush border and
fractures in the osteoclast cytoskeleton. All these actions of AL-Na ultimately lead to an
increase in bone mineral density and to osteoclast-mediated inhibition of bone resorption. It
is important to note that the anti-resorptive effect of AL-Na occurs the day after the first dose,
the intensity of the therapeutical effect being directly dependent on the active substance dose
administered [1, 2]. The results of the Fosamax Fracture Intervention Trial Long-term Exten‐
sion (FLEX) showed that patients treated with AL-Na for 5 years presented an obvious increase
in bone mineral density in the femoral neck, as well as in the lumbar spine. The results of this
10-year study showed a 17.7% decrease in the risk of vertebral fracture compared with placebo
[3, 4]. Currently, AL-Na is used in daily (10 mg/tablet) or weekly (70 mg/tablet with or without
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2 800 I.U. of vitamin D3) conventional release tablets. Tablets with a higher concentration of
vitamin D3 (70 mg AL-Na/5600 IU cholecalciferol/tablet) have also been introduced in therapy
quite recently [5]. The exogenous intake of cholecalciferol contributes to the normalization of
calcium homeostasis in the body and to the optimization of the anti-resorptive effect caused
by AL-Na. Furthermore, it is known that a low level of vitamin D3 manifests in muscle
weakness which can cause accidents with high risk of fracture [6].Once-weekly administered
tablets (70 mg/tablet) have largely increased patient compliance with alendronate and led to
a reduction in the incidence of gastrointestinal side effects. Pharmacokinetic studies have
shown that oral doses of alendronate in the range 5-80 mg generate a bioavailability of 0.1-1%,
with a fraction of 50% of the amount deposited in the bone. In addition, it was shown that oral
administration of 10 mg alendronate daily and of 70 mg alendronate once-weekly generates
the same level of increase in bone mineral density: 5-6% in the vertebrae and 3-9% in the femoral
bone. Alendronate administered orally in the form of a solution (70 mg/vial) is intended for
patients with deficiencies in swallowing. The latest alendronate formulation approved by Food
and Drug Administration (FDA) and European Medicines Evaluation Agency (EMEA) is the
association of 70 mg alendronate with 2800 I.U. vitamin D in immediate release tablets [7, 8].
According to FDA guidelines, there is no deadline or optimal duration for the treatment with
AL-Na. The treatment with AL-Na is recommended for as long as necessary along with regular
reassessment of patients (at intervals of no longer than five years) in order to determine bone
mineral density and fracture risk [9].
However, low oral bioavailability (under 1%) is the most important disadvantage of AL-Na.
It is caused by several factors such as: low permeability due to its negatively charged molecules
(AL belongs to the 3rd class of biopharmaceutical classification system); short plasma half-time
(T½ = 0.5-2 h); its chelatation by Ca2+ ions resulting in non-absorbable complexes. Research in
bisphosphonates in general aims to increase the bioavailability of these substances, to decrease side
effects, to increase adherence to treatment especially for elderly patients. AL-Na has been in the
attention of drug researchers and literature has presented a large number of studies on this
topic. Investigations conducted in the formulation of alendronate sodium are directed to
conventional pharmaceutical forms (solutions, emulsions, gels) as well as to modified-release
forms (matrix tablets, microemulsions, micro– and nanoparticulate drug delivery systems)
administered on various routes (Table 1).
In this study we have investigated the possibility of improving the oral bioavailability of AL-
Na by including it in hydrophilic matrix tablets based on various sorts of Carbopol. The role
of chitosan (CHT) and trimethyl chitosan (TMC) as AL-Na absorption enhancers was also
researched.
Carbopol polymers form an important class of excipients used for the formulation and
preparation of sustained release hydrophilic matrix tablets. Carbopols were synthesized and
patented in 1957 [24]. Since then, a variety of therapeutic agents (such as the agents in the 3rd
group of the biopharmaceutical system of drug classification: atenolol, verapamil, theophyl‐
line, metoprolol, ranitidine, etc.) have been formulated and prepared in different Carbopol-
based formulations with controlled release [25-30].
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Administration route Pharmaceutical dosage form References
Oral route
Modified-release tablets:
1. HPMC-based matrix tablets with different degrees of viscosity;
2. Gastro-resistant tablets using various sorts of ethyl cellulose and acrylic




Effervescent tablets [12, 13]
Solutions [14]
H/L Microemulsions with Captex 200 ® and lecithin as emulsifier [15]
Microparticulate therapeutic systems based on Eudragit S100/HPMC PLGA [16-18]
Gingival-dental mucosa Carbopol-based gels [19]
Vaginal mucosa HPMC-based gels [20]
Nasal mucosa




Reservoir-type transdermal therapeutic systems based on acrylic polymers in
combination with various percutaneous absorption promoters: lauric
acid, oleic acid, linoleic acid, myristic acid
[22]
Gels prepared with different sorts of Duro-Tak® (acrylic acid
copolymers) using propylene glycol and fatty acids as absorption
promoters (lauric acid, oleic acid, linoleic acid and myristic) at various
concentrations
[23]
Table 1. Examples of studies focused on increasing AL-Na bioavailability
From the chemical point of view, Carbopols are crosslinked polymers of acrylic acid (Figure
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Figure 1. General chemical structure of Carbopol polymers
According to the literature, Carbopol polymers generally exhibit good compressibility
characteristics, and this achieves compression at low pressures; are compatible with other
matrix forming hydrophilic agents and many excipients; may help mask taste and have
bioadhesive properties [31].
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In the formulations studied, we used three Carbopol sorts with different crosslinking degrees:
Carbopol 971 C (C 971), Carbopol 71 C (C 71) and Carbopol 974 C (C 974). These polymers are
obtained by the crosslinking reaction of acrylic acid with allyl penta erythrol, followed by a
polymerization reaction in ethyl acetate and neutralization with aqueous potassium hydroxide
1-3%. Although C 971 and C 974 are obtained by a similar technological process, the difference
is that sort C 971 has a lower level of crosslinking agent compared to C 974. C 71 is the granular
form of C 971 recommended to be used in direct compression [32-34]. Unlike the hydrophilic
linear polymers soluble in polar solvents, whose absorption capacity is dependent on molec‐
ular weight, crosslinked Carbopol polymers are insoluble in water, since crosslinking degree
is the determinant parameter of he matrix absorption capacity [35-37].
2. Investigations on the influence of carbopol sort on the release of
alendronate sodium from modified release matrix tablets
Prior to this research, in our department of Pharmaceutical Technology we have also studied
the influence of the concentration of Carbopol on the hydration and erosion characteristics of
matrices in order to establish the optimal conditions for the development of these formulations
[38-40]. Based on these results, in the present study we introduced 15% hydrophilic matrix
forming polymer in the formulation. We used three sorts of Carbopol with different cross-
linking degrees as matrix generating polymers: C 71 to C 971, polymers with a low of cross‐
linking degree, and C 974, a Carbopol with a high crosslinking degree. The research conducted
has been focused on investigating the influence of the Carbopol sort on the release of alendr‐
onate from modified release matrix tablets.
2.1. Materials and methods
2.1.1. Materials
Alendronate sodium trihydrate (Apotex Pharmaceutics INC, USA), Carbopol 974 P NF, 971 P
NF, 71 G NF (Noveon Inc.), Ludipress LCE (BASF), Aerosil 200 (Degussa), Magnesium stearate
(Union Derlivan S.A. Spain).
2.1.2. Methods
2.1.2.1. Preparation of matrix tablets
Three formulations of alendronate sodium matrix tablets were prepared by the method of
direct compression in the Korsh EK0 tablet machine (punch diameter of 9 mm, 8 to 10 kN
compression force). As matrix forming polymer, formulations denoted F1, F2, F3 contain, as
follows: 15% C 71 in F1, 15% C 971 in F2, and a mixture of 15:2% C 971:C974 – 15:2% in F3
(Table 2).
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C 71 15 – –
C 971 – 15 15
C 974 – – 2
AL-Na 13.05 13.05 13.05
Mg Stearate 0.5 0.5 0.8
Aerosil – 0.5 1.5
Ludipress LCE 71.45 70.95 67.65
Table 2. Formulations of matrix tablets with AL modified release based on Carbopol
2.1.2.2. “In vitro” dissolution investigations
“In vitro” dissolution tests were carried out on a SR 8 Plus Series (AB & L Jasco) device, under
the following experimental protocol: dissolution medium: pH 1.2 solution (0.1 N HCl) for the
first 2 hours (a medium simulating gastric fluids) and solution pH 6.8 (phosphate buffer
solution) for the next 10 hours (a medium simulating intestinal fluids); Apparatus 2 (paddle);
bath temperature: 37ºC±0.5 ºC; rotation speed: 50 rpm; sampling interval was set to every hour
during the 12 hours of the test (at every collection, 7 ml of sample were replaced with the same
volume of medium).
One sample from the aliquot was subjected to the derivation and dosage procedure described
in the USP monography for the HPLC analysis of sodium alendronate. The quantitative
determination equipment included the following modules: HPLC type HP 1090 series II
provided with a diode array detector, UV-VIS spectrophotometer Agilent technologies 8453
and Zorbax C18 column. The mobile phase was a mixture of methanol, acetonitrile and water
in the following proportions: 17.5:17.5:65. Mobile phase flow was set at 0.3 mL/min., the
injection volume was 20μL and the detection was performed at 266 nm [41]. All the experi‐
ments were performed in triplicate.
Quantitative data were presented as mean ± standard deviation and statistical analysis was
performed using a one-way analysis of variance (one-way ANOVA). A comparison between
two means was made using Tukey's test, with statistical significance set at p < 0.05.
2.1.2.3. The analysis of the difference factor (f1) and the similarity factor (f2)
The two factors assessing the AL release profile in the investigated formulations were
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where: n = the number of sampling time points, Rt = released AL percentage of the reference
formula at time point t, Tt = released AL percentage of the test at time point t and log10x
represents the logarithm of x to the base 10 [42].
Difference factor f1 is a measure for quantifying the differentiation degree of the release profile
followed by a drug substance in the formulation. The value of this factor is in the interval 0 -
50. The analogy degree varies inversely with f1 value. Thus, a value closer to 0 indicates a high
similarity between two or more compared formulations. When the dissolution profile between
the tested and the reference formula is identical, f1 is 0 and increases with the dissimilarity
between the formulas analyzed. In general, the values of the f1 factor in the range 0-15
correspond to very small differences between the formulations tested, while values greater
than 15 indicate major differences in the release profiles of the drug substances in the compared
formulations.
Similarity factor f2 is a parameter commonly used to compare the dissolution profiles of the
solid oral pharmaceutical forms.
When two dissolution profiles of the drug substance are similar, f2 is in the range of 50-100 [43,
44]. According to the FDA guidelines in force, the values of the f2 similarity factor included
between 50 and 100 show a high degree of similarity (≥ 90%) between the release profiles of
the tested formulation against the reference formulation. Theoretically, values of the similarity
factor f2 smaller than 50 are accepted in the interpretation of the in vitro dissolution tests.
Mention should be made that these values show a similarity <90% between the formulas
analyzed.
Note that these two parameters are accepted and recommended by international quality
guidelines for the comparative evaluation of the release profile of two or more formulations
compared to a reference formulation, as can be seen in equations 1 and 2. While EMEA has
not issued any regulations on the determination and analysis of difference factor f1 and
similarity factor f2, FDA and USP regulate the applicability of these factors for the comparison
of the release profile of two or more pharmaceutical formulations by the following clarifica‐
tions: 1. release profiles between two or more formulas can be compared only when the
dissolution test includes a minimum of 12 sampling points; 2 the conditions of the in vitro
dissolution test should be identical for the reference formulation and for the tested formula‐
tions [45-47].
2.2. Results and discussions
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2.2. Results and discussions
Figure 2 presents the results obtained from the in vitro dissolution test for the studied formu‐
lations.
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Figure 2. In vitro dissolution profile for AL in hydrophilic matrix tablets based on Carbopol
We can see from the results obtained that the dissolution profile of alendronate sodium in
formulation F2 based on C 971 is superior to other formulations (99.7889% AL-Na released; t
= 12 hours). In theory this result was not foreseeable because C 71 and C 971, the polymers in
formulas F1 and F2, have the same degree of crosslinking, sort C71 actually having flow
properties optimized by the granular particle form.
The influence of the crosslinking degree of the polymer in the formulation was also highlighted
by the pH value of the dissolution medium. Thus, at acidic pH 1.2 simulating gastric fluids, C
71 and C 971, which are polymers with a low degree of crosslinking, showed a uniform
hydration resulting in a uniform release of alendronate sodium in the matrix gel layers.
C 974, a polymer with a high degree of crosslinking, optimizes the retardation effect at gastric
level through the closely crosslinked gel structure which acts as an element that reduces the
diffusion of the drug substance in the hydrated matrix layers during the first hours of the test
and accelerates this process after the total hydration of the matrix.
Finally, after performing the dissolution test within 12 hours, we found that the dissolution
profile of alendronate sodium is identical in F1, the formula based on C 71, and in F3, the
formula in which we associated C 974 as well (F1 = 85.1128% AL-Na released; F3 = 85.5984%
AL-Na released), specifying that sort C 974 generates a slow dissolution profile within the first
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two hours of the test, at pH 1.2 (F1 = 44.9356% Na released; F2 = 46.5233% AL-Na released, F3
= 28.0566% AL-Na released, t = 2 hours).
The different behavior as regards the dissolution profile of alendronate sodium in modified
release matrix tablets is also confirmed by the results obtained in the determination of f1, the
difference factor, and f2, the similarity factor (Table 3).
Reference formula (Rt) Test formula (Tt) f1 f2
F1 F2 25.149 37.041
F1 F3 12.608 50.940
F2 F3 26.9546 34.1921
Table 3. Values of f1 and f2 factors obtained in the comparative analysis F1-F3
In the comparative analysis of the three formulations studied, the difference factor f1 has values
> 0. The similarity factor f2, which is the most representative for the comparison of the disso‐
lution profile of solid dosage forms also has values that indicate a different dissolution profile
for the three formulations investigated (f2 <50), with the exception of the comparison F1,
reference, F3, test, when f2 = 50, 940. We estimate that this value is determined by the evolution
of the release pattern of AL-Na towards the end of the in vitro dissolution test, in 6.8 buffer
system because there were no significant differences between the two formulas during the first
two hours of the test, under conditions of simulated gastric fluid.
2.3. Conclusions
The results of the in vitro dissolution test reveal that every sort of Carbopol influences the
release profile of alendronate sodium in matrix tablets with modified release. The crosslinking
degree of Carbopol is the defining element of the release properties of hydrophilic matrix
tablets. Sorts C 71 and C 971, with a low degree of crosslinking, hydrate much better at pH 1.2,
a phenomenon which facilitates the dissolution of alendronate sodium, its diffusion through
the gel layers of the matrix, and therefore, the release of a greater amount of drug substance
compared to formula F3, in which we associated C 974, a high crosslinking polymer, which
causes a slowing of the hydration process. The influence of the crosslinking degree of Carbopol
also manifests at pH 6.8; F2, the formula based on C 971, generated a release profile of AL-Na
superior to formula F3, in which we associated C 974 and C 971, and to formula F1 based on
C 71, respectively.
The different dissolution profile of alendronate sodium in modified release matrix tablets
based on Carbopol is further confirmed by the values of the two control parameters f1 and f2.
The similarity factor f2 is set to 50.940, little over 50, the lower limit of the acceptance criteria,
when comparing F1 as reference formulation and F3 as test formulation, but this value is
determined by the percentage of sodium alendronate dissolved in the second half of the period
of the dissolution test, after t = 6 hours. In the first part of the test, especially in the first two
hours, at pH 1.2, the two formulations have very different dissolution profiles.
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3. Investigation of the influence of some absorption promoters on the
release of alendronate sodium in modified release matrix tablets
Chitosan is a natural polysaccharide produced by the partial deacetylation of chitin which
includes in its structure two copolymers: N-acetylglucosamine and glucosamine (Figure 3).
This biodegradable and biocompatible polymer was investigated in various pharmaceutical
formulations as absorption promoter, excipient for controlled release tablets or bio-mucoad‐
hesive preparations [48].
Chitosan is soluble in acidic media, pH < 6.5, when the amino groups in its structure are
protonated. At pH values > 7, the solubility of chitosan is lower, the occurrence of the transition
from the solution to the gel state, which gives chitosan unique properties as an absorption
promoter for the oral administration of hydrophilic macromolecular substances including
peptides and proteins [49-52]. Some quaternary chitosan derivatives, for example, trimethyl
chitosan (TMC), are soluble in a higher pH range (pH=1-9) in a concentration of up to 10% m/
m, which results in widening the scope and applicability in this field.
The main action mechanism of CHT and TMC as absorption promoters is to open the inter‐
cellular junctions at membrane level, as a result of the interaction between CHT or its positively
charged derivative and the negative charges of the sialic acid present in the intestinal mucosa.
The absorption of the drug substance is therefore facilitated by para- and transcellular
mechanisms [53-58].
In this study we aimed to analyze the influence of the two main absorption promoters, CHT
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Figure 3. Chitosan - chemical structure
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3.1. Materials and methods
3.1.1. Materials
Sodium alendronate trihydrate (Apotex Pharmaceutics INC, USA), Carbopol 974 P NF, 971 P NF,
71 G NF (Noveon Inc.), Ludipress LCE (BASF), Aerosil 200 (Degussa), Magnesium stearate (Union
Derlivan S.A. Spain), high molecular weight Chitosan (CHTh) (degree of deacetylation > 85%,
Aldrich), N - Trimethyl chitosan (G.L.S. Chemicals & Materials, India).
3.1.2. Methods
3.1.2.1. Preparation of matrix tablets
Nine alendronate sodium matrix tablets formulas were formulated and subjected to direct
compression in a tablet machine Korsh EK0 (punch diameter 9 mm, 8.10 kN compression
force). Table 4 presents the raw materials used in the preparation of studied formulations.
Ingredients (mg %)
Formulation
F1 F2 F3 F4 F5 F6 F7 F8 F9
C 71 15 – – 15 – – 15 – –
C 971 – 15 15 – 15 15 – 15 15
C 974 – – 2 – – 2 – – 2
CHT – – – 6 6 6 – – –
TMC – – – – – – 6 6 6
AL 13.05 13.05 13.05 13.05 13.05 13.05 13.05 13.05 13.05
Mg stearate 0.5 0.5 0.8 0.5 0.5 0.8 0.5 5 0.8
Aerosil – 0.5 1.5 – 0.5 1.5 – 5 1.5
Ludipress LCE 71.45 70.95 67.65 65.45 64.95 61.65 65.45 64.95 61.65
Table 4. Pharmaceutical formulations of modified release matrix tablets with AL-Na based on Carbopols, with
absorption promoters
3.1.2.2. “In vitro” dissolution studies
“In vitro” dissolution tests were carried out on a SR 8 Plus Series (AB & L Jasco) device, under
the following experimental protocol described in section I. The tests were carried out on a total
of six tablets and the results shown are the average of the six determinations.
The analysis of the difference factor f1and similarity factor f2 was performed according to the
equations described in Section I.
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3.2. Results and discussions
The results of the in vitro dissolution test shown in Figure 4 reveal that the AL-Na release profile
of the Carbopol-based matrix tablets is maintained even in the presence of CHT. It is worth
noting that the released AL-Na amount for formula F5 is approximately 5% lower than for
formula F2 without CHT. This result can be explained by the different behavior of CHT at the
two pH values.
Figure 4. In vitro AL dissolution profile in F1-F6 formulas
To reveal the influence of CHT on the alendronate sodium release profile in modified release
matrix tablets, we calculated the two control factors f1 and f2. The results obtained are presented
in Table 5 and show that the dissolution profile is different in formulations F4 and F5 compared
to formulas F1 and F2. The comparative analysis of formula F6 as test and formula F3 as
reference led to a similarity factor value f2 greater than 50 (f2 = 57.187), which means that CHT
does not alter the dissolution profile for this formulation. We assume that the mechanism by
which CHT influences AL-Na dissolution is based on the low solubility of CHT at pH 6.8. In
the case of F6, there is also the influence of C 974, which, as we noted in the previous section,
due to its high crosslinking degree, causes a slower hydration of the matrix. In this context we
argue that between CHT and C 974 there is a synergism of action on the release profile of
alendronate sodium in modified release matrix tablets.
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Reference formula (Rt) Test formula (Tt) f1 f2
F1 F4 28.991 31.947
F2 F5 12.422 46.748
F3 F6 10.799 57.187
Table 5. Values of f1 and f2 factors obtained in the comparative analysis F1-F3 versus F4-F6
The comparative results of TMC-containing formulations F7-F9 to formulations F1-F3 are
shown in Figure 5.
Figure 5. In vitro AL dissolution profile in F1-F3-F7-F9 formulas
From the analysis of the data obtained we find that all formulas in which we introduced TMC
provide an alendronate sodium release in percentages above 90% during the 12 hours of the
dissolution test. For this absorption promoter as well we assume that the influence on the
dissolution profile of AL-Na is based on the TMC optimal solubility in the two dissolution
media, a property which determined the proper hydration of the matrix tablet, thus facilitating
the diffusion and release of alendronate sodium in the matrix. Difference factor f1 and similarity
factor f2 have values that reveal for formulations F7-F9 a different release profile compared to
reference formulations F1-F3 (Table 6).
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Reference formula (Rt) Test formula (Tt) f1 f2
F1 F7 23.247 39.942
F2 F8 13.119 47.307
F3 F9 27.969 39.230
Table 6. Values of f1 and f2 factors obtained in the comparative analysis F1-F3 versus F7-F9
3.3. Conclusions
The comparative analysis of the results obtained from the in vitro dissolution test showed that
formulas containing absorption promoters have an alendronate sodium dissolution profile
that differs from the formulas of the modified release matrix tablets based on Carbopol without
absorption promoters, test formulas (F1-F3). This conclusion is confirmed by the values of the
two parameters assessing the dissolution profile: difference factor f1 and similarity factor f2.
The influence of absorption promoters on the AL-Na dissolution profile in the studied
modified release matrix tablets can be assigned to the different solubility of CHT and TMC in
the two dissolution media.
4. Assessment of the release kinetics of alendronate sodium in modified-
release matrix tablets
The analysis of the release kinetics of a drug substance from a dosage form is particularly
important in characterizing and defining the pharmacotechnical and biopharmaceutical
properties of that particular preparation. In the case of the modified release tablets based on
matrix forming hydrophilic polymers, in order to determine the mechanism by which the drug
is released and its evolution over time, the understanding of its kinetic release profile is a
prerequisite.
The objective of this study is to identify a representative pattern for each formulation studied;
taking into account the multiple formulation factors that may influence drug substance release
from the modified-release matrix tablet.
4.1. Materials and methods
4.1.1. Materials
Sodium alendronate trihydrate (Apotex Pharmaceutics INC, USA), Carbopol 974 P NF, 971 P NF,
71 G NF (Noveon Inc.), Ludipress LCE (BASF), Aerosil 200 (Degussa), Magnesium stearate (Union
Derlivan SA Spain), high molecular weight chitosan (CHTh) (degree of deacetylation > 85%,
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4.1.2.1. Preparation of matrix tablets
Nine formulations of matrix tablets with alendronate sodium were prepared by the direct
compression method according to data presented in Table 4, section II.1.
4.1.2.2. “In vitro” dissolution studies
“In vitro” dissolution tests were carried out on a SR 8 Plus Series device, under the following
experimental protocol described in section I. The tests were carried out on a total of six tablets
and the results shown are the average of the six determinations.
4.1.2.3. Data fitting and kinetics of drug release
The kinetics of AL-Na release from the formulations studied was analyzed by fitting on five
mathematical models according to the following equations:
The equations corresponding to the models applied in the study are:
0The zero-order kinetics: tM K t= × (3)
The first-order kinet 100i ( )cs: 1 k ttM e
- ×= × - (4)
0.5Higuchi release model: t HM K t= × (5)
The Korsmeyer-Peppas relea ( 0.45)semodel: nt pM K t n= × = (6)
The Hopfenberg release model 100 [1 (1: ) ] ( 2; 3)nt HFM K t n n= × - - × = = (7)
where:
Mt = the amount of the drug dissolved at time t;
K0 = zero order rate constant;
K = first order rate constant;
KH = Higuchi rate constant;
KP = Korsmeyer-Peppas rate constant;
KHF = Hopfenberg rate constant;
n = the release exponent which characterizes the mechanism of drug release;
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t = time
Data fitting was performed by linear and nonlinear regression, using Matlab 7.1 software.
The Akaike index (AIC) and the correlation coefficient R2 were the criteria for the selection of
the model which describes with the highest fidelity the release profile for each formulation
studied. The best model prediction requires that the value of R2 is as close as possible to 1, and
the Akaike index has the smallest values [59-61].
The two model prediction parameters were calculated according to the following equations:
ln( / ) 2AIC n SSR n p= × + × (8)
where:
n = number of data points;
SSR = sum of squared errors;




























yi = data obtained experimentally;
y∧i = values approximated by the model;
ȳ = average of experimental values
4.2. Results and discussions
The results obtained from fitting data on the five experimental models are shown in Table 7
and Figures 6-11.
Analyzing these data we can see that the zero-order release kinetic model is not representative
for the formulations studied (Figure 6); this conclusion was predictable considering the data
in the literature according to which this model is representative for the description of the
release profile of drug substances in osmotic systems with a constant speed independent of
the concentration (62-65). Mention should be made that the inclusion in the formula of C 74, a
polymer with a high degree of crosslinking which causes a reduction in the rate of matrix
hydration in an acidic environment, has led to good values of parameter R2. However, the
values of the Akaike index are not representative as to validate the zero-order kinetic release
model for the formulations containing this polymer (Table 7).
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The fitting of data from the nine formulas analyzed on the Higuchi and Korsmeyer-Peppas
models confirms the release of alendronate sodium in Carbopol-based matrix tablets by a
process of diffusion. The values of the parameters of the equation corresponding to the Higuchi
model are representative enough to suggest that the release of the active substance in the
studied matrices occurs through a diffusion process based on Fick's law according to which
the release of the active substance is directly proportional to the square root of time. The
Korsmeyer-Peppas model, where n is equal to 0.5 defines the active substance release through
a phenomenon of Fickian diffusion from plane shapes. Fitting on this model is further
substantiated by the data obtained in previous studies in which we have investigated the
hydration behavior of matrix tablets, when we found an increase in direct proportion between







F1 F2 F3 F4 F5 F6 F7 F8 F9
Zero-order
K0 8.3238 10.2973 7.6325 7.9905 9.4400 7.8339 9.6863 8.8962 9.6104
R2 0.8401 0.9073 0.9511 0.8678 0.8990 0.9678 0.7391 0.8765 0.9036
AIC 73.12 72.36 59.09 70.98 70.50 50.12 82.49 73.56 72.38
First-order
K 0.1900 0.2500 0.1200 0.1700 0.2100 0.1500 0.2600 0.1800 0.2100
R2 0.9371 0.9758 0.9572 0.9138 0.9677 0.9460 0.9514 0.9308 0.9624
AIC 57.95 43.41 48.59 59.70 44.21 52.35 55.10 56.43 48.44
Higuchi
KH 24.7646 30.3197 22.2784 23.7095 27.7771 22.5600 29.1919 26.4044 28.3790
R2 0.9652 0.9885 0.9720 0.9646 0.9728 0.9391 0.9364 0.9763 0.9871
AIC 42.33 32.38 37.67 41.67 41.41 54.16 56.61 40.81 32.29
Korsmeyer-
Peppas
KP 27.4199 33.5240 24.6139 26.2487 30.7108 24.8812 32.3696 29.2325 31.3944
R2 0.9726 0.9862 0.9631 0.9697 0.9697 0.9214 0.9565 0.9814 0.9872
AIC 37.12 36.96 42.47 37.41 43.82 57.80 50.42 34.65 30.73
Hopfenberg
(n=2)
KHF 0.0548 0.0844 0.0495 0.0521 0.0679 0.0517 0.0686 0.0612 0.0703
R2 0.9160 0.9835 0.9631 0.9228 0.9575 0.9806 0.08664 0.9499 0.9771
AIC 65.57 47.84 50.97 64.66 54.60 41.43 73.27 65.06 58.29
Hopfenberg
(n=3)
KHF 0.0405 0.0706 0.0363 0.0383 0.0521 0.0382 0.0522 0.0461 0.0545
R2 0.9324 0.9732 0.9562 0.9290 0.9672 0.9794 0.9022 0.9578 0.9840
AIC 62.95 44.36 48.73 62.55 49.26 42.77 70.05 62.21 53.58
Table 7. Parameter values of the mathematical equations corresponding to the evaluation models of release kinetics
and their predictability indicators
Data fitting on the Hopfenberg model revealed the presence and involvement of the erosion
phenomenon in the process of release of alendronate sodium. The prediction parameter R2 has
acceptable values (> 0.90) for all formulations studied, but the Akaike index does not allow the
validation of this model, regardless of the value of n. According to data obtained from the
analysis of the hydration behavior of matrices, erosion increases after 7-8 hours after the
introduction of the matrix in the dissolution medium. Figures 10-11 show a good fitting of the
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model particularly for formulations based on C 971, C 971 associated with C 974, as well as in
similar formulas in which we introduced CHT and TMC after moment 6-7 of the study.
Therefore, we consider that the Akaike index values are determined by the nonlinearity of the
erosion process.
Figure 6. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the zero-order kinetics model
Figure 7. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the first-order kinetics model
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Figure 8. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the Higuchi model
Figure 9. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the Korsmeyer-Peppas model
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Figure 8. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the Higuchi model
Figure 9. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the Korsmeyer-Peppas model
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Figure 10. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the Hopfenberg (n=2) model
Figure 11. The fitting plot of the AL-Na dissolution profiles from formulations F1-F9 with the Hopfenberg model (n=3)




The results obtained showed good data fitting on the Higuchi model for all formulations
studied, which leads to the conclusion that AL-Na release from hydrophilic matrix tablets
occurs through a diffusion process based on Fick's law. In addition, the results obtained when
fitting data on the Korsmeyer-Peppas mathematical model is an additional argument for
considering diffusion as the main mechanism of AL-Na release from flat modified-release
hydrophilic matrix tablets. The Hopfenberg model applied to modified-release matrix tablets
with a complex formulation based on combinations of matrix-forming polymers in order to
highlight the involvement of erosion in the process of active substance release generated a
good fitting of the data in the analysis of the correlation coefficient R2, but the Akaike index
has high values, which does not allow the validation of the model. Data analysis shows that
in the second half of the duration of the dissolution test, the data obtained experimentally
generate a better fitting for the Hopfenberg model both for n = 2 and for n = 3. In conclusion,
the data obtained from fitting on the Hopfenberg model confirms the involvement of erosion
as a mechanism of alendronate sodium release from modified-release hydrophilic matrix
tablets, but the predictive parameter values of the model do not allow the validation of this
model due to the nonlinearity of erosion.
In conclusion, Fickian diffusion is the main mechanism of alendronate sodium release from
modified-release hydrophilic matrix tablets and erosion is the secondary mechanism.
5. Assessment of the pharmacokinetic parameters of alendronate sodium
in modified-release matrix tablets administered on the oral route
Alendronate absorption occurs through passive diffusion, predominantly in the upper small
intestine (duodenum, jejunum, pH = 6-6.5), only a very small amount being also absorbed at
the gastric level [66].
Alendronate has a low oral bioavailability (0.6 to 0.9%) for doses ranging from 5 to 70 mg, in
conventional release formulations administered in the morning on an empty stomach or two
hours after breakfast. The bioavailability of the 10 mg tablet is 0.59, while the weekly dose
administration of 70 mg in tablets or solution leads to a bioavailability of 0.64% [67, 68]. These
values are determined by the following general characteristics of bisphosphonates:
• low lipophilicity, which restricts intra-and intercellular transport;
• high polarity given by the negative charge, which prevents paracellular transport [69].
Plasma distribution of alendronate exhibits very low concentrations (<5 ng/ml) at therapeutic
doses. Plasmatic t½ of alendronate is short 0.5 to 2 h compared to t½ in deposits at the site of
bone resorption that have values expressed in years for alendronate being > 10 years. Alendr‐
onate binds to plasma proteins in the ratio of 78% and also forms complexes with some divalent
cations, eg calcium, magnesium, iron [70].
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Excretion of alendronate is in the ratio of 99% in the feces and only 0.4% of the amount absorbed
is eliminated through the kidneys by glomerular filtration and tubular excretion.
Storage of alendronate in the bone tissue depends on the affinity for hydroxyapatite, the in
vitro affinity constant KL alendronat 2.9 x 106 mol/l [71].
Pharmacokinetically, alendronate does not present any significant differences between the
main groups of patients. The oral bioavailability of this active substance is similar in both
children and adults [66, 72]. The main objective of these studies is to evaluate the pharmaco‐
kinetic parameters of alendronate administered as modified-release matrix tablets.
5.1. Materials and methods
5.1.1. Materials
According to the results obtained in the research presented in subsections I-III, in order to
achieve the pharmacokinetic studies we selected matrix tablets formulas that exhibited optimal
characteristics of release (Table 8).
Ingredients (mg %)
Formulation
F2 F5 F8 Fm
C 971 15 15 15 -
CHTh - 6 - -
TMC - - 6 -
AL 13.05 13.05 13.05 13.05
Mg Stearate 0.5 0.5 0.5 0.5
Aerosil 0.5 0.5 0.5 0.5
Ludipress LCE 70.95 64.95 64.95 85.95
Table 8. The formulations of modified-release matrix tablets containing alendronate sodium
The tablets used in pharmacological research were prepared by direct compression, in
accordance with the technology described in Section I.
5.1.2. Methods
5.1.2.1. Experimental protocol
The research was performed on adult male dogs weighing 30-40 kg, divided into four groups
of 2 animals. Samples containing 20 mg alendronate sodium/tablet corresponding to the three
formulations studied were denoted F2, F5, F8. Fm, the control sample, comprised immediate-
release tablets with Alendronate sodium. The samples were administered to the four groups
as follows:
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• F2 →  group I;
• F5 →  group II;
• F8 →  group III
• Fm →  group IV.
The experimental study was conducted over a period of 48 hours and the tablets were
administered orally after the animals had fasted for 12 hours. During the experiment, the
animals had free access to water and food, except for 4 hours of food deprivation following
the administration of tablets.
Mention should be made that in the literature we did not identify the lethal dose 50 (DL 50) of
alendronate sodium administered to dogs, being conducted research by administering 200
mg / kg, a dose for which a mild renal toxicity was recorded [8, 73].
Preparation of the animals: 7 days prior to the experiment, each animal had free access to food
and water and was kept under normal conditions of light and temperature.
Blood sampling was performed using the following procedure:
• in order to collect the blood samples a catheter was placed in the femoral vein;
• to characterize the pharmacokinetic parameters, samples of 4 ml of blood were collected at
each moment in heparin vacutainers;
• sampling times were as follows: M 0 - prior to administration; M 1 - 30 min. after adminis‐
tration; M 2 - 1 h after administration; M 3 - 1 h and 30 min. after administration; M 4 - 2
hours after administration; M 5 - 2 h and 30 min. after administration; M 6 - 3 hours after
administration; M 7 - 3 h and 30 min. after administration; M 8 - 4 hours after administration;
M 9 - 6 hours after administration; M 10 - 8 h after administration; M 11 - 10 h after admin‐
istration; M 12 - 12 h after administration; M 13 - 24 hours after administration;
Processing of the blood samples consisted in:
• centrifugation after 30 minutes from collecting, at a speed of 3000 rpm, for 10 min.;
• serum was transferred into Ependorff test tubes and stored in a freezer, at – 20 °C, until the
HPLC quantitative analysis, according to the method described in section I.
All animals used in this study were clinically healthy and haematological and biochemical
analyses had been performed prior to the experiment.
5.1.2.2. Calculation of pharmacokinetic parameters
The main pharmacokinetic parameters that were evaluated directly, without a pharmacoki‐
netic modeling, based on the experimental data, are: the coordinates of the peak (Cmax and Tmax),
the areas under the curve (AUC0-t, AUC0-∞, AUCt-∞), the total clearance (Cl) and the average residual
time (MRT). These parameters are independent of the representation model of drug kinetics
in the body, and are very useful in bioavailability studies. A series of other parameters depend
on the pharmacokinetic model, so that it should be taken into account in calculating them.
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In the case of extravascular administration, the following parameters dependent on the model
can be calculated: elimination rate constant (ke), biological half-life (t1/2), absorption rate constant
(ka) and volume of distribution (Vd).
The main pharmacokinetic parameters calculated were:
• coordinates of the peak (Cmax and Tmax) – individual Cmax values expressed in μg/ml and Tmax,
expressed in hours, were obtained from the examination of experimental data;
• areas under the curve (AUC0-t, AUC0-∞, AUCt-∞) - the area under the plasma concentration
curve, noted AUC, is a parameter that reflects the extent of absorption in the administered
dose and that is proportional to the amount of drug that reaches the blood after oral
administration. As a result, this parameter is essential for the determination of bioavaila‐
bility.
• the area under the experimental plasmatic concentration curve AUC0-t was calculated by using
the trapezoidal rule, which is the most common method. We calculated the area from time
zero (initial time) to the time when the last blood sample was collected to determine the
concentration of the drug substance. The area under the curve is equal to the sum of the
areas of the trapezoids realized between two concentrations corresponding to two succes‐
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where, n = number of trapezoids in which we divide the area under the curve (n is the number
of collections of biological samples);
• the total area under the plasmatic concentration curve AUC 0-∞ is equal to the sum of the area
under the experimental concentration curve and the area extrapolated from the time of the
last sample collection to infinity.
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where ke is calculated based on the end points of the plasma concentration curve in time.
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• the extrapolated area is the area from the last sampling time extrapolated to infinity and it







where cn is plasma concentration of the last determination.
Totalclearance (Cl) – for oral administration, the absorbed dose and the total clearance cannot




where F – correction factor
• the elimination rate constant (ke) was determined by the method of residuals, based on
plasmatic concentrations of the drug substance determined at different time intervals. This
method is also called the “least squares method” or the “method of the least sums of the
squares errors” and is used to estimate the true values with the help of the experimentally
determined values.
• biological half-life (t1/2) was calculated by the mathematical method. Starting from the equation
of the plasma concentration dependent on time in the disposal phase
0( ) e
k tc t C e-= (15)
and knowing that the initial concentration is Co, and at the time t1/2 concentration is reduced
by half, the equation becomes
1/20
0 2
ek tCC e-= (16)
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where: ke was obtained by linear regression as a slope of the terminal phase of the logarith‐
mically transformed plasma concentration curve versus time
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where: ke was obtained by linear regression as a slope of the terminal phase of the logarith‐
mically transformed plasma concentration curve versus time
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• volume of distribution (Vd) – similar to total clearance, Vd cannot be evaluated exactly for






Statistical analysis of data was performed using the PHARM-STAT program for the investi‐
gation of bioavailability.
5.2. Results and discussion
5.2.1. Bioavailability of alendronate sodium in modified-release hydrophilic matrix tablets based on
Carbopol
Results from the comparative analysis of serum concentrations of alendronate administered
as immediate-release tablets to the animals in (control) group IV and as modified-release
matrix tablets to group I, show a higher absorption of alendronate sodium from the modified-
release tablets.
We can distinguish two major phases in the evolution of the absorption of alendronate, in close
correlation with the swelling characteristics of matrix tablets. Modified-release matrix tablets
with sodium alendronate administered to the animals in group I generate an absorption
maximum at 2.5 to 3 hours, after which there is a plateau condition in the concentration range
of 0.25 to 0.30 μg/mL alendronate until time 12, i.e. 10 hours after administration (Figure 12).
Initially, in the first 1.5 hours after administration, the animals in control group IV exhibit an
alendronate serum concentration that is higher compared to group I. Subsequently, after about
2 hours from the administration, when the matrix tablet has hydrated and the phenomenon
of alendronate diffusion in the inner matrix layers occurs, the serum concentration of alendr‐
onate in the animals in group I increases significantly (Figure 13)
By analyzing the data obtained, we consider that the formulation of alendronate in matrix
tablets based on Carbopol C 971 resulted in a considerable increase in oral bioavailability.
5.2.2. Bioavailability of alendronate sodium in modified-release hydrophilic matrix tablets in the
presence of absorption promoters
In the first hour after administration, the animals in the control group had a higher serum
concentration of alendronate compared to the modified-release formulations (Figure 14).
Subsequently, at collection time 4, that is 1.5 hours after administration, the formulation
corresponding to the modified-release matrix tablets containing trimethil chitosan as an
absorption promoter exhibits the highest concentration. This superiority lasts until time 5, that
is 3 hours after administration (Figure 15). According to these results, we consider that over
this time the absorption enhancer action of trimethilchitosan manifests itself.
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Figure 12. In vivo release of AL-Na from hydrophilic matrix tablets with modified release (0-12 hours)
Figure 13. In vivo release of AL-Na from hydrophilic matrix tablets with modified release (0-4 hours)
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Figure 13. In vivo release of AL-Na from hydrophilic matrix tablets with modified release (0-4 hours)
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Figure 14. In vivo release of AL-Na from hydrophilic matrix tablets with modified release in the presence of absorption
promotors (0-4 hours)
Figure 15. In vivo release of alendronate sodium from hydrophilic matrix tablets with modified release (0-12 hours)
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An unexpected development was recorded for animals in group II, which were administered
modified-release matrix tablets in which we had introduced chitosan as an absorption
promoter. The serum concentration of alendronate in this group was lower than in the control
formula throughout the experiment. There are two surprising aspects related to this: on the
one hand, the fact that chitosan does not act as absorption promoter and, on the other, that
there occurs a cancellation of the retardation effect and of the release optimization resulting
from the administration of the modified-release of matrix tablets based on Carbopol.
5.2.3. Pharmacokinetic parameters: Cmax, Tmax, t1/2, areas under the curve
The comprehensive review of the individual values of plasma concentrations over time and
of the corresponding individual graphs allows for a primary pharmacokinetic analysis of
results. Based on plasma concentration values over time the pharmacokinetic parameters
(Tmax, Cmax, AUC0-t, AUC0-∞, AUCt-∞, Cl, ke, t½, Vd) were determined. Subsequently, the data were
analyzed statistically to determine the possible existence of significant differences.
Mean Cmax peak plasma concentrations (Table 9) of the modified-release matrix tablets and of
the formula related to the control group, respectively, in a single dose study, reveal differences
between the formulations studied. Thus, for formula F2 given to group I, Cmax = 0,34μg/ml,
formula F5 associated with group II provides a Cmax = 0.24 μg/ml, formula F8, group III, has
Cmax = 0.48 μg/ml, and the control formula given to group IV, Cmax = 0.28 μg/ml. Result
processing through the ANOVA test shows that the differences between peak plasma con‐
centrations after administration of formulation F2, compared to control formulation and after
administration of F8 compared to the control, are not statistically significant. For parameter
Cmax only the differences between group I and III are statistically significant.
Mean value
GROUP
I II III IV
Cmax 0.34 0.24 0.48 0.28
Tmax 2.00 2.25 3.00 1.50
AUC 0-t 2.93 1.28 2.65 1.94
AUC 0-∞ 3.17 1.40 2.72 1.94
AUC t-∞ 0.24 0.12 0.07 0.00
% AUCextra 7.57 8.56 2.37 0.00
Cl 0.03 0.05 0.04 0.05
ke 0.08 0.08 0.13 0.08
t1/2 8.31 8.26 5.79 8.63
Vd 0.37 0.62 0.32 0.63
Table 9. Pharmacokinetic parameters of AL-Na
The mean values of time taken to reach peak concentration, Tmax (Table 9) exhibits equal values
for groups I and II compared to control group IV. The highest value was determined for group
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III, i.e. Tmax = 3 h. By applying a non-parametric test it was found that the differences are not
statistically significant.
The mean of the values of the extrapolated area AUC t-∞ is below 20% in all situations, which
proves the right choice for the last sample collection time. Analysis of the mean total area under
the plasma concentration-time (AUC0-∞) reveals differences between products. The highest
value was recorded for group I. Analysis of the mean values of Cl and Vd does not reveal
statistically significant differences between products.
5.3. Conclusions
The results obtained reveal an optimization of the bioavailability of alendronate administered
in modified-release matrix tablets from collection moment 5, i.e. two hours after administra‐
tion, as the animals in group I, corresponding to this formula, had a serum concentration of
alendronate superior to the control group.
The two absorption promoters used, trimethyl chitosan and chitosan, had completely different
influences on the absorption of alendronate in the modified-release matrix tablets. Thus,
trimethyl chitosan acted as an absorption promoter in the range 1.5 to 3 hours after adminis‐
tration, and caused the highest serum concentrations of alendronate, sometimes double
compared to the control. After that moment, concentrations are above the values of the control
group, but slightly lower than the values of group I, coresponding to the modified-release
matrix tablets based on Carbopol.
The administration of modified release tablets with alendronate sodium in which we associ‐
ated chitosan as absorption promoter has led to surprising results, because over the whole
experiment, the serum concentration of alendronate sodium was lower than of group IV
(control group). Chitosan exhibited virtually no absorption promoting action; it additionally
canceled the release retardation and optimization effect proved on group I after the adminis‐
tration of alendronate in modified-release matrix tablets based on carbopol.
6. Conclusions
The crosslinking degree of Carbopol has a major influence on the release properties of the
hydrophilic matrix tablets. The C71 and C971 Carbopol types, having a low crosslinking
degree, hydrate much better in pH 1.2, and this facilitates the AL-Na dissolution, its diffusion
through the gel layers of the matrix and, consequently, an optimized release of AL-Na. On the
contrary, C 971 – a polymer with a high crosslinking degree, slows the hydration process of
the matrix. Sort Carbopol 71 in a concentration of 15% results in hydrophilic matrix tablets
with optimal release of AL-Na. The different dissolution profile of Al-Na in the Carbopol-
based modified release matrix tablets is also confirmed by the values of the two control
parameters f1 and f2. Fitting the release data to the kinetic analysis with the Higuchi and the
Korsmeyer-Peppas model confirms the release of the Al-Na in the Carbopol-based matrix
tablets by a diffusion process. The Hopfenberg model applied to modified-release matrix
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tablets with a complex formulation based on associations of matrix-forming polymers to
highlight the involvement of erosion in the release of the active substance generated a good
fitting of the data (R2> 0.90), but the high values of the Akaike index do not allow the validation
of the model. In vivo studies have shown a higher bioavailability of AL-Na in modified release
matrix tablets at 1.5 hours after dosing. The results of the evaluation of the in vivo AL-Na release
indicate the optimization of the bioavailability of AL-Na in the Carbopol 71-based matrix
tablets, the optimal concentration being reached after 2 hours from the administration of the
tablet. The two absorption promoters used - chitosan and trimethyl chitosan - had a totally
different effect on alendronate absorption. Trimethyl chitosan showed a strong absorption
promoting effect by doubling AL-Na serum concentration while CHT did not show this effect.
According to the results obtained, Carbopol 71 is a good forming agent for modified-release
tablets to improve the oral bioavailability of AL-Na.
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